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Reed, Steven (Jim), Doctor of Philosophy, Summer 2019                            Immunology 
Impacts of trogocytosis-mediated intracellular signaling on CD4+ T cell effector cytokine 
production and differentiation 
Chairperson: Scott Wetzel 
Trogocytosis is the direct intercellular transfer of membrane and membrane 
associated molecules. Unlike other passive-membrane transfer events, trogocytosed 
molecules may remain fully functional and become re-expressed on the surface of the 
trogocytosis-positive (trog+) recipient. This phenomenon commonly occurs between 
various cell types, including those of the immune system. CD4+ T cell trogocytosis 
occurs during their activation by antigen presenting cells (APC). Consequently, the 
acquired molecules include ligands for signaling receptors on the T cell. 
The impacts of CD4+ trogocytosis on the immune response are largely unknown. 
While it has been demonstrated that trog+ cells can present trogocytosed peptide:MHC 
(pMHC), and costimulatory molecules to activate other T cells, the consequences of 
trogocytosis on the individual trog+ CD4+ T cell have not been studied in-depth. We 
previously reported that trog+ cells perform cell-autonomous signaling by trogocytosed 
ligands engaging surface receptors, referred here to as trogocytosis-mediated signaling. 
This signaling led to the enhanced survival of trog+ cells in vitro compared to trog– cells 
after APC removal. Because the duration of T cell signaling influences the activation, 
lineage determination, and effector functionality of CD4+ T cells; trogocytosis-mediated 
signaling has the potential to uniquely modulate the effector-cytokine production and 
differentiation of trog+ CD4+ T cell after separation from APC. 
Examining this possibility is the foundation for this dissertation. Here, I will report 
my findings that: 1. Between 0-72 hrs post-separation from APC, trogocytosis-mediated 
signaling drives IL-4 and GATA-3 expression, consistent with T helper type-2 (TH2) 
differentiation; 3. Extended trogocytosis-mediated signaling (>72 hrs) leads to the 
expression of Bcl-6, PD-1, CXCR5, and IL-21, consistent with T follicular helper (TFH) 
differentiation; 4. In absence of exogenous antigen (Ag), trogocytosis-mediated 
signaling is critical for the survival of the activated CD4+ T cells with high memory-
potential.  
         Despite the critical role for CD4+ T cells in generating protective immunity in the 
host, much remains unknown about the differentiation of CD4+ T cell effector subsets. 
The findings here present a novel mechanism for CD4+ T cell activation and 
differentiation via trogocytosis-mediated signaling, demonstrating the broad implications 
for such signaling in matters of public health.  
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Chapter 1 
Introduction 
 
Part I 
Brief overview of the immune response 
 
The immune system provides protection against infection from a multitude 
of pathogens in a series of events orchestrated by various leukocytes (white 
blood cells). The immune response is broadly broken down into three major 
stages, the first being the innate immune response, followed by adaptive 
immunity, and finally, long-lasting protective memory. As suggested by its title, 
the innate immune response occurs rapidly (minutes to hours), and 
independently of specific antigens (Ag). Cells of the innate immune system 
consist of those derived from common myeloid progenitors including: neutrophils, 
mast cells, basophils, and dendritic cells (DC); as well as natural killer (NK) cells, 
NK T cells, γδ T cells, and innate-like lymphocyte (ILC) derived from common 
lymphoid progenitors. A portion of innate cells reside in mucosal and epidermal 
layers to increase detection of pathogens by proximity, while others are found in 
circulation. Innate cells are activated by signaling through pattern recognition 
receptors (PRR) which include toll-like receptors (TLRs), rig-like receptors (RLR) 
and nod-like receptors (NLRs). These receptors detect conserved, pathogen 
associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS), viral 
CpG DNA and RNAs, and flagellin. Signaling through PRRs triggers a rapid 
inflammatory response that recruits other immune cells to the site of infection [1-
2 
 
3]. During this stage of the immune response, activated PAMP-stimulated 
antigen-presenting phagocytes, primarily DC, mature and migrate to secondary 
lymphoid organs, such as the lymph nodes. In these tissues they present peptide 
fragments of phagocytosed pathogens loaded into major histocompatibility 
complexes (MHC) to T cells, which are key mediators of the adaptive immune 
response [4].    
 
The Adaptive Immune Response  
Unlike the innate immune response, cells of the adaptive response respond to 
specific antigenic epitopes. Adaptive immunity is established by two primary 
types of lymphocytes; T cells, named after the location of their development in 
the thymus, and B cells which develop in the bone marrow. T cells make up the 
largest proportion (40-75%) of the peripheral blood mononuclear cell population 
and are broken down further into two major subsets determined by CD4 (CD4+) 
and CD8 (CD8+) surface antigens. Cytotoxic CD8+ T cells are associated with 
cell-mediated immunity and the killing of infected cells, whereas the primary role 
of CD4+ “helper” T cells is to mediate the activity of other cells of the immune 
system through contact-dependent stimulation and cytokine secretion. B cells 
secrete protective antibodies (Abs) against Ags on pathogens leading to their 
neutralization, opsonization, or lysis through initiating the classical complement 
cascade and antibody-dependent cellular cytotoxicity (ADCC). An important 
hallmark of the adaptive immune response is the rapid clonal expansion of 
responding lymphocytes resulting in an increase of several orders of magnitude 
3 
 
in the number of Ag-specific lymphocytes within days after initiation. This 
expansion typically peaks 5-7 days post-infection and is followed by a rapid 
contraction phase, which coincides with clearance of Ag. Once Ag has been 
cleared, ~90-95% of activated lymphocytes die within a matter of days. The 
remaining cells survive as long-lived memory cells, which are maintained at 
relatively stable numbers for years after infection. In addition to increasing the 
pool of antigen-specific cells, memory cells respond more quickly, and cells are 
pre-differentiated to generate the appropriate type of response for the given 
pathogen. The difference in memory responses vs primary responses is quite 
significant, and the generation of stable memory populations is the basis of 
modern-day vaccines.  
 
Part II 
 CD4+ T cell Activation, Differentiation, and 
Functions in the Immune Response 
 
CD4+ T cell Activation 
CD4+ T lymphocytes play a central role in generating protective immunity against 
infection. The importance of CD4+ cells has been exemplified through the HIV 
epidemic of recent decades, in which viral-depletion of CD4+ cells leads to AIDS 
progression. While low CD4+ levels result in impaired immunity against infection, 
aberrant CD4+ T cell responses can lead to, or exacerbate, autoimmune 
diseases such as asthma [5, 6], allergy [6], multiple sclerosis [7-9], [10-12], 
systemic lupus erythematosus (SLE) [13], psoriasis [14], irritable bowel disease 
4 
 
(IBD) [10, 15-20], and tumor persistence, amongst others [21]. Despite the clear 
implications of T cells in modulating the immune response, the mechanisms 
behind T cell activation and subsequent differentiation are still being elucidated. 
Thus, additional research is necessary to develop a comprehensive 
understanding of the mechanisms which govern these events and have far-
reaching implications in human health. 
 
T cell Maturation and Central Tolerance  
                     Due to the profound impact T cells have on the generation of 
immune responses, T cell development is a highly regulated process. The model 
for central tolerance involves two phases known as positive selection and 
negative selection. Both CD4+ and CD8+ T cells arise from common progenitors 
which express CD2 but are double-negative for CD4 and CD8. The majority of T 
cells contain  TCR (while ~20% have  TCR). In early development, diversity 
among the TCR repertoire is established through genetic recombination of DNA 
encoding segments for TCR by RAG1 and RAG2 recombinases. This leads to 
different variable (V) and common chain subunits to be expressed by each T cell 
through recombination of V(D)J regions of the of TCR  chain, and VJ 
recombination in the  chain. For a developing CD4+ T cell to progress through 
primary selection, the rearranged TCR must be able to recognize self-MHCII. 
This step, in positive selection is necessary due to the diversity of MHC proteins 
between individuals. In fact, the Human MHC is locus (referred to as HLA, for 
human leukocyte antigen) is the most polymorphic region in the human genome, 
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with >10,000 different alleles identified to-date [22, 23]. As a result, depending on 
the number of different inherited alleles, an individual may express up to 6 
different MHC I molecules, or haplotypes. MHC II are made up of two subunits (A 
and B), and humans can express between 3 and 12 different MHC II molecules 
[23]. In mice, there are three classical MHC I subclasses, (H2-K, D, L) and two 
MHCII classes H-2A(I-A) and H-2E(I-E) with many haplotypes indicated by lower 
case superscripts (such as I-Ek) seen later in this dissertation [24]. Endogenous 
T cells in the periphery only recognize Ag presented by host MHC haplotypes, 
but foreign MHC molecules have the potential to be antigenic as evident through 
the large role these molecules have in transplant rejection [25, 26]. During 
positive selection, if the re-arranged TCR cannot recognize self-MHC, the T cell 
dies from lack of stimulation in the cortex of the thymus. Negative selection 
subsequently serves to eliminate strongly self-reactive T cells which could lead to 
autoimmunity. During negative selection, single-positive CD4+ T cells which have 
survived the process of positive selection are exposed to a variety of self-Ag by 
medullary thymic epithelial cells (mTECs), along with DCs and macrophages, 
which present various self and non-self Ags. T cells that have high affinity TCR 
for self-Ags are eliminated through APC-induced apoptosis, while some lower-
affinity self-reactive T cells are programmed to become natural T regulatory 
(nTreg). T cells that recognize self-Ag weakly, or not at all are able to exit as 
mature, naïve T cells and circulate throughout the periphery. Central tolerance 
results in a population of mature T cells that display, each of which displays 
unique T cell receptor (TCR) specificity for a single peptide epitope (Ag). Thus, 
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the population of T cells can recognize a diverse array of Ags, while limiting the 
risk of unwanted immune responses by maintaining high Ag specificity. 
                The peptides presented to CD4+T cells are typically 12-25 amino acids 
in length, and alterations in the sequence may alter the T cell response 
significantly. While each TCR has a precise sequence for optimal Ag-recognition, 
TCR may recognize similar peptide sequences (with ~1-3 amino-acid 
substitutions) with varying affinity. Lower affinity interactions typically lead to a 
weaker TCR ligation, and subsequent TCR signaling. Therefore, a single amino 
acid replacement could be the difference between a T cell becoming activated or 
not [27]. Due to the immense diversity among TCRs, and physiological  
limitations of an organism, the frequency of circulating naïve T cells which 
recognize a particular epitope is approximately 0.01%, or roughly 100 cells in a 
WT mouse [28]. Peripheral naïve CD4+ T cells circulate throughout the lymphatic 
system where in lymph nodes (LN), they scan 160-200 DC per hour in search of 
cognate peptide:major histocompatibility complexes (p:MHC) complexes [29]. 
 
Regulation of T cell Activation  
T cell activation requires TCR recognition of antigenic peptide presented 
by MHC on the surface of an APC. However, recognition of cognate p:MHC and 
subsequent TCR signaling alone is insufficient to drive complete activation. In 
order to become fully activated, naïve CD4+ T cells require concurrent 
costimulatory receptor engagement including CD28, ICOS, and CD27 [30, 31]. 
The critical role of costimulatory signaling in T cell activation is apparent, as in 
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models where costimulatory molecules were knocked out, ~8000 TCR:pMHC 
contacts were required to induce T cell activation and proliferation. In the 
presence of CD28 signaling, this number was reduced to only ~1500 contacts 
[32]. In typical immune settings, insufficient costimulatory signaling following Ag 
recognition results in the T cell becoming hyporesponsive, or “anergic” [33].  
This checkpoint limits the activation of CD4+ T cells in absence of 
infection, as T cell costimulatory ligands such as CD80/CD86 (ligands for CD28), 
ICOS-L, and OX40L are not highly expressed on resting APC, but become 
upregulated following PRR stimulation [34]. Initial priming and activation of naïve 
T cells primarily occurs through interaction with DC [35], however B cells are also 
potent APC later in the response after many Ag-bearing DC have died, and Ag-
specific B cells have become abundant following clonal expansion [36].  
              Activated T cells, and memory cells have been observed to respond 
more quickly to stimuli compared to naïve T cells [37], although the exact 
mechanism for these differences is unclear. One study has proposed that it may 
be attributed to differential signaling through Erk pathways in naïve vs previously 
activated cells [38]. Other studies have found that memory cells have higher 
levels of ZAP-70, thus may more readily form TCR signaling complexes than 
naïve cells [39]. In addition, activated cells are significantly larger than naïve 
cells, so the number of initial TCR:pMHC contact points is likely greater on 
activated cells. These results suggest that CD4+ T cells that have passed through 
the initial activation checkpoints and undergone clonal expansion require less 
stimuli compared to naïve T cells. 
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T cell:APC Interactions 
The Immune Synapse 
A single T cell expresses ~30,000 TCR, while an APC typically displays ~100 
cognate ligands spread across the cell surface [40, 41]. In the case of naïve 
CD4+ T cells, interaction between a single TCR:pMHC is insufficient for complete 
activation. In order to obtain sufficient levels of TCR and costimulatory signaling 
required for activation, engagement of TCR with cognate p:MHC complexes 
leads to the formation of the immunological synapse [42-49]. Initiation of the 
immunological synapse may be triggered by a single TCR:pMHC interaction, but 
an elegant study by Irvine et al., visualized labeled peptide bound to MHC, and 
found 10 or more TCR:pMHC ligands are necessary to produce a functional 
immunological synapse [50]. The formation of the immunological synapse 
involves the spatio-temporal rearrangement of the TCR, costimulatory molecules, 
and adhesion molecules into distinct, spatially-segregated supra-molecular 
activation complexes (SMACs)  [48, 51-54]. This rearrangement is actin-
dependent [55, 56], and is initiated by a rapid calcium influx initiated upon 
TCR:pMHC ligation. In effector cells, TCR and costimulatory molecules such as 
CD28 and ICOS, as well as the regulatory molecule CTLA-4, form connections at 
multiple points of T cell:APC contact and rapidly migrate towards the center of 
the SMAC forming the central SMAC (c-SMAC) [45, 57, 58]. Exclusion of 
adhesion molecules from the c-SMAC leads to the formation of a proximal ring 
(p-SMAC) of adhesion molecules such as LFA1-ICAM1, talin, and CD4 around 
the c-SMAC, stabilizing the interaction. Surrounding the p-SMAC are larger 
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molecules not directly involved in the immune synapse including CD43, CD44, 
and CD45, which form a distal SMAC (d-SMAC) [42, 47]. 
                This entire process of rearrangement typically occurs within 2-3 
minutes of initial Ag recognition [31, 59]. As TCR reach the center of the c-
SMAC, they lose signaling capacity and become internalized by the T cell and 
are either recycled to the surface or are ubiquitinated, leading to their 
degradation [60]. The loss of TCR signaling and surface expression have been 
proposed as a mechanism for dissociation from APC [61], though the exact 
events which initiate the termination of the immunological synapse remain 
unknown. The inhibitory molecule CTLA-4 which shares the APC ligands CD80 
and CD86 with the T cell costimulatory molecule CD28 may also be involved in 
dissociation of the immune synapse by outcompeting CD28 for shared ligands on 
APC [62]. Dissociation from APC generally occurs within 15-60 minutes in 
activated CD4+ cells [31]. Naive CD4+ T cells tend to maintain longer synapses 
and have been commonly observed to maintain contact with APC for hours [63]. 
One study found that at the immunological synapse, as many as 20,000 TCRs 
could be triggered by only 100 p:MHC complexes [64], showing the great 
efficiency of the immunological synapse in T cell activation. Depictions of the 
formation of the immunological synapse, and molecules involved are seen in 
figure 1 below. 
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Kinapses, and Microvessicles and the Distal Pole 
Complex 
 
Immune Kinapses 
Immune synapses are not the only mechanism for T cells to receive stimulation. 
Shorter-lived interactions between highly motile T cells and APC also occur and 
have termed kinapses [46, 57]. Similar to the immunological synapse, kinapses 
typically have a focal point of contact between the T cell and APC. However, 
unlike synapses that are stable structures, with kinapses the T cell does not 
arrest upon TCR signaling thus, these are unstable structures and signaling is 
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intermittent [65]. From imaging experiments, signaling molecules that are found 
in the cSMAC of a classical synapse appear to be localized to the trailing edge 
(uropod) the migrating T cell (Fig. 1.2B). 
 
 
 It has been proposed that kinapses may form as opposed to a classical synapse 
due to the high mobility of the T cell, or in cases where chemokine receptor 
signaling is greater than signaling triggered by APC molecules [57]. Recently, an 
elegant study by Akkaya et al., proposed a model for kinapse morphology 
involving T cell microvilli, (small protrusions containing TCR/costimulatory 
molecules on the surface of T cells) that form the main points of contact during 
synapses [66].  
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            Kinapses are not generally associated with the activation of naïve T cells, 
though it has been found multiple kinapses can result in the accumulation of 
sufficient signaling to drive T cell activation [67]. Kinapses also serve as a 
mechanism to maintain the activation state of already activated T cells [67]. 
These findings, combined with the proposed model for kinapse formation via 
microvilli [66], suggest that microvilli may play a larger role than previously 
thought in the context of active TCR signaling. 
 
Microclusters 
                  A third physically distinct signaling mechanism that has been 
observed between T cell and APC involves small clusters of TCR and 
costimulatory molecules such as CD28 termed microclusters. The initiation of 
both the immune synapse and formation of microclusters involve filamentous like 
protrusions on the T cells known as microvilli [66, 68]. Microvilli have high 
concentrations of TCR, thus enabling T cells to efficiently scan the surface of 
APC for pMHC complexes. Microvilli also contain costimulatory molecules such 
as CD28. Microclusters form outside of the dSMAC upon microvilli binding pMHC 
and costimulatory molecules on APC. These microcluster signaling complexes 
provide a major source of TCR/costimulatory molecule signaling. The synaptic 
microcluster morphology commonly occurs in synapses formed with DC [45], 
while the classical “bulls-eye” centrally focused synapses are predominantly 
formed during Ag presentation by B cells [45, 69]. Because DC play a primary 
role in the activation of naïve T cells, this is a notable observation. 
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One particularly interesting aspect of TCR microclusters is their unique migration 
patterns. Signaling via microclusters precedes the formation of the immunological 
synapse, and rapidly initiates (0-30 seconds) following engagement of TCR and 
MHC and CD28:CD80/86. Microclusters generally migrate towards the cSMAC, 
but also have been observed to migrate away from the immunological synapse 
and localize at the distal pole of the T cell [70].  In contrast to some of the original 
models of the immune synapse, where maximal signaling was predicted to occur 
in the cSMAC, more recent models suggest that TCR signaling primarily occurs 
in microclusters outside of the SMAC  [69, 71-73]. It has been proposed that 
while active signaling is occurring in the microclusters, the cSMAC mainly serves 
as the location where TCR that are no longer actively signaling are endocytosed 
and either recycled to the surface or ubiquinated, leading to their destruction [69, 
74, 75].              
             Curiously, microclusters migrating away from the immune synapse have 
been shown to retain active TCR signaling, despite their apparent lack of APC 
contact [70, 76]. An interesting study by Hashimoto et al., observed that TCR 
microclusters form a surrounding ring of adhesion molecules, and on a micro-
scale are similar in structure to the immunological synapse [71] (Fig. 1.3). 
Microclusters outside of the cSMAC have also been observed to exclude the 
phosphatase protein CD45 [74]. CD45 can act to enhance TCR signaling through 
the dephosphorylation of autoinhibitory tyrosine in clusters of Lck [77]. On the 
other hand, CD45 also plays an important role in regulating TCR signaling by 
dephosphorylating ITAMs and TCR in the sMAC, leading to the termination of the 
14 
 
TCR signaling [78, 79]. The formation of the ring surrounding TCR microclusters 
has been thought to aid in their exclusion of CD45, permitting TCR signaling to 
be maintained in absence of APC contact.  
 
 
The Distal Pole Complex 
During the formation of the immunological synapse, cytoskeletal rearrangements 
and establishment of an active signaling location leads to distinct polarity within 
the T cell. This axis of polarity is established as TCR and costimulatory 
molecules migrate towards the T cell:APC interface to form the proximal pole, 
which is the location of the highest active signaling. Concurrent with the 
formation of the synapse, surface molecules not involved in the immune synapse 
such as CD43, SHP-1, PI3K, scribble (PKCζ), Numb, Par3/6, and Disks Large 
(hDLG) [80], migrate to the side of the T cell directly opposite the immune 
synapse. Together these molecules form the distal pole complex (DPC) [70].  
                While the DPC contains negative-regulators of T cell activation, 
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surprisingly, active signaling of molecules including ZAP-70, have also been 
observed to occur at the DPC [76, 81]. Although the mechanism is unknown, the 
presence of active TCR signaling at the DPC has been observed to precede the 
formation of the immune synapse in a TCR-independent, but contact-dependent 
manner [70]. Randriamampita et al. have termed active signaling at the DPC the 
“antisynapse”. [76]. Upon formation of a stable immunolocigal synapse, actively-
signaling TCR at the antisynapse are recruited to the proximal pole until 
eventually signaling localized to the distal pole is no longer detectable [70]. The 
mechanisms behind active TCR signaling at the distal pole have not yet been 
characterized [76]. However, it is likely that the antisynapse is formed by 
microclusters which retain active signaling outside of the cSMAC [74, 76]. 
 
Additional Variables That Influence Synapse 
Morphology  
 
               While it has been suggested that T cell activation via microclusters vs 
classical synapse are dependent on APC cell type, factors such as Ag dose, or T 
cell subset also have been shown to influence the morphology of the T cell:APC 
interaction [31, 82]. For example, Thauland et al., found that the majority of pre-
polarized TH2 cells formed multifocal synapses with low doses of Ag, while high 
doses lead to the majority of synapses forming the classical “bull’s-eye” 
morphology [83]. Meanwhile, polarized TH1 cells formed canonical synapses 
under both low and high Ag dose [83] (Fig. 1.4). 
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         The existing models of T cell activation, requires the ligation of many TCR 
by pMHC, CD28 ligation with CD80/CD80, and the interaction of adhesion 
molecules. Thus, regardless of the physical location of these interactions, 
synaptic or microclusters, a period of stable signaling molecule ligation is 
necessary to achieve full CD4+ T cell activation. 
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T cell Signaling: Pathways, Consequences, and 
Regulation 
 
T cell activation 
 
Following TCR and costimulatory receptor engagement, downstream signaling 
leads to the activation of three canonical transcription factors which play the 
primary roles in T cell activation, proliferation, and differentiation. These 
transcription factors are; nuclear factor-κB (NF-κB) (required for proliferation and 
differentiation), activator protein 1 (AP-1) (involved in IL-2 production and 
activation), and nuclear factor of activated T cells (NFAT) (drives IL-2 and IL-2Rα 
expression, and important in effector functions and differentiation) [84]. An 
overview of T cell signaling events is shown in figure 1.5.  
Following recognition of p:MHC by TCR formed by αβ heterodimers, the 
Src-family kinase p56Lck (Lck), which is non-covalently associated with CD4 
molecules, is recruited to the TCR signaling complex [85]. Lck is recruited to the 
early synapse, upon CD4 binding to the non-polymorphic β2 domain of MHCII 
[86]. CD4 is therefore often categorized as part of the TCR signaling complex, 
and also acts as a coreceptor because it enhances the sensitivity of TCR by up 
to 100-fold [87-90]. Upon removal of an autoinhibitory phosphate by CD45, and 
phosphorylation of Tyr 505, activated Lck phosphorylates immunoreceptor 
tyrosine-based activation motifs (ITAMs) on the CD3 and TCR ζ chains, which 
then become binding sites for the SH2 domains of the Syk-family kinase zeta 
associated protein 70 kDa (ZAP-70) [91]. Lck phosphorylates and activates 
recruits ZAP-70. Phosphorylated Ltk/ZAP-70 stabilize the TCR signal [92] and 
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phosphorylate four major tyrosine sites on the adaptor protein linker of activated 
T cells (LAT). The proximity of LAT to TCR-signaling complexes is maintained via 
its single transmembrane domain, and the multiple cytoplasmic binding domains 
of LAT serve as scaffold for multiple signaling molecules. The recruitment of 
these signaling molecules to activated LAT forms the proximal signaling complex 
which plays a central role in the initiation of the multiple signaling pathways 
downstream of TCR signaling [93]. The formation of this complex promotes 
interaction with recruited proteins including the adaptor Grb2-related adaptor 
protein-2 (GRAP2/Gads), SLP-76, IL-2 inducible T cell kinase (ITK), Grb2, p85 
PI-3 kinase, and phosphoinositide-specific phospholipase C1 (PLCγ1) [94]. Here 
the signal diverges through signaling of GRB2/SOS and SLP-76, as well as 
PLCγ1, to act on different transcription factors involved in T cell activation.   
               Grb2 and Gads are adaptor proteins which bind Son of Sevenless 
(SOS) and SLP-76, leading to Ras and subsequent MAP kinase cascade. This 
signaling cascades leads to ERK1/2 activation, which acts in the nucleus to 
regulate c-Jun and c-Fos, which form the AP-1 transcription factor. AP-1 plays 
roles in IL-2 production by binding to the IL-2 promotor to induce gene 
expression and also stabilizes IL-2 mRNA [95]. Its activation also promotes 
survival by indusing expression of the anti-apoptotic gene Bcl-xL [96]. 
Downstream of AP-1, NF-κB activation occurs, which drives T cell proliferation 
and differentiation through IL-2 expression, enhancing translation of subset-
specific transcription factors, increased effector functions, and upregulation of 
surface activation and costimulatory markers [93, 97-99].  
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           PLCγ1 hydrolyzes PIP2 to generate the secondary messengers inositol 
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), which activate different 
downstream pathways. IP3 diffuses in the cytoplasm and becomes bound by its 
receptor (IP3R) on the endoplasmic reticulum (ER). This causes the release of 
Ca2+ stores from the ER leading to the subsequent influx of extracellular calcium 
through channels in the plasma membrane. Elevated levels of cytosolic 
Ca2+ activate various proteins, including the phosphatase calcineurin. Calcineurin 
dephosphorylates the transcription factor nuclear factor of activated T cells 
(NFAT), allowing it to traffic into the nucleus. In the nucleus, NFAT is involved in 
stabilization and induction of lineage-specific transcription factors T-bet (TH1), 
Gata3 (TH2), RORγt (TH17), and Foxp3 (iTreg) [100]. The specific transcription 
factor NFAT promotes is dependent on the convergence of other signaling 
pathways such as cytokine receptor signaling to activate respective STAT 
signaling pathways. NFAT also is critical for the expression of IL-2 and IL-2Rα 
(CD25), which enable T cell proliferation [101].  
Activated DAG initiates signaling in two pathways. The first pathway 
involves the calcium independent activation of protein kinase Cθ (PKCθ). DAG 
binding to PKCθ leads to conformational changes in PKCθ to form an open, 
active state. Activated PKCθ can phosphorylate cytoplasmic IkB kinase (IKK), 
leads to NF-κB translocation to the nucleus where it acts as a transcription factor 
driving T cell proliferation and differentiation [102]. The second role for DAG is to 
initiate the RAS – MAPK cascade ending with the activation of kinases ERK1/2 
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which, as described above, leads to the nuclear translocation and activation of 
AP-1.   
At the immunological synapse, costimulatory signaling primarily involves 
the costimulatory receptor CD28. CD28 ligation activates phosphoinositide 3-
kinase (PI3k) which subsequently phosphorylates phosphatidylinositol 4,5-
bisphosphate (PIP2) to yield phosphatidylinositol (3,4,5)-trisphosphate (PIP3). 
PIP3 recruits proteins to the inner leaflet of the plasma membrane, such as ITK 
kinase [103]. ITK binds to PIP3 and SLP-76, which localize it to the plasma 
membrane and cause its activation. Activated ITK can then phosphorylate 
PLCγ1, thus CD28 signaling pathways converge with TCR signaling to amplify 
RAS/MAPK and PCKθ signaling. CD28 signaling also increases expression of 
the costimulatory CD40L to aid in the maintenance of T cell activation [104]. 
Signaling through CD28 alone can enhance the survival of activated T cells.  
Importantly, TCR + CD28 activation of PI3k also activates the protein 
kinase B (Akt) / mammalian target of rapamycin (mTOR) signaling pathway. 
mTOR includes two unique signaling complexes mTORC1 and mTORC2. 
Through inhibition of STAT signaling, mTORC1 has been found to play a role in 
TH1, TH2, and TH17 differentiation, while a role for mTORC2 has only been found 
in the differentiation of TH1, and TH2 [105]. While early studies suggested the 
absence of mTOR signaling in the presence of TCR signaling led to anergy [106], 
more recent studies have found that absence of mTOR signaling leads to 
induction of Treg [107]. mTORC1 signaling leads to glycolysis, and trafficking of 
the glucose transporter Glut1 to the cell membrane [108].The induction of 
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mTORC glycolic metabolism is associated with CD4+ effector function. It also is 
directly involved in protein synthesis through inhibition of eukaryotic initiation 
factor 4E binding protein (4EBP1) (which inhibits protein translation), and 
activation of p70 S6K ribosomal protein [109, 110]. In addition, mTORC1 
increases lipid metabolism and synthesis, as well as mitochondrial biogenesis 
which aids in T cell effector functionality and clonal expansion [111]. mTORC2 
acts by phosphorylating other proteins including Akt, which forms a positive 
feedback loop [112], leading to increased cell survival, cytoskeletal organization 
and migration [113]. mTOR signaling can lead to increased effector functionality 
by promoting the production of effector cytokines [114]. Collectively, the mTOR 
signaling complex integrates multiple cell signaling events to regulate cell 
proliferation, differentiation, effector functionality, and survival.   
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Regulation of T cell signaling 
Proximal signaling through ZAP-70 is negatively regulated by the binding of the 
E3-ubiquitin ligases Cbl c-Cbl and Cbl-b. Cbl ubiquinates lysine residues on ZAP-
70 targeting it for proteasomal degradation [115]. Excessive Cbl-recruitment can 
lead to insufficient signaling for activation and is largely associated with T cell 
anergy. While anergic T cells are able to form mature immunological synapses, it 
was found by Doherty et al., that anergic synapses showed higher recruitment of 
Cbl-b to the cSMAC compared to control cells, leading to decreased pERK 
signaling [116]. Cytoplasmic phosphatases have also been shown to reduce 
ZAP-70 activity through removal of activating tyrosine phosphate [117]. 
Dysregulation of ZAP-70 signaling can lead to cell exhaustion, or excessive 
responses implicated with autoimmune diseases. Along these lines, inhibitors of 
ZAP-70 signaling have been proposed for use in treatment of autoimmune 
diseases and organ transplant rejection [118, 119].    
The Cytotoxic T lymphocyte-associated molecule-4 (CTLA-4), which is 
expressed after T cell activation, binds to the same ligands as CD28 
(CD80/CD86), but rather than providing positive costimulation, CTLA-4 signaling 
inhibits T cell activation [120]. CTLA-4 resides in intracellular vesicles and upon 
strong TCR ligation, these vesicles move to and fuse with the plasma membrane 
delivering CTLA-4 into the immunological synapse [121, 122]. Although 
expressed at much lower levels than CD28, CTLA-4 binds to CD80/86 with 
significantly higher affinity than CD28. CTLA-4 ligation provides competitive 
inhibition of costimulatory signaling, as well as inducing unique signals that inhibit 
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IL-2 production [120]. The immunoregulatory effects CTLA-4 comes from studies 
using antibody-mediated blockade of CTLA-4 signaling, which has become a 
promising component in anti-tumor therapies [123, 124]. However, the absence 
of CTLA-4 has also been shown to lead to CD28-mediated autoimmunity in mice 
and humans [62, 125]. In these particular cases, it is likely that CTLA-4 blockade 
not only increased costimulatory signaling through CD28, but also decreased the 
function of Treg. The high expression levels of CTLA-4 by Treg plays an important 
role in peripheral tolerance, and are discussed in greater detail in later sections.   
 
Events Following T-cell Activation 
T cell Clonal Expansion 
Following activation, naive CD4+ T cells rapidly proliferate, resulting in clonal 
expansion of up to 100,000-fold within 3-4 days [126]. Despite early contradictory 
findings [127], continued Ag signaling is not required during the expansion phase 
[128, 129]. This allows for rapid T cell proliferation without the requirement for 
daughter cells to scan APC for Ag. Clonal expansion leads to a massive increase 
in Ag-specific lymphocytes which can then rapidly clear an infection. It also 
underscores the necessity for the regulation of T cell activation through activation 
checkpoints and Treg, in order to conserve physiological resources and prevent 
unwanted inflammation and autoimmunity due to potential self-reactive T cells 
that have escaped negative selection.  
Following expansion, activated CD4+ effector cells provide “help” to other 
cells of the immune system through effector-cytokine secretion and contact 
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dependent mechanisms [130]. Effector T cells undergo a genetic reprogramming 
into specialized lineages of T helper TH subsets. Each TH subset exhibits effector 
functions associated with protection against a given type of pathogen, or 
interacts with a specific type of cell, such as TFH help for B cells. This 
reprogramming from undifferentiated precursors is known as T cell differentiation.  
 
CD4+ T Helper Differentiation 
The immune system must be highly adaptable in order to provide protection 
against a diverse array of pathogens with various modes of infection. For 
example, a cell-mediated response is optimal for combating intracellular 
pathogens, while a humoral response leading to the production of antibodies is 
more effective at neutralizing extracellular infections. Typically, a fine balance is 
required to provide optimal protection. CD4+ T cells play a central role in directing 
the type of immune response generated.  They are differentiated from naïve, 
undifferentiated precursors, into specialized subsets upon activation. While some 
T cell lineages such as natural T regulatory (nTReg) [131], and NK T cells [132] 
are predetermined during maturation in the thymus, the majority of naïve CD4+ T 
cells in the periphery are undifferentiated. 
The first insights into TFH differentiation came from the work of Mossmann 
and Coffman in the late 1980s when they observed two distinct subsets of CD4+ 
T cells that produced either IFNγ (TH1), or IL-4 (TH2) [133, 134]. In the years 
since, new subsets with specialized functions have been discovered including 
TH17, TH9, TH22, induced T regulatory (iTreg/ Treg), T follicular helper (TFH), and 
26 
 
cytotoxic CD4+ T cell (CD4+ CTL) [135-137].  The primary model for naïve TH 
differentiation, known as the three-step model, proposes that TCR signaling 
primes the T cell (step 1), while costimulatory signaling is required for T cell 
activation (step 2). The effector subset differentiation is driven by cytokine 
signaling concomitant with, or shortly after, activation (step 3). This differentiation 
is ultimately controlled by PRR signaling in APCs, which leads to the expression 
of cytokines associated with protection against the encountered pathogen. In this 
way, CD4+ T cells differentiate into lineages which promote the most effective 
immune response against the pathogen at hand [138] (Fig. 1.6).   
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While this model holds true for the majority of TH differentiation cases, 
recent evidence has found this process to be more complex than initially thought. 
One example comes from findings that the strength of TCR signaling may 
override cytokine signaling in the context of TH2 differentiation. Weak TCR 
signaling has been found to drive cells to differentiate towards TH2 even when 
cells are in a TH1 -polarizing environment  [139]. In contrast, strong TCR signaling 
has been shown to favor TH1 differentiation [82, 140, 141]. The duration, or 
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persistence, of TCR and costimulatory signaling also impacts TH  differentiation, 
with short-lived interactions favoring a TH2 phenotype and longer synapses 
promoting TH1 differentiation [82]. In the case of TFH cells, repeated cognate 
interactions with cognate APC are required for their differentiation  [142, 143]. To 
add to the complexity, under opposing polarizing conditions, there is plasticity 
between differentiated TH  subsets, and concurrent expression of two or more 
subset-characteristic cytokines and/or transcription factors in the same TH  cell is 
possible [144-149] (Fig. 1.7B) 
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Functions of CD4+ TH Subsets 
As described above, while TH differentiation is a complex process, the cytokines 
present at the time of activation play a major role in TH-subset differentiation. 
Through the activation of specific STAT proteins, cytokine signaling is able to 
activate transcription factors that act as master regulators of differentiation, and 
the expression of cytokines which further drive TH differentiation, or by inhibiting 
the expression of transcription factors associated with other TH subsets. The 
cytokines, transcription factors, and primary functions associated with known 
effector subsets is shown in table 1 below.  
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TH1: Cell-mediated immunity against intracellular pathogens 
TH1 differentiation is driven primarily by the polarizing cytokine IL-12, while IL-18, 
IL-23, and IL-27 also favor TH1 differentiation [150]. Meanwhile opposing signals 
from IL-4 can inhibit TH1 differentiation and effector functionality [151]. Although 
other APC are capable of driving TH1 differentiation, CD8α+ dendritic cells (DC) 
localized in lymphoid organs [152] secrete IL-12, thus are effective promoters of 
promoting TH1 differentiation [153]. The master transcriptional regulator T-bet 
inhibits GATA3 expression [154], and is a defining marker for TH1 lineage [150]. 
Strong TCR and costimulatory signaling through high Ag dose [155-157], and 
extended T:DC interactions also favors TH1 differentiation [157]. TH1 cells aid in 
cellular-mediated immunity through secretion of IFNγ, IL-2, TNFα and TNFβ, 
which activate cytotoxic CD8+ T cells (CTL) and NK cells to kill infected cells 
[158], or tumors [159, 160]. These cytokine also induce nitric oxide production in 
macrophages to enhance pathogen killing [161, 162]. IFNγ induces B cell class 
switching towards IgG2 Ab production which are highly effective in activating the 
classical complement pathway [163, 164]. Aberrant TH1 responses contribute to 
pathogenicity of organ-specific autoimmune diseases including type 1 diabetes, 
psoriasis, Crohn’s disease, and multiple sclerosis [7, 153, 165] 
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TH2: Humoral-Mediated Immunity and Protection Against 
Extracellular Pathogens 
TH2 differentiation cells are identified by the master regulator transcription factor 
GATA3 [166, 167], and produce effector cytokines IL-4, IL-5, IL-6, and IL-13. The 
presence of IL-4 following activation drives GATA3 expression via STAT6 
signaling [168], while IL-12 negatively regulates TH2 differentiation [169]. IL-4R 
signaling not only prevents TH1 differentiation, but also negatively regulates IFNγ 
expression [170], following a clear pattern for TH1/TH2 negative regulation. In 
addition, IL-2-induced STAT5 has been found to be required for TH2 
differentiation [171]. Lower signal strength or short interactions with APC favor 
TH2 differentiation [139, 156, 172], thought to be due to weaker signaling  leading 
to early IL-4 production [173]. Some contrasting reports have found high signal 
strength to drive TH2 differentiation [174, 175], and the consensus is that either 
low, or high signal strength can drive TH2 differentiation, while medium to high 
signal strength drives TH1 [155-157].  
These cells specialize in providing B cell help through directed cytokine 
secretion upon recognition of cognate Ag displayed by the B cell. The cytokines 
IL-4 and IL-6 in particular are important in driving B cell class switching and 
proliferation in the germinal center response, with IL-4 favoring class switching 
towards IgE and IgG1 isotypes [6, 176]. TH2 cells activate eosinophils [177] and 
play a role in airway inflammation. TH2 responses are also associated with 
protection against large extracellular pathogens such as helminths [178]. 
Dysregulation in the activation of TH2 cells can lead to increased allergic 
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inflammation, ulcerative colitis, atopic dermatitis, chronic rhinosinusitis, as well as 
airway inflammation and asthma [6, 165, 179].  
TH17: Mucosal and Surface-Barrier Immunity 
The third effector subset of CD4+ T cell to be identified were TH17 cells, induced 
by a combination of TGFβ + IL-6 or IL-23 signaling leading to the expression of 
transcription factors STAT3, RORγt, and RORα [180]. While TNFα, IL-21, and IL-
23 can enhance TH17 differentiation, IL-4, IFNγ, IL-12, and IL-27 inhibit their 
differentiation. TH17 cells secrete IL-17A, IL-17F, IL-21, IL-22, and granulocyte-
macrophage colony-stimulating factor (GM-CSF) [181, 182]. These cells are 
associated with inflammation and mucosal immunity, primarily act at barrier 
tissues, and provide protection against extracellular bacteria, fungi, and enteric 
parasites such as Giardia [183, 184]. IL-17 in combination with IL-22 has been 
found to induce expression of β-defensin 2 and other antimicrobial peptides, 
suggesting that TH17 cells play a role in skin immunity [185]. Cytokines produced 
by TH17 cells can induce neutrophil production, and lead to recruitment of other 
immune cells to sites of inflammation. TH17 cells are also able to regulate the B 
cell Pigr gene, which is crucial for the expression of the poly Ig receptor for IgA, 
pIgR. The pIgR enables IgA molecules to cross luminal membranes [183], again, 
demonstrating the important role TH17 cells play in mucosal immunity. As TH17 
cells are associated with inflammation, excessive TH17 responses have been 
found to play a role in exacerbation of diseases in a manner similar to TH1 cells. 
Excessive numbers of TH17 likely increases pathology of psoriasis [14], as drugs 
which neutralize IL-17A have been effective in reducing the symptoms of 
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psoriasis [186]. IL-17A has also been associated with rheumatoid arthritis, 
multiple sclerosis, airway inflammation and COPD, asthma, atopic dermatitis, 
and irritable bowel disease [10, 15-20].  
 
TH22: Surface barrier immunity 
TH22 cells are a more recently described subset of cells, which are related TH17 
cells. it has been found that TH22 cells are identified by expression of the 
transcriptional regulator, the Aryl Hydrocarbon Receptor (AhR) and they produce 
TGFα and IL-22, but not IFNγ, IL-4, or IL-17 [187]. It has been proposed that IL-
22 differentiation is driven by IL-6, IL-23, IL-1β, and FICZ [188]. While originally 
considered to be identical to TH 7 [185] these cells have roles in immune function 
distinct from TH17 cells [189]. High numbers of TH22 localize to the epidermis and 
TH22-produced IL-22 has been found to play important roles in protection against 
enteropathogenic bacteria [190]. The impact of IL-22 differs between locations, 
as pathogens may enter through the skin, gut, and respiratory tract [191, 192]. 
However, the end result is production of antimicrobial peptides on surface 
barriers, and mucus-associated glycoproteins at mucosal barriers, both which 
provide defense against bacterial infection [193]. IL-22 also exhibits epithelial 
reparative and regenerative properties [194]. Interestingly, the depletion of TH22 
cells during HIV infection led to the epithelial barrier becoming compromised due 
to decreased IL-22 levels, suggesting IL-22 may play a role in protection from 
HIV, among other viral infections, at mucosal membranes [194]. Excessive TH22 
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responses can exacerbate symptoms of rheumatoid arthritis [10, 19], skin allergy 
[195] and atopic dermatitis, psoriasis, irritable bowel syndrome, and potentially 
systemic lupus erythematosus (SLE) [13]. 
 
TH9: Type-2 Associated extracellular Pathogen, (and anti-tumor?) Immunity 
The recently discovered TH9 subset [196] is induced by IL-2 and IL-4 + TGFβ 
[197] and is typically associated with a type 2 Immune response. TH9 cells 
require transcription factors STAT6, IRF4, GATA3, and are identified by 
expression of PU.1 [198]. While the redundancy of TH9 cells with TH2 has led to 
uncertainty whether they play an indispensable role in immune protection, TH9 
cells have been found to uniquely  produce IL-10, IL-21, and IL-9 [137]. IL-9 
stimulates growth, proliferation and survival of T cells and mast cells, increases 
secretion of mucus, and enhances IgE production by B cells [199-202]. 
suggesting a protective role for TH9 cells in mucosal immunity. Results have 
found TH9 cells drive immunity against helminth infection [203] through 
increasing IL-5 and IL-13 production in T cells, and basophil and eosinophil 
numbers at the site of infection [204]. IL-9-secreting cells have also recently been 
found to play a role in anti-tumor immunity in melanoma models [205, 206]. While 
the mechanism for IL-9 driven anti-tumor activity is unclear, it was proposed that 
IL-9 induced recruitment of mast cells [205], DC and cytotoxic CD8+ cells to the 
site of the tumor through increasing expression of the chemoattractant CCL20 
[206]. The impacts of TH9 cells on autoimmunity are still undetermined, though 
transfer of TH9 cells in a colitis model led to increased inflammation [197]. It was 
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unclear however, if this was a result of IL-9 production, as transferred cells were 
observed to increase IFNγ expression, thus the results may have been due to a 
TH9-TH 1 effector transition [197].  
 
T follicular helper cells: Key Players in the Humoral Response 
T follicular helper cells (TFH) play an essential role in providing B cell help in the 
germinal center (GC) reaction. Their proximity to B cells, secretion of IL-21 and 
IL-6, maintained expression of the C-X-C chemokine receptor type 5 (CXCR5) 
along with inducible T-cell costimulatory (ICOS) and programmed cell death 
protein-1 (PD-1) [207-211], sets them apart from the TH 2 subset.  Unlike other 
CD4+ T cell effector subsets, TFH differentiation does not occur following initial 
priming of naïve TH0 cells by antigen-bearing DC, but requires subsequent 
interaction with APC for full differentiation [142, 212-215]. The current model of 
TFH differentiation seen in Fig. 1.8, holds that pre-TFH are primed by DC through 
IL-6 and ICOS signaling which leads to the upregulation CXCR5. As activated T 
cells downregulate CCR7 (which keeps cells in T cell zones), the expression of 
CXCR5 enables them to chemotax in response to the CXCL13 chemokine 
gradient present in B cell zones [212, 216-218]. At the edge of the B cell follicle, 
pre-TFH interact with antigen-bearing, cognate B cells and these repeated 
interactions in combination with either IL-6 or IL-21 induce STAT3 signaling [219, 
220]. STAT3 signaling leads to upregulation of the transcription factor Bcl-6 to 
drive full TFH differentiation (in the absence of the transcription factors Blimp-1 
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and KLF2) [209, 213, 215, 219, 221-225]. Bcl-6 acts as a transcriptional 
repressor for GATA3 and inhibits the activity of T-bet and RORγt, thus inhibiting 
TH2, TH1, and TH17 differentiation, respectively [226]. The transcription factor 
Tcf1 has also been found to be necessary for full differentiation in the context of 
viral infection [227].   
 
 
The proposed requirement for B cells in TFH differentiation is potentially 
due to the fact that pre-TFH are much more likely to encounter antigen-bearing B 
cells than DC upon their CXCR5-driven migration to the B cell follicles. In 
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addition, about 3 days following the initiation of the immune response, the 
majority of APC are Ag-specific B cells. This possibility is supported by the fact 
that continual stimulation by repeated immunizations in the absence of B cells 
was found to produce TFH [213]. This, combined with results from other studies 
[228], suggests that B cells do not provide unique signals which drives TFH 
differentiation, but simply serve to prolong Ag stimulation that is required for TFH 
differentiation.   
        Upon full TFH differentiation, high Bcl-6 expression leads to loss of Epstein-
Barr virus-induced G-protein coupled receptor 2 (EBI2). EBI2 is present in the B 
cell follicle, but not the germinal center (GC) where the majority of B cell class 
switching and somatic hypermutation occurs. The high expression of CXCR5 and 
CXCR4, in combination with low surface expression of CCR7 and sphingosine 1-
phosphate 1 receptor (S1P1R) displayed by TFH allows them to migrate into the 
GC [229, 230]. Once in the GC, TFH provide B cell help through contact-
dependent co-stimulation and secretion of high levels of IL-21 and IL-6, which 
induce B cell maturation, proliferation, and class switching [208, 231-233]. TFH 
cells in mice have also been found to produce intermediate amounts of IL-4 
[234], and low amounts of IL-5, IFNγ, and IL-17 [235, 236]. The diverse cytokine 
profile of TFH is in part, due to the fact that differentiated TH1 [237], TH2 [238], 
TH17 [148], and possibly Treg [239], cells have the ability to convert to TFH. The 
differentiation of these cells is driven in the same manner as un-differentiated T 
cells, through repeat cognate interactions. These effector-TFH retain the 
expression of their lineage-associated cytokines in addition to TFH-associated 
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markers and are classified by their co-localization with B cells in the GC. Less 
evidence exists for the differentiation of Treg to TFH TFH-regulatory (TFR), and it has 
been speculated that these cells may arise from naïve precursors, or transition 
from TFH to TFR [239-241]. TFR regulate the GC reaction and play an important 
role in preventing excessive humoral responses which could lead to Ab-mediated 
autoimmune disease. Interestingly, CXCR4-expressing cells that otherwise 
resemble TFH in surface phenotype and function, have been detected outside of B 
cell follicles and can induce class switching in extrafollicular B cells [242]. The 
exact mechanisms that drive this phenotype have yet to be elucidated. 
 Due to the heterogenicity of the TFH pool, the Ig subclasses produced 
generally correlate with the effector-like phenotype of the TFH themselves (i.e. TH 
2-like TFH) [243]. Since their identification as a distinct subset of TH cells, TFH cells 
have been found to be crucial in GC formation and effective antibody-mediated 
protection [244]. Dysregulation of TFH function is a major cause of systemic Ab-
mediated autoimmunity such as SLE [245], and has been implicated in human 
diseases including myasthenia gravis (MG), autoimmune thyroiditis, Sjögren’s 
syndrome (SS), rheumatoid arthritis (RA), multiple sclerosis (MS), ulcerative 
colitis, Crohn's disease, ankylosing spondylitis (spinal arthritis), and type 1 
diabetes [245, 246]. 
 
 
Cytotoxic CD4+ (CD4+ CTL): MHCII-Restricted Killers 
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CD4+ CTL secrete granzyme B and perforin to kill infected cells in a similar 
fashion to CD8+ T cells [247, 248]. IL-2 is required for their differentiation through 
upregulation of the transcription factor EOMES which leads to IFNγ expression 
and perforin [249, 250]. It also appears that there is an inverse correlation 
between CD4+ CTL and TFH differentiation, as CD4+ CTL express high levels of 
Blimp-1, which inhibits Bcl-6 expression [251]. These cells are thought to be 
related to TH1 cells as they most often occur in viral infection models, express T-
bet, and secrete IFNγ [252]. Although they have also been found to develop from 
TH0 [253, 254], TH2 [255], TH17 [256], and Treg [257]. Class I-restricted T cell-
associated molecule (CRTAM) has been identified as a likely early marker for 
identification of CD4+ CTL [258]. The majority of CD4+ CTL are found in 
peripheral tissues, such as in the lung, but this is likely due, at least in part, to 
their increased presence in viral infection models of the lung. CD4+ CTL have 
been found to have a major role in late-onset EAE with implications for 
exacerbation of multiple sclerosis in humans [259]. It is also possible that these 
cells play a major role in the onset of colitis [257]. 
 
Regulatory T cells (Treg): Preventing Excessive, and Undesirable 
Immune Responses 
 
Regulatory T cells (Treg) function to suppress the activities of the other effector 
subsets and play a role in tolerance to non-self Ags [260, 261]. While nTreg exit 
the thymus pre-differentiated, inducible Treg (iTreg) are differentiated by a 
combination of TGF-β and IL-10. Treg express the transcription factor Foxp3 [262, 
263], and often display the surface marker CD25. Foxp3 acts as a transcriptional 
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regulator which suppresses the activation of T cells by inhibiting NFAT and NF-
κB [264]. Foxp3+ Treg regulate peripheral tolerance through multiple inhibitory 
mechanisms and are a critical component in preventing the activation of cells 
reactive to self or allergy-associated Ags, as well as limiting infection-induced 
organ pathology, fetal and transplant rejection, and graft versus host disease 
(GvHD) [265-271]. The immunosuppressive roles by Treg are carried out both in a 
contact-dependent manner and through secretion of inhibitory cytokines and 
other glycoproteins. Unlike conventional CD4+ effector cells, Treg constitutively 
express the inhibitory molecule CTLA-4 which binds costimulatory CD80 and 
CD86 on APC. CTLA-4 binds these ligands with a significantly higher affinity than 
CD28 and can inhibit the activation of conventional T cells via competitive ligation 
[272-274]. Interestingly, in addition to limiting conventional TH access to 
costimulatory molecules through the binding of CD80/CD86, Treg have been 
observed to physically remove CD80/CD86 from DC in a process which has 
been termed transendocytosis [275, 276]. While studies have proposed this 
acquisition resembles trogocytosis [277], transendocytosis by Treg differs slightly 
from trogocytosis [278, 279] in that acquired molecules are degraded within the 
Trreg rather than expressed on the surface as they are after trogocytosis [275, 
280-287]. In addition to the physical removal or engagement of CD80/86 from 
APC, ligation with CTLA-4 itself drives signaling through CD80/86 on the DC 
which lead to the nuclear translocation of Foxo3, which then inhibits the 
expression of IL-6 and TNFα [288]. It has also been observed that ligation with 
CTLA-4 induces production of the immunosuppressive tryptophan catabolizing 
41 
 
enzyme IDO by DC [289], which would further inhibit T cell activation. It has been 
speculated that the high expression of CD25 (IL-2Rα) by Treg may also act as a 
sink for IL-2, limiting the amount of IL-2 available to effector T cells and thus 
hampering their proliferation and activation  
 Treg can also directly influence the activation of conventional T cells by 
secreting the cytokines TGF-β, IL-10 and IL-35, as well as Granzyme-B, perforin, 
cAMP, Galectin, and Neutropilin. [290, 291]. In an immunosuppressive context, 
TGF-β inhibits T cell proliferation. While TGF-β + IL-6 can drive TH17 
differentiation [292]. Treg can limit TH17 differentiation through CTLA-4:CD80/86-
mediated downregulation of IL-6 by DC. IL-10 can inhibit TH1 and TH2 responses 
through activation of STAT3, while enhancing the differentiation of Treg in a 
positive-feedback loop [293]. The immunosuppresive cytokine IL-35 is produced 
almost exclusively by regulatory cells, and reduces the activation of naïve T cells, 
and inhibits proliferation in activated cells [290].  
Treg have been observed to release cyclic-AMP (cAMP) onto effector cells 
through gap-junctions between Treg and effector T cells [294]. Granzyme B and 
perforin secreted by Treg has been shown to kill effector T cells and activated B 
cells in vitro [295-297]. Treg have been found to generate high levels of the β -
galactoside–binding protein galectin-1 which is secreted as well as found on the 
surface membrane. Galectin-1 binds to surface glycoproteins on effector T cells, 
such as CD7, CD43, and CD45, leading to cell-cycle arrest, apoptosis, and the 
inhibition of inflammatory cytokines such as IL-2 and IFNγ [298-301]. 
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 Through the mechanisms mentioned above, Treg play a critical role in 
peripheral tolerance. Thus, excessive Treg responses may hamper an immune 
response leading to insufficient protection, and decrease anti-tumor immunity 
[266, 302, 303]. On the other hand, insufficient Treg presence can result in 
excessive immune responses associated with all TH subsets and therefore has 
been associated with numerous autoimmune diseases, allergy, and asthma [8, 
304-307]. 
In addition to conventional Treg, other regulatory T cell subsets that can 
conditionally express Foxp3 include Tr1 and TH3 cells. Tr1 secrete IL-10 and 
TGFβ which inhibit proinflammatory TH1 responses [308]. TH 3 cells share many 
similarities with conventional Treg, and Tr1 cells, but can also secrete IL-4 [309-
311]. Both Tr1 and TH3 cells are important for oral tolerance, as secreted TGFβ 
increases IgA production by B cells plays a large role in mucosal immunity [309, 
312]. Further contributing to Treg diversity is the ability for naive nTreg to 
differentiate into effector Treg (eTreg) in the context of the current immune 
response [313]. eTreg occurs concurrently with effector T cell activation, and by 
receiving similar stimuli from APC, eTreg differentiate similarly to T effector cells. 
This allows the eTreg to display similar homing patterns to the effector T cells, 
enhancing their ability to regulate the activation of effector T cells in the periphery 
[313, 314]. The multiple pathways for Treg development, and high diversity of 
regulatory mechanisms show the high diversity of the Treg pool and emphasizes 
the broad implications in Treg-mediated immunological tolerance and 
homeostasis.  
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Memory CD4+ T cells: Providing Long-Term Immunity 
Following Ag clearance, the vast majority of activated T cells die within days 
while ~ 5 -10% persist as long-lived memory cells, which maintain stable 
populations for years. Due to the ability of multiple CD4+ effector subsets to 
become memory cells, memory CD4+ T cells are comprised of a heterogenous 
population [315]. Therefore, memory cells are largely defined by the ability to 
survive for extended periods of time in absence of Ag [316], and exhibit rapid 
recall responses upon re-encountering their cognate Ag [39]. 
The exact mechanisms which drive activated CD4+ T cells to become 
memory remain unclear. Studies have found that T cells that receive weaker 
signals upon activation, along with late cognate interactions are more likely to 
become memory cells [317-320]. A proposed mechanism for the survival of 
previously activated CD4+ T cells is through the permanent upregulation of the 
IL-7 receptor alpha chain (CD127) [321-323].  IL-7 is secreted throughout the 
body by multiple cell types, including epithelial cells [324], stromal cells [325], 
skeletal muscle cells [326], and follicular DCs [327]. CD127 ligation signals 
through Jak3/1 - STAT5 promotes cell survival by inducing expression of the anti-
apoptotic genes Mcl-1 and Bcl-2 [328]. CD127 is highly expressed on naïve cells, 
but is downregulated on activated cells, facilitating their clearance during the 
contraction of the immune response. While the mechanisms which allow 
memory-fated cells to survive during the contraction phase are unknown, it has 
been suggested that autocrine IL-2/CD25 (IL-2Rα) signaling induced by TCR 
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signaling late in the immune response may be required, by driving constitutive 
CD127 (IL-7Rα) expression [317, 319].   
 A second path to becoming memory cells is through asymmetrical cell 
division, where one daughter cell becomes a memory-precursor or maintains a 
quiescent memory phenotype, and the other displays effector functionality [329-
331] (Fig. 1.9). Existing memory T cells have also been observed to 
asymmetrically divide upon restimulation to produce effector cell progeny and a 
daughter cell which retains memory-like capacity [331].  
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CD4+ Memory Subsets 
Memory CD4+ cells are categorized into various subsets based on their 
physiologic locations and recall responses. Variable expression of CD44 and 
CD62L was the basis for the initial characterization of two distinct CD4+ memory 
populations. Cells expressing both CD62L and CD44 are classified as T central 
memory (TCM), while CD44+ CD62L- are classified as T effector memory (TEM) 
[332]. Additional subsets of CD4+ memory cells have been identified in recent 
years, including Tissue-resident memory (TRM) T cells, and stem cell-like memory 
T cells (TSCM). These subsets are largely defined by their physiological location 
that is dictated by expression of the chemokine receptor CCR7, and CD62L (L 
selectin), (Fig. 1.9). The ligands for CCR7, CCL19 and CCL21, are highly 
expressed by stromal cells in T cell zones of the lymph node [333], mature DCs, 
and on the luminal side of HEVs [334, 335]. Thus, expression of CCR7 by naïve, 
and memory subsets allow these cells to exit the periphery and home to T 
cell/DC rich areas in the LNs. CD62L is a member of the selectin family of 
adhesion molecules. Expression of CD62L contributes to the tethering and rolling 
action of lymphocytes along luminal surfaces of venules through interactions with 
P-selectin glycoprotein ligand 1 (PSGL1) [336, 337]. Therefore, CD62L 
expression permits T cells to cross endothelial barriers and enter lymphoid 
organs from the periphery.  
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         Another marker commonly used to identify memory T cells is CD44. This 
surface protein is not expressed by naïve T cells but is upregulated following 
activation. Thus, expression of CD44 indicates that T cells have been previously 
activated. After contraction of cells during the effector phase, its presence can be 
used to identify Ag-experienced cells. The primary receptor for CD44 is 
hyaluronic acid (HA) which is a component of the extracellular matrix, and is also 
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expressed by some by endothelial cells [338-340]. It has been speculated that 
CD44 may aid in lymphocyte trafficking through the extracellular matrix, through 
HEV, and aid in the retention of T cells to luminal barriers. CD44 has been found 
to also act as costimulatory molecule [341-343].    
 
T central memory (TCM)  
TCM cells account for a large percentage of CD4+ memory cells and may arise 
from undifferentiated precursors, or from differentiated effector cells [344, 345]. 
TCM are identified by surface expression of both CD44+ and CD62L+, while also 
commonly expressing CCR7 [346]. The expression of CD62L and CCR7 allows 
these cells to circulate in blood, cross through high endothelial venules (HEVs), 
and traffic through lymphoid organs [332]. As a result, TCM are the primary CD4+ 
memory population found in lymphoid tissue and upon restimulation, rapidly 
produce IL-2 and proliferate to produce effector cell progeny, and can serve to 
stimulate Ag-presenting DCs to increase costimulatory molecule expression [332, 
347].  
 
T effector memory (TEM)  
TEM cells share a similar phenotype to activated effector cells and are thought to 
arise  primarily from effector cells which have transitioned to memory. This is 
supported through the observations that TEM show less plasticity between TH  
subset phenotypes compared to TCM [348]. As mentioned above, these cells 
express CD44, but not CD62L or CCR7. As a result, TEM continually scan 
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peripheral tissue and circulate in blood, and are able to rapidly migrate to sites of 
inflammation. Upon re-activation, TEM quickly exert effector functions, but do not 
rapidly proliferate compared to TCM. [332, 349, 350] However, there has been 
some debate whether TEM are simply effector cells that arise from TCM upon 
reactivation and subsequent proliferation. 
 
Tissue resident memory (TRM)  
During infection, activated CD4+ T cells migrate to peripheral tissue to induce 
local responses and clear pathogens. Among the memory cells that survive after 
Ag clearance include a subset of cells that take up residence in tissues such as 
the lung, small intestine, and skin [351-353]. Upon Ag-reencounter, localized TRM 
induce rapid localized inflammation to recruit other immune cells [354]. These 
cells are retained in peripheral tissue through constitutive expression of CD69 
[355], and many maintain expression of CD103. While CD69 is commonly used 
as an early activation marker, one of its biological roles is to suppress the 
function of sphingosine 1-phosphate receptor-1 (S1P1) [356]. As high 
concentrations of S1P are found in blood and lymph, CD69 expression prevents 
the egress of CD69+ cells into these fluids [357]. Different migration patterns 
have been observed between CD8+ and CD4+ TRM. While CD8+ migrate and 
localize at sites of infection, CD4+ cells were more mobile and continually 
scanned through skin [358]. One study using mice, as well as mice bearing 
human skin xenografts, found that human skin TRM were able to downregulate 
CD69 expression and enter circulation [353]. These cells then took up residency 
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in secondary skin sites where they resumed a TRM phenotype [353]. As such, TRM 
may not be as strictly compartmentalized as previously thought, and TRM that 
develop early may downregulate CD69 to become more evenly distributed 
throughout the body. Although the mechanism for TRM re-entry into circulation 
remains unknown, it is possible that this could also play a role in recruitment of 
TRM to sites of subsequent infection.  
 
T stem cell-like memory (TSCM) 
Human TSCM are identified by the surface expression pattern CD45RO−, CCR7+, 
CD45RA+ CD62L+, CD27+, CD28+ and IL-7Rα+  [359]. In mice, the surface 
phenotype of TSCM largely resembles that of a naïve T cell (CD62L+ CD44-). 
Similar to TCM, the expression of CD62L and CCR7 allows these cells to circulate 
in blood, cross through high endothelial venules (HEVs), and traffic through 
lymphoid organs. TSCM cells are Ag-specific, but retain sTEM cell-like properties in 
that they are able to undergo homeostatic proliferation and replenish the memory 
pool of Ag-specific cells of both TEM and TCM [359, 360]. Human TSCM have also 
been found to rapidly proliferate, to a greater extent than TCM or TEM  [359]. TSCM 
were produced upon Mycobacterium tuberculosis infection [361], however the 
exact mechanisms that drive TSCM differentiation have yet to be elucidated.  
 In all, the rapid recall responses of the various populations of memory 
CD4+ T cells provide long-lived Ag-specific immunity. This is accomplished by 
TCM in the LN rapidly proliferating to produce effector cells and stimulating the 
activation of other responding cells; TEM and TRM residing in surface and 
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peripheral organs to rapidly exert effector functions upon encountering Ag in the 
periphery; and TSCM performing homeostatic proliferation to replenish the memory 
pool.   
 
Part III 
                         Trogocytosis 
                 Trogocytosis, stemming from the Greek words trogo, or “to gnaw” and 
cyto meaning cells, is the direct, intercellular transfer of membrane and 
membrane-associated molecules in a contact-dependent manner. Trogocytosis 
occurs rapidly and between live cells, and therefore is not a simply a result of 
phagocytosis of apoptotic vesicles. In addition, unlike endocytosis of CD80/CD86 
by Treg where acquired molecules become degraded [275, 276], a defining feature 
of trogocytosis is that acquired molecules remain functional, and may become re-
expressed on the surface of the trogocytosis-positive (trog+) T cell. Images of a 
live-cell experiment showing trogocytosis by CD4+ T cells is shown in Fig. 1.11 
  The first report of trogocytosis came from the research of Cone, Sprent, 
and colleagues in 1972, where they detected donor B cell MHCII molecules on 
adoptively transferred T cells in mice [362]. They concluded that the MHC 
molecules were integrated into the T cell surface, and similar in composition to the 
membrane-bound form on B cells. While the mechanism was unknown at the 
time, mouse T cells do not endogenously express MHCII [363], thus these 
molecules were acquired from the host B cells. One year later, Bona et al were 
the first to detect the transfer of Ag from APC to lymphocytes using B cells that 
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acquired LPS from macrophages in a B cell receptor-dependent manner [364]. 
Several years later, Hudson and Sprent became the first to report the transfer of 
surface molecules between APC and T cells when they found B cell-derived IgM 
on the surface of activated T cells that had been transferred into irradiated 
allogenic (MHC-mismatched) mice [365]. This discovery provided an explanation 
for the earlier findings by Cone and Sprent, as well as other instances where 
signaling molecules were detected on cells in which they are not endogenously 
expressed (as determined by the absence of mRNA for these molecules). Shortly 
after two, separate groups observed MHC transferred to T cells in donor 
thymocytes cells from host splenic cells [366], and in cultures of proliferating T 
cells [367]. In the years since, this phenomenon has been observed in CD4+ [81, 
285, 287, 368-372], CD8+ [370, 373-376], and  [377] T cells, B cells [378, 379], 
NK cells [380-382], basophils [283], macrophages [383, 384], neutrophils [385-
387], dendritic cells [388, 389], and between tumor cells [390]. Despite the 
widespread occurrence and immunomodulatory potential of trogocytosis by 
immune cells, the biological impacts of trogocytosis remain largely unknown.  
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Mechanisms for Trogocytosis 
Contributions of T cell Signaling and Activation State on 
Trogocytosis 
 
Although significant work over the past decade has been conducted in 
deciphering the mechanism of T cell trogocytosis, the exact details of this event 
remain unknown. This is in part, due to multiple factors which appear to influence 
trogocytosis such as the activation state of the T cell  [391-396] and APC [383]; 
Ag-dose  [287, 373, 397] and affinity [397, 398]; and costimulatory molecule 
signaling  [394].  In contrast to B cells, Natural killer (NK) cells [399], and DCs that 
may passively perform trogocytosis [370, 400, 401], evidence suggests that active 
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signaling is required for T cell trogocytosis. We, and others, have previously 
shown that trogocytosis by CD4+ T cells occurs at the immunological synapse 
formed between Ag-specific CD4+ T cells and APC (Fig 1.11) [287, 392, 394, 397, 
402]. This is consistent with the vast majority of reports which have found Ag-
specificity to be a requirement for T cell trogocytosis [285, 287, 375, 399, 403]. In 
fact, the presence of trogocytosed molecules has been used as an identifying 
marker for tumor- [399, 403], and viral-, reactive cells [404]. In addition, this 
method has recently been described as a method to identify antigen-epitopes for 
specific T cells in vivo [399]. 
             The strength of TCR signaling by Ag-dose positively correlates with the 
trogocytosis [287, 373, 397]. The activation state of T cells impacts the efficiency 
in which cells perform trogocytosis, as activated T cell blasts perform trogocytosis 
to a greater extent than naïve T cells [391-396]. This could be due, in part, to the 
larger size of activated T cells compared to naïve cells, which have increased 
surface area contact with APC. It has also been hypothesized that increased 
avidity of the activated T cells due to their increased expression of adhesion and 
costimulatory molecules, such as CD28 and LFA-1, and CD44, stabilizes the 
immune synapse to facilitate trogocytosis [394, 405]. Costimulatory molecule 
ligation such as CD28:CD80/CD86 can also lead to acquisition of CD80 and 
CD86 [394], thus increasing the amount of total material trogocytosed by the T 
cell.  
Similar to the effect of adhesion molecules in stabilizing the immune 
synapse and promoting trogocytosis, T cell microvilli (as mentioned under 
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kinapses and microclusters) are also central factors in trogocytosis. These 
filamentous like protrusions concentrated with TCR form multiple contact points 
with APC and enhance signaling in both the T cell and APC [68]. In a recent 
study, Akkaya et al., found that microvilli stabilize T:APC interactions and 
correlate with the acquisition of MHCII by the T cell [66]. iTreg had the highest level 
of microvilli, formed the most stable contacts, and showed the highest acquisition 
of MHCII, compared to activated effector T cells which had higher levels of 
microvilli compared to naïve t cells (Fig. 1.12). They also found that microvilli 
acquired MHCII with cognate, but not irrelevant peptide, suggesting that the 
acquisition of MHCII occurred in an Ag-specific manner.  
 
Further insight into the mechanism of trogocytosis comes from studies 
showing that treatment of cells with latrunculin or cytochalasin D to inhibit actin 
polymerization severely limited trogocytosis [370, 405]. Blocking proximal TCR 
signaling through ZAP-70 has also been found to significantly reduce the rate of 
trogocytosis [373]. Intriguingly, trogocytosis of CD80 and CD86 may occur 
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independently of CTLA-4, or CD28-signaling in Treg [277]. Studies with 
conventional effector cells found that antibody blockade of CD80 had minimal on 
trogocytosis of GFP-tagged MHCII, while blocking MHCII or CD3 significantly 
reduced the amount of trogocytosed MHCII [287]. 
Collectively, the above data suggests that trogocytosis is an active 
process in T cells that occurs predominantly in an Ag-specific manner and 
requires stable-T cell:APC interactions.  
 
Proposed Physical Mechanisms of Trogocytosis 
The possibility that more than one pathway exists for the acquisition of APC 
molecules by T cells has contributed to the elusiveness in defining the underlying 
mechanisms. While it is understood that trogocytosis requires stable, cognate 
interactions and trogocytosed molecules may be re-expressed on the T cell 
surface, the pathways leading to this end-result may differ. For example, CD8+ 
CTL have been observed to acquire membrane and associated proteins from 
target cells through small regions of fused membrane termed membrane bridges 
(Fig. 1.13A) [406]. These membrane bridges are distinct from the significantly 
longer nanotubules formed between T cell and APC (Fig. 1.13B) that are thought 
to extend cell communication [407].   
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However, the presence of T cell:APC membrane bridges in CD4+ T cells has not 
been reported. Live-cell imaging data from Wetzel et al., showed that GFP-
tagged MHCII was removed from APC during spontaneous dissociation from the 
immune synapse [287] (Fig. 1.11). As the immune synapse is comprised of a 
multitude of ligated molecules, the strength of these interactions is greater than 
the integrity of the APC membrane. Spontaneous dissociation during the 
immunological synapse results in the stripping of APC molecules by the 
migrating T cell.  
                Multiple proposed models for trogocytosis suggest that APC-derived 
molecules become internalized by the T cell through endocytosis. These models 
diverge from one another in how the APC molecules arrive on the surface of T 
cell. In one theory, APC-derived exosomes containing various molecules are 
taken up by the T cells and then re-expressed on the surface [408]. It has been 
observed that strong MHCII:TCR interactions leads to the migration of late 
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endosomal compartments containing MHCII towards the immunological synapse, 
thus TCR signaling may increase the release of APC exosomes directed towards 
the T cell [409]. In a separate study, electron microscopy revealed that MHCII 
was transferred to T cells in T cell:DC conjugates via exosomes which were 
concentrated at the immunological synapse [408]. Here, the authors proposed 
that the exosomes were endocytosed by the T cell during TCR recycling, then 
were re-expressed on the T cell. Similar results were observed by Huang et al., 
in a model using Drosophila APC transfected with mouse MHC and costimulatory 
molecules, where they observed small packets containing MHCII localized 
between T:DC synapses [397]. The authors in this study observed that acquired 
MHCII were co-internalized with recycling TCR and were found to be present in 
both endosomes and lysosomes. Thus, they concluded that TCR-endocytosis 
was driving the internalization and subsequent acquisition of APC-derived 
signaling molecules [397]. However, results from numerous studies suggest that 
the acquisition of APC-derived molecules via exosomes is distinct from 
trogocytosis. For example, the transfer of PD-L1 and MHC is blocked when co-
cultured T cells and APC are separated by a trans-well membrane [375, 410]. In 
addition, blocking exosome formation by DC with the ATPase inhibitor CMA was 
found to only slightly decrease the amount of trogocytosed material compared to 
untreated controls [375].  
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     The most recent model for trogocytosis comes from studies by Martinez-
Martin et al., proposing that APC-derived membrane and membrane proteins 
are internalized in tandem during TCR downmodulation. Consistent with much 
of the published research, this model proposes that T cell trogocytosis is an 
active event occurring in a TC21/RhoG dependent manner. Once internalized by 
the T cell, recycling endosomes containing acquired APC fragments fuse with 
the T cell plasma membrane resulting in APC-derived molecules being 
displayed on the T cell surface in their native topological orientation (Fig. 1.14, 
above) [278, 411] This model is consistent with the majority of published data 
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including results of Sprent and colleagues that found trogocytosed GFP-tagged 
MHCI is internalized by CD8+ T cells before surface re-expression [397]. Finally, 
pre-treatment of T cells with the vacuolar ATPase CMA to inhibit endosomal 
formation and trafficking led to a significant decrease in trogocytosis [375], 
strengthening a model for endocytosis-dependent trogocytosis.   
                 Our live-cell imaging experiments also show that GFP-labeled p:MHC 
found on the surface of the T cell moves from the immunological synapse and 
localizes at the distal pole region (Fig. 1.15). We also observed that in fixed 
T:APC conjugates, >82% of T cells with detectable trogocytosed molecules had 
p:MHCII localized to the distal pole [81]. Similar distal pole localization of 
trogocytosed MHCI was reported by Huang et al., using CD8+ T cells and 
Drosophila APC [397]. Regardless of the mechanisms in which the molecules are 
acquired from APC, true trogocytosis results in the expression, or re-expression, 
of the acquired molecules on the T cell surface. 
 
Biological Consequences of T cell Trogocytosis 
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While the intracellular exchange of proteins is common among various cell types, 
the outcome of trogocytosis has distinct biological implications in that; 1. the 
molecules acquired may be involved in active signaling; and 2. these signaling 
molecules become re-expressed in the native topological orientation on the 
surface of recipient cell. As mentioned above, molecules trogocytosed from APC 
by T cells include molecules that can trigger active signaling within the T cells 
including pMHCI/MHCII complexes [66, 81, 282, 285, 287, 376, 399, 412], 
CD80/CD86 [277, 281, 282, 284], OX40-L [368], and PDL-1 [375], as well as 
adhesion molecules such as ICAM-1 [400]. Due to the nature, and accessibility of 
these trogocytosed molecules, this event has numerous biological implications. 
Elevated levels of trogocytosis have been documented in sites of autoimmune 
inflammation [391], viral and parasitic infections [282, 413, 414], rheumatoid 
arthritis [11], and in tumor environments [284, 403]. While the function of 
trogocytosis in these cases is not yet established, this widely-observed event has 
been proposed to play a role in the modulation of immune responses [277, 388, 
415-419].  
 
Antigen Presentation by Trog+ T cells 
The potential for trog+ cells to act as APC themselves has inspired significant 
research focused on the ability of the trogocytosis-positive (trog+) T cells to 
present antigen, in the context of other acquired molecules, to responding T cells 
[369, 371, 372, 415, 420-426]. The outcome of such presentation appears to 
correlate with the nature of the acquired molecules and phenotype of the trog+ 
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cell. For example, trog+ CD4+ cells displaying acquired costimulatory molecules 
such as CD80, along with MHC:peptide can activate responding naïve T cells 
both in vitro, and in vivo [371, 410, 420, 424]. One such example comes from the 
work of Zhou et al., who found that FACS-sorted hemagglutinin (HA)-specific 
trog+ T cells induced proliferation of naïve HA-specific T cells in vitro [406]. 
Through bystander acquisition of MHCI from DC, OVA-specific trog+ CD4+ T cells 
have been found to activate naïve CD8+ T cells both in vitro, and in vivo after 
adoptive transfer of trog+ cells [421]. In a study using human T cells, Game et al. 
showed that in an allogenic response, trog+ cells can stimulate both naïve and 
allogenic and autologous T cells to proliferate [410]. The antibody blockade of 
CD80/86 limited these responses, suggesting that, similar to Ag-specific 
responses, the presence of allogenic MHC alone on T cells is insufficient to 
induce a response in other allogenic T cells.  
 A separate study compared the effects of trogocytosed CD80 in both an 
allogenic and Ag-specific response. Similar to the results above, they found that 
the trog+ cells could induce activation of other cells in both types of responses. 
However, the trog+ cells only were shown to have significant effects on 
stimulating naive T cells in the first 48 hours of their activation [427]. In the case 
of allogenic responses they proposed that T cells expressing CD80 could act to 
as a mechanism to boost the costimulatory presence for responding naïve T 
cells. Interestingly they also noticed a difference in the chemokine receptor 
pattern between allogenic and Ag-specific responses. T cells that performed 
antigen-independent acquisition of CD80 retained expression of CCR7 and low 
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levels of CCR5, thus were more likely to remain in the T cell zones of the lymph 
node after activation. On the other hand, CD80+ cells which were stimulated with 
cognate Ag-presenting DCs downregulated CCR7 and increased expression of 
CCR5, thus, they would be more likely to exit the lymph node and act on 
peripheral sites to modulate the response of peripheral T cells. Finally, it was 
observed in samples from human donors with either malignant ascites or 
autoimmune thyroiditis, circulating T cells had increased levels of CD86 
compared to healthy controls, suggesting that these cells may play a role in 
augmenting these autoimmune disorders [428]. 
While T:T Ag-presentation has been shown to augment an immune 
response, numerous studies have also found it may play a role in suppressing 
the immune function of other cells. In an in vivo study,  Helft et al., found that Ag 
presentation by trog+ cells to activated T cells induced responder cell death, but it 
stimulated naïve T cells to proliferate. The authors proposed that this was likely 
due to insufficient levels of costimulatory molecules upon p:MHC presentation by 
trog+ cells [429]. The authors speculated that T cell Ag-presentation may play a 
role in preventing peripheral memory, but not naïve T cells, from entering 
activated lymph nodes by interacting with T cells in the periphery.  
Attenuation of the immune response via presentation of trogocytosed 
molecules to T cells has also been observed in T cells from donors with multiple 
myeloma. In vitro incubation of patient cells with myeloma cell lines led to 
trogocytosis of CD86 and the immunosuppressive molecule HLA-G by T cells 
[284]. These HLA-G+ trog+ cells were functionally comparable to nTreg in 
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proliferation of trog- cells. In samples directly from patients, a significantly higher 
frequency of circulating T cells had detectable HLA-G and CD86 compared to 
healthy controls, and the increase in the frequency of these trog+ cells was 
associated with poor prognosis [284]. 
            In addition to conferring regulatory functions to non-Treg cells [277, 375, 
415, 417, 430-432], Treg themselves display high-rates of Ag-specific trogocytosis 
[66]. CD80 and CD86 have been detected on the surface of both nTreg and iTreg  
[277], and has been proposed that these trog+ Treg use trogocytosed molecules to 
form connections with activated T cells, thus enhancing their suppressive 
[431,432].  
               Trogocytosis itself also has been found to suppress the immune 
response in a manner similar to Treg, where pMHC complexes and costimulatory 
molecules are removed via trogocytosis rendering APC inefficient stimulators of 
other responding T cells, or inhibiting the detection and killing of tumor cells [284, 
433-436]    
                     Another means of immune suppression is the killing of Ag-
presenting T cells by CTL through fratricide. This phenomenon is most widely-
associated with viral infection, but CD8+ T cells with trogocytosed PD-L1 can 
induce fratricide of neighboring T cells expressing PD-1. In addition, trog+ 
themselves may be targeted by cytotoxic cells through displaying trogocytosed 
pMHC [434]. 
        Collectively, the studies described underscore the biological significance of 
trogocytosis and subsequent Ag presentation by trog+ T cells  
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Trogocytosis-Mediated Signaling 
                  While the ability of trog+ T cells to present trogocytosed molecules to 
other T cells has been fairly well-documented, much less is known about the 
biological consequences of trogocytosis on an individual trog+ cell. Trogocytosed 
molecules are retained in punctate areas on the CD4+ T cell surface and co-
localize with their receptors and signaling molecules [81, 287]. This raises the 
possibility that trogocytosed molecules may drive intracellular signaling within the 
T cell. It has been observed that trog+ cells are more activated compared to their 
trog- counterparts, as indicated by expression of CD44, CD69, and/or CD25  
[277, 417, 420, 422, 432, 437, 438], and, in some cases, express higher levels of 
effector cytokines compared to similarly-stimulated trog- cells [81, 282, 412, 439]. 
One possible explanation for these observations is that highly activated cells are 
more efficient at performing trogocytosis. Another possibility is that the 
trogocytosed molecules induce intracellular signaling and are playing a role in 
augmenting the activation state and effector functions of the trog+ cells.  
 In our previous studies, TCR signaling was detected in trog+, but not  
trog–, CD4+ T cells up to 72 hours after separation from APC. This sustained 
signaling was mediated by trogocytosed molecules engaging their cognate 
receptors on the trog+ T cell, resulting in autopresentation, referred to here as 
trogocytosis-mediated signaling. This signaling led to the enhanced survival of 
trog+ cells compared to trog– cells, up to five days after APC removal [81]. This 
was not due to residual signaling from the T-APC interaction, as treatment with 
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the Src-family kinase inhibitor PP2 was used to halt signaling after APC removal. 
Signaling, as measured by ZAP-70 and ERK 1/2 phosphorylation resumed only 
in trog+ cells. Consistent with these findings, Zhou et al. found that trog+ CD4+ T 
cells displayed sustained activation of NFB and AP1, 24 hours after removal 
from APC. Interestingly, the trog+ cells also developed a unique cytokine profile 
[439]. This suggests that a qualitative difference may exist between trogocytosis-
mediated signaling and signals received from APC, raising the possibility that this 
non-canonical signaling has the potential to modulate the immune response.  
Trogocytosis-mediated signaling, by altering the activation state, survival, 
and effector cytokine production has the potential to significantly impact the 
physiology and subset differentiation of the trog+ cell, and by extension, an 
immune response. This paradigm-shifting event may play a significant role in the 
generation and control of protective immune responses, cancer immunotherapy, 
and vaccine efficacy. However, we have a very limited knowledge of 
trogocytosis-mediated signaling, and more work is necessary to improve our 
understanding of this underappreciated phenomenon and the role it plays in 
modulating the immune response.  
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Rationale for the Current Study 
 
While the ability of CD4+ T cells to differentiate into specific subsets with 
specialized roles is a defining feature of the adaptive immune response, the 
mechanisms behind their differentiation are not fully understood. While canonical 
T cell activation is dependent on APC, trog+ CD4+ cells can sustain active TCR 
signaling through engaging trogocytosed molecules with their surface receptors 
(trogocytosis-meidated signaling) [81]. This signaling was observed up to 72 hrs 
after APC removal, and despite being similarly activated by APC, the trog+ cells 
displayed enhanced survival compared to trog- cells in the absence of exogenous 
stimulation [81]. These findings strongly suggest that trogocytosis-mediated 
signaling in the trog+ T cells can modulate their survival. 
The overall objective of this study was to determine the biological effects 
of trogocytosis-mediated signaling on CD4+ T cell activation, effector cytokine 
production, and differentiation. Due to the demonstrated ability for trog+ cells to 
retain active signaling and maintain a heightened state of activation, I 
hypothesized that trogocytosis-mediated signaling would drive sustained 
effector cytokine production and influence the differentiation of the 
recipient trog+ cell.  
This was examined through the following three aims: 
Aim 1. Determine the activation state, effector cytokine production, and TH -
subset differentiation of trog+ and trog- cells after APC removal, and the 
contribution of trogocytosis-mediated signaling to the observed phenotype 
Rationale and supporting data: Sustained T cell signaling is not only required for 
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effector T cell and survival, but also mediates T cell activation state and effector 
cytokine production. In addition, trog+ cells display higher levels of activation and 
increased effector functionality in vitro and in vivo. Whether trogocytosis is a 
result, plays a causative role in these phenotypes has yet to be determined.  
               Because variations in signaling events, including the frequency, and 
duration, of TCR signaling, can significantly impact the differentiation of CD4+ 
cells [82, 139-143], it is plausible that sustained trogocytosis-mediated signaling 
may also impact these aspects in the trog+ cell.  
 
Aim 2. Ascertain the impacts of trogocytosis-mediated signaling in the 
differentiation of trog+ CD4+ T cells towards TFH  
Rationale and supporting data. 
While events during initial T cell activation are sufficient to drive CD4+ cells to 
differentiate into common effector subsets including TH1, TH2, and TH17, the 
differentiation of T follicular helper (TFH) requires prolonged, and/or repeated 
TCR and costimulatory signaling [142, 143]. Multiple studies have suggested that 
following T cell activation, subsequent interactions with B cells presenting 
cognate Ag are required for full TFH-differentiation, [209, 221-224]. However, 
signaling from DC in absence of B cells is capable of driving TFH differentiation 
[213]. Thus, the key factor in TFH differentiation is likely sustained T cell signaling, 
and not a signal uniquely attained through B cell interactions. It is possible that 
sustained trogocytosis-mediated signaling may promote TFH differentiation after 
separation from APC. 
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Aim 3. Determine the impact of trogocytosis-mediated signaling in the 
generation of memory-precursor CD4+ T cells.   
Rationale and supporting data: Though the exact requirements for driving CD4+ T 
cells to become long-lived memory cells are unknown, sustained and/or repeated 
TCR and costimulatory signaling from APC promote CD4+ transition to memory. 
It is possible that by emulating T:APC interactions, trogocytosis-mediated 
signaling may satisfy signaling requirements to transition into memory cells. One 
of the defining criteria for memory cells is the ability to survive in the absence of 
Ag. We previously found that sustained trogocytosis-mediated signaling leads to 
enhanced survival of trog+ cells compared to trog- cells after APC removal, 
suggesting that such signaling could play a role in the survival of 
memory/memory-precursor cells. 
            Results from aim 1 showed that trog+, but not trog- cells produced IL-4 
and IL-21, both of which have been shown to aid in CD4+ survival. In addition, IL-
21 has also been found to be critical for CD4+ and CD8+ memory cell generation 
[440]. Therefore, it is possible that autocrine signaling through IL-4 and IL-21 
produced by the trog+ cells would enhance their survival, as well as promote 
transition to memory. 
            In addition to effector-to-memory transition, T cells may be fated to 
become memory cells during initial T cell activation and subsequent asymmetric 
division. In our previous study, during T:APC synapses, it was found that over 
83% of these cells had trogocytosed molecules at the distal pole, and these 
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molecules were driving TCR signaling. Thus, it is possible that the commonly 
observed TCR signaling at the distal pole is due to TCR engagement with 
trogocytosed pMHC complexes. If trog+ cells undergo asymmetric division and 
trogocytosed molecules are retained on the distal daughter cell, this would 
implicate that trogocytosis-mediated signaling may play a role in the survival of 
memory cells that are generated through asymmetric division.  
 
These aims were addressed primarily using our well-established standard in-vitro 
trogocytosis-assay using fibroblast cell line and peptide-loaded mouse BMDC 
cells as APC. Briefly, naïve or non-polarized resting CD4+ T Cell blasts were 
incubated with fibroblasts which constitutively express covalently-attached MCC 
to the I-Ek -chain, or MCC-loaded BMDC, for 90’ at 37 oC. T cells are removed 
from APC from T cell cultures and are analyzed immediately, or cultured at low 
density to limit potential T:T interactions. In addition, in vivo experiments were 
conducted using MCC-specific TCR-transgenic mice, and wild-type (WT) mouse 
models. These experiments involved immunization of whole protein to examine 
the phenotype of cells which have performed in vivo trogocytosis. Studies on 
memory T cell survival included the adoptive transfer of CD4+ T cells recovered 
from an in vitro trogocytosis assay into naïve animals. Full details of these 
experiments are described in the materials and methods section.  
Results from this study provide insight into both, the biological 
consequences of trogocytosis, as well as the mechanisms behind CD4+ 
activation and differentiation. Due to the common occurrence of trogocytosis by 
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CD4+ T cells upon activation, and the central role of CD4+ T cells in immune 
responses, these findings are of significance in advancing our current knowledge 
of basic cell biology while also providing insight into better understanding the 
pathology of infectious and autoimmune diseases, allergies, along with future 
drug or vaccine design. 
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Chapter 2 
 Materials and Methods 
  
Animals 
B10.A and C57BL/6 CD45.1 mice were purchased from The Jackson Laboratory 
(Sacramento, CA). 5C.C7 TCR (V3+) transgenic Rag-1-/- mice specific for pigeon 
cytochrome c fragment 88–104 and reactive against moth cytochrome c (MCC) 
fragment 88–103 [441] were purchased from Taconic (Rensselaer, NY). For 
some experiments, 5C.C7 mice were crossed with B10.A mice and the 
splenocytes from F1 generation animals were used. Both male and female mice 
were used in this study, and no differences were observed between male and 
female T cell phenotypes. Mice were housed in the University of Montana 
Laboratory Animal Resources facility and were allowed food and water ad 
libitum. All procedures were supervised and in accordance with the University of 
Montana Institutional Animal Care and Use Committee. 
  
Antibodies and Reagents  
The following conjugated or unconjugated antibodies were purchased from: 
Biolegend (San Diego, CA): anti-CD3 (145-2C11), anti-CD4 (RM4-5), anti-CD69 
(H1.2F3), anti-CD80 (16-10A1), anti-Foxp3 (150D), anti-I-Ek (17-3-3), anti-IA/IE 
(M5/114.15.2), anti-IFN (XMG1.2), anti-IL-2 (JES6-5H4), anti-IL-4 (11B11), anti-
IL-6 (MP5-20F3), anti-IL-9 (RM9A4), anti-IL-17A (TC11-18H10.1), anti-IL-21 
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(FFA21), anti-Bcl-6 (IG19E/A8), anti-T-bet (4B10), anti-PD-1 (29F.A12), anti-
CCR7 (4B12), anti-Ki-67 (16A8), anti-CD25 (3C7) anti-CD62L (MEL-14), anti-
CD127 (A7R34), anti-ICOS-L (HK.53),  anti-CD44 (IM7), anti-GATA-3 
(16E10A23), Streptavidin (PE-Dazzle594). Conjugated or unconjugated 
antibodies were also purchased from BD Biosciences (Franklin Lakes, NJ): anti-
pZAP-70 (17A/P-ZAP-70), anti-V3 (KJ25), anti-IL-12 (C15.6), anti-CD80 (16-
10A1), anti-CD86 (GL1), anti-CD90.2 (30-H12)], and eBiosciences (San Diego, 
CA): anti-IL-5 (TRFK5), anti-IL-10 (JES5-16E3), anti-RORt (AFKJS-9), anti-
Tcf1/Tcf7 (S33-966). AlexaFluor 488- and AlexaFluor 647-conjugated 
Streptavidin were purchased from Jackson ImmunoResearch Laboratories (West 
Grove, PA).  
 
Whole pigeon cytochrome c (PCC) and Ovalbumin (Ova) proteins were obtained 
from Sigma-Aldrich (St. Louis, MO) and moth cytochrome C fragment 88-103 
(MCC88-103) peptide was obtained from Genscript (Piscataway, NJ). Peptides 
were dissolved in sterile nano-pure water at 500 µM and aliquots were stored at -
80 °C until used.  
 
Culture Media 
Fibroblast APC were cultured in DMEM (Life Technologies, Carlsbad, CA) 
supplemented with 10% FBS (Atlanta Biologicals, Atlanta, GA), 1 mM L-
glutamine, 100 mg/ml sodium pyruvate, 50 mM 2-ME, essential and nonessential 
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amino acids (Life Technologies), 100 U/ml penicillin G, 100 U/ml streptomycin, 
and 50 mg/ml gentamicin (Sigma-Aldrich). 
 
Primary splenocytes, T lymphocytes, and bone marrow-derived dendritic cells 
(BMDC) were maintained in complete RPMI which consisted of RPMI 1640 
medium (Life Technologies) supplemented with 10% FBS (Atlanta Biologicals, 
Flowery Branch, GA), 1 mM L-glutamine, 100 mg/ml sodium pyruvate, 50 mM 2-
ME, essential and nonessential amino acids (Life Technologies), 100 U/ml 
penicillin G, 100 U/ml streptomycin, and 50 mg/ml gentamicin (Sigma-Aldrich).  
 
Antigen Presenting Cells           
In in vitro trogocytosis experiments, peptide-pulsed B10.A BMDC or the 
previously described MCC:FKBP cell line [287] were used as APC. The 
MCC:FKBP is a CD80high Ltk– fibroblast cell line that has been transfected with 
ICAM-1, I-Ek α-chain, and an I-Ek -chain with covalently attached antigenic 
MCC88–103 peptide via a flexible linker, and a cytoplasmic tail containing 3 copies 
of FK506-binding protein (Ariad Pharmaceuticals, Cambridge, MA). This cell line 
expresses levels of CD80 and ICAM-1 comparable to B10.BR splenocyte APC 
[287].  
 
Surface-Labeling of APC 
MCC:FKBP APC or BMDC APC cells were surface biotinylated using EZ-Link 
Sulfo-NHS-Biotin (Thermo Scientific, Waltham, MA), or in some cases surface 
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labeled with BODIPY™ FL NHS Ester (Succinimidyl Ester) conjugated to 
AlexaFluor 647 (ThermoFisher), in PBS pH 8.0 for 20 min at RT. Following 
surface labeling, excess biotin or BODIPY dye was quenched with 15x volume of 
PBS pH 7.4 containing 100mM glycine, followed by an additional 3 washes with 
PBS + 100 mM glycine. Cells were then resuspended in cRPMI prior to counting 
and plating for use in the trogocytosis assay.   
 
Generation of BMDCs 
Bone marrow cells were isolated from femurs and tibiae of B10.A mice and 
cultured for 6 days in sterile non-tissue culture grade petri dishes at 105 cells/ml 
in complete RPMI medium containing 30 ng/ml recombinant murine granulocyte 
macrophage-colony stimulating factor (GM-CSF) (PeproTech, Rocky Hill, NJ) at 
37 °C and 5% CO2. Fresh culture media and GM-CSF were added on day 3, and 
non-adherent cells were harvested on day 6. Cells were activated by plating on 
tissue culture-coated 6-well plates with addition of Sigma adjuvant sysTEM at 125 
ng/ml 18 hours prior to use. Adherent cells were surface biotinylated and 
exogenously loaded with MCC88–103 peptide at a final concentration of 2.5 µM for 
2 hours prior to use. Purity was verified via flow cytometry to be >90% CD11c+.    
 
In vitro T cell priming       
Non-polarized TCR-transgenic CD4+ T cell blasts were generated in vitro to 
increase the potential for trogocytosis relative to naïve CD4+ T cells [392]. Single-
cell suspensions of splenocytes from 6- to 12-week-old 5C.C7 or 5C.C7 x B10.A 
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F1 transgenic mice were depleted of erythrocytes by hypotonic lysis using Gey’s 
balanced salt solution (155 mM NH4Cl, 10mM KHCO3) and resuspended in 
complete RPMI 1640. Splenocytes from 5C.C7 x B10.A F1 mice were activated 
in vitro for 6 days by addition of 2.5 µM MCC88–103 peptide to splenic cell 
suspensions. 5C.C7 splenocytes were stimulated for 48 hours on pre-coated 
anti-CD3 (1 µg/ml) and anti-CD28 (1 µg/ml) plates followed by a 2-day incubation 
after removal from antibody-coated plates prior to use. Viable lymphocytes were 
isolated from priming cultures by density centrifugation using Lympholyte M 
(Cedarlane Labs, Burlington, NC). When culturing B10.A x 5C.C7 F1 or C57BL/6 
cells, B cells were depleted from cultures by incubating cells for 30 min with 
biotin-labeled anti-B220 (BioLegend), followed by 3 washes in PBS. Cells were 
then incubated for 20 min with 3.75 µm streptavidin-coated magnetic particles 
(Spherotech) followed by removal of B220+ cells by magnetic separation.  
Cultures of cells from peptide T cell blast cultures were 90-95% CD4+ 
immediately prior to use in the trogocytosis-assay.   
 
In vitro TH1 and TH2 polarization to induce TH1 or TH2 effector subset 
differentiation 
 Primary T cells were stimulated directly ex vivo on anti-CD3 (1 µg/ml) and anti-
CD28 (1 µg/ml) coated plates, as described above, with either TH1 (5 ng/ml IL-12 
and 20 µg/ml anti-IL-4 (11B11), or TH2 (10 ng/ml rmIL-4 and 20 µg/ml anti-IFN) 
differentiation cocktails [83]. On day 2, 5 U/ml rmIL-2 was added to all cultures. 
The exogenous cytokines were obtained from Peprotech, (Rocky Hill, NJ) and 
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neutralizing antibodies were purchased from Biolegend. Cells were removed 
from Ab-coated plates on day 4. Polarization was confirmed through flow 
cytometry analysis of transcription factor and cytokine staining for GATA-3, T-
Bet, IL-4 and IFN. Immediately prior to use in the trogocytosis assay, >95% of 
CD4+ blasts generated under TH1-polarizing conditions were T-bet+, and >60% of 
CD4+ blasts generated under TH2-polarizing conditions were GATA-3+.  
      
Standard in vitro trogocytosis assay 
To assess trogocytosis by the CD4+ 5C.C7 T cells, we used our previously 
described standard in vitro trogocytosis assay ([81] Fig. S3.1A). Briefly, 0.5 x 106  
surface biotinylated or BODIPY labeled MCC:FKBP fibroblast or 1 x 106  similarly 
labeled BMDC  APC were plated into individual wells of a 6-well tissue culture 
plate (Greiner, Monroe, NC) and incubated overnight at 37 °C. The MCC:FKBP 
cell line doubling time is approximately 12 hours, so following the overnight 
incubation wells contained 106 APC at the time T cells were added. To facilitate 
magnetic depletion of APC from recovered T cells, iron-containing polystyrene 
2.22 µm beads (Spherotech, Green Oaks, IL) were added to the overnight 
cultures at a final concentration of 0.01% w/v. Twelve to 18 hours later, free 
magnetic beads were removed from cultures by rinsing, and 2.5 x 106 in vitro-
primed T cells, (for a final 2.5:1 T:APC ratio), were added to each well and 
subsequently incubated for 90 min at 37 °C. For experiments using naïve CD4+ T 
cells, B220 negative selection was performed as described in in vitro T cell 
priming, and the same 2.5:1 T:APC ratio was used, but T cells were incubated 
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with APC for 18 h at 37 °C. After the co-incubation, T cells were recovered from 
the cultures by rinsing with cold PBS pH 7.4. Greater than 95% of residual APC 
were removed by magnetic separation and greater than 70% of the input T cells 
were routinely recovered from the culture at 90 min after the PBS wash. After two 
additional PBS washes, recovered T cells (containing both trog+ and trog– cells) 
were analyzed immediately by flow cytometry, or were resuspended in complete 
RPMI 1640 medium at low density (104 /ml) to minimize T:T contact, and cultured 
for 60 min in 6-well plates or petri dishes to allow for residual APC to settle and 
bind to the surface of the 6-well plate. Cells were then gently aspirated and 
placed into unused 6-well plates with 2 mL/well at 104 cells/ml additional time 
periods. These cultures of recovered cells contained >95% CD4+ cells, and 
<0.1% residual APC (Fig. S3.1B). 
 
Inhibition of TCR Signaling 
To confirm the role of trogocytosis-mediated signaling in effector function, TCR 
signaling was extinguished using the reversible Src family tyrosine kinase 
inhibitor PP2 (Life Technologies), as previously reported [81, 442]. Immediately 
post-trogocytosis assay, recovered T cells were incubated for 20 min in 20 µ 
PP2, followed by three washes in PBS to remove the PP2. Cells were then 
assessed immediately to confirm the treatment halted all TCR-signaling, or were 
cultured as described above and assessed for TCR-downmodulation, 
transcription factor, and intracellular cytokine expression via flow cytometry.   
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CFSE / CellTrace Violet Labeling of T cells 
Primary mouse splenocytes were washed twice with CFSE loading buffer ( 0.1% 
FBS in PBS pH 7.4). Cells were then resuspended at 107 cells/ml in pre-warmed 
CFSE loading buffer containing 5 µM CFSE (Sigma-Aldrich), or 5 µM CellTrace 
Violet (ThermoFisher) and incubated at 37 °C for 10 minutes. The reaction was 
stopped by addition of an equal volume of complete RPMI 1640 medium 
containing 10% FBS, followed by two additional washes in complete RPMI. 
 
In vivo Trogocytosis Experiments 
In adoptive transfer experiments, B10.A mice were immunized via subcutaneous 
injection (s.c.) (base of tail) with either 300 µg pigeon cytochrome c (PCC) 
protein (Sigma-Aldrich) in 100 µl of Sigma Adjuvant System (SAS) or with 100 µl 
of PBS as a negative control. 24 hours later, 2 x 106 CFSE labeled 5C.C7 
primary splenocytes in PBS were injected i.v.  Draining inguinal lymph nodes 
were collected five days post-adoptive transfer and analyzed using flow 
cytometry. Donor 5C.C7 cells were identified as being V3+ and CFSE+. Of these 
transferred donor cells, trog+ cells were identified as CD3+ CD4+ CD80+ I-Ek+ (Fig. 
S.31D). 
 
To generate in vivo trog+ cells in a non-transgenic setting, C57Bl/6 CD45.1 mice 
were subcutaneously immunized at the base of tail with 300 µg of chicken egg 
white albumin (OVA) (Sigma-Aldrich) in 100 µl SAS, or 100 µl SAS alone as a 
control. 14 days later, OVA-immunized mice were boosted s.c. with 300 µg OVA 
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in 100 µl of PBS, control mice were injected with 100 µl PBS alone. Five days 
post-boost, draining inguinal lymph nodes and spleens were harvested and 
analyzed via flow cytometry. Trog+ cells were identified as CD3+ CD4+ CD80/86+ I-
A/E+ (Fig. S3.5). To confine analysis of cytokine and transcription factor 
expression to cells with similar activation states, CD4+ CD69High cells were gated 
on prior to identification of trog+ and trog– populations.  
 
Flow cytometry 
Cells were recovered from cultures and resuspended at 106 /ml in FACS buffer 
(PBS pH 7.4 containing 2% BSA Fraction V (Sigma-Aldrich), 2.5 mM EDTA, and 
0.1% NaN3). To assess viability of cells, cells were stained for 10 min at RT with 
Zombie NIR fixable viability dye (Biolegend) diluted in PBS then washed 3x with 
PBS. Cells were then stained for surface markers with the indicated reagents for 
30 min on ice in FACS buffer. After three additional washes in FACS buffer, cells 
were stained for 20 min with secondary reagents in FACS buffer, when 
necessary. Following a final set of three washes in FACS buffer, cells were 
resuspended in 400 µl of FACS buffer and stored on ice until being analyzed 
within 2 hours of staining. Alternatively, cells were fixed in ice-cold fixative (4% 
paraformaldehyde and 0.5% glutaraldehyde), or Biolegend Fixation Buffer, for 30 
min at 4 °C followed by 3 washes in FACS buffer. Fixed cells were resuspended 
in 400 µl of FACS buffer and stored in the dark at 4 °C until being analyzed the 
following day.  
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For the detection of antigen-specific cells, an MCC:I-Ek (88–103)  MHC class-II 
tetramer was obtained through the NIH tetramer core facility (Emory University, 
Atlanta, GA). Prior to surface staining, tetramer was diluted 1:100 in FACS buffer, 
and spun down at 1000 x g for 10 minutes to remove aggregates. Cells were 
blocked with FC receptor-block, then stained with recovered tetramer in 
suspension, for 30 min at 37 °C, or with an irrelevant isotype control tetramer. 
For detection of previously-activated cells gating included selection of CD44+ 
cells (Fig. S4.3) 
 
Intracellular Cytokine Staining 
To enhance detection of intracellular cytokines, in Figs. 3.2, 3.4A-C, 3.6, 3.7,  
3.8, 4.4, 4.8, 4.12, 4.16-18, 4.29, and 4.35B, cells were re-stimulated at for 5 
hours 37 °C with 500 ng/ml PMA (Phorbol 12-myristate 13-acetate) (Sigma-
Aldrich), 1 µg/ml Ionomycin (Sigma-Aldrich), in the presence of 5 µg/ml brefeldin 
A (BioLegend). After staining surface molecules on live cells, as described 
above, cells were fixed for 30 min in BD Bioscience cytofix/cytoperm followed by 
three washes in 1x Biolegend permeabilization/wash buffer (PWB). Cells were 
then stained for intracellular targets for 60 min on ice or overnight at 4 °C with 
staining reagents diluted in 1x PWB. Following intracellular staining, cells were 
washed three times in PWB and were either analyzed immediately, or were 
stored in FACS buffer in the dark at 4 °C and analyzed the following day. 
 
Transcription Factor Staining 
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For transcription factor staining, live cells were stained for surface molecules, as 
described above, then fixed in Biolegend True-Nuclear transcription factor 
fixation buffer for 60 min at room temperature. Following 3 washes in True-
Nuclear Perm Buffer, intercellular targets cells were stained with antibodies 
diluted in True-Nuclear Perm Buffer for 60 minutes on ice, or overnight at 4 °C. 
After a final set of 3 washes in Perm Buffer, cells were resuspended in 300 µl 
FACS buffer and analyzed immediately via flow cytometry.  
 
Cells were analyzed on a FACSAria (BD Bio-sciences) in the University of 
Montana Fluorescence Cytometry Core, or an LSRII (BD Bio-sciences) in the 
University of Montana Center for Translational Medicine. Data were analyzed 
with FlowJo 8.8.7 and FlowJo 10 software (Tree Star, Ashland, OR). Geometric 
mean flourescence intensity (MFI) values were determined, where indicated.   
  
Gating Strategies 
Identification of trog+ cells was done by gating on lymphocyte population (SSC-A 
vs. FSC-A) followed by rigorous doublet exclusion (FSC-W vs. FSC-H, and SSC-
W vs. SSC-A). Live CD3+ CD4+ cells were identified by the absence of fixable 
live/dead staining, and trog+ cells were identified by the presence of trogocytosed 
biotinylated-APC membrane protein (greater than stained, anti-CD3/CD28-
stimulated, or unstimulated controls), or the presence of CD80/CD86 + I-Ek for 
experiments using 5C.C7 TCR transgenic mice, or presence of CD80/CD86 + 
MHCII I-A/E for experiments using C57BL6/J mice (Fig. S3.5). Ag-specific 
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staining was confirmed by comparison to respective isotype controls of matched 
populations confirmed by background levels on unstimulated CD4+ T cells (Fig. 
S3.5). 
 
Intracellular cytokines and transcription factor gating was established using 
matched-isotype control Ab staining for respective populations. trog+ and trog- 
isotype control intensities were nearly identical, and vertical lines in histogram 
data depict fluorescence intensity greater than 99% of cells stained with isotype 
controls.  
 
Removal of Peptide from Trogocytosed-MHCII  
Recovered T cells were washed in PBS at RT and 5 x 106 cells/ml were 
incubated at RT for 2.5 min with citric acid buffer (0.1M sodium citrate (Sigma), 
0.1M citric acid (Sigma) in PBS pH 4.5 to induce reversible-conformational 
changes in MHCII [443]. The reaction was neutralized by adding 15x volume of 
cRPMI, followed by two additional washes in cRPMI. Following washing of 
unbound peptide, aliquots of cells were supplemented with 10 mM hemoglobin 
(Hb) peptide, or MCC peptide. When MCC-loaded BMDC were exposed to the 
same treatment, then used in a trogocytosis-assay, in cultures with 
supplemented Hb the rate of trogocytosis, and activation (as measured by CD69 
expression) of CD4+ T cells recovered from the trogocytosis-assay were reduced 
by >80% relative to cells recovered from BMDC cultures supplemented with 
MCC-peptide. Trog+ cells recovered from cultures where peptide was stripped 
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and replenished with Hb showed a substantial reduction in pZAP-70 signaling 
compared to untreated, or peptide-stripped cultures where MCC was replenished 
(Fig. S4.2). Acid treatment did not have a significant effect on activation state of 
cells as determined by CD69 expression (data not shown). 
 
Antibody-Neutralization of Trogocytosed MHCII/CD80 
 Following recovery from the trogocytosis-assay and removal of contaminating 
APC, 20 µg/ml of purified anti-I-Ek (17-3-3) (BioLegend) and anti-CD80 (Clone) 
(BioLegend) were added to an aliquot of recovered cells, and replenished 3d 
post-recovery. In experiments involving neutralizing antibodies, trogocytosis was 
measured by the presence of trogocytosed biotin-labeled APC membrane 
proteins. trog+ cells recovered from cultures containing neutralizing antibodies 
showed a substantial decrease in pZAP-70 compared to trog+ cells from 
untreated cultures (Fig. S4.2) 
 
In vitro Cytokine Supplementation  
Immediately following recovery from the trogocytosis assay, an aliquot of 
recovered T cells was supplemented with recombinant mouse IL-2 to a final 
concentration of 100 iU/mL. Cultures were re-supplemented with IL-2 at 24, and 
48 hrs post-recovery.  
 
Isolating Lymphocytes from Blood 
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Blood was collected into tubes containing 0.2 mM EDTA followed by RBC lysis 
with Gey’s solution then stained as described above.  
 
 
 
Isolation of lymphocytes from skin 
Prior to immunization mouse hair was trimmed in a ~2 cm2 patch around the 
injection site. At the time of harvest, ~1.5 cm 2 skin was collected from the 
injection site and minced into 3-5mm pieces. Tissue was incubated with 2.5 mM 
HBSS for 30 min at 37 °C degrees followed by an additional 60 min digestion at 
37 °C after the addition of collagenase D (Sigma) to a final concentration of 100 
U/ml. Skin was washed in cRPMI and tissue was dissociated with glass slides, 
and filtered through a 70 µm filter prior to staining for flow cytometric analysis.  
 
Treatment of T cells with Cytochalasin D 
Prior to imaging of proliferating naïve cells, cytochalasin D (Sigma), was added to 
cultures for a final concentration of 10 µM, followed by a 4 hr incubation at 37 °C 
before collection and staining.  
 
Edu Incorporation Assays 
Twenty-four hours prior to collection and analysis, 2 mM 5-Ethynyl-2´-
deoxyuridine (EdU) was added aliquots of recovered cells. After collection, cells 
were stained for surface molecules, with the exception of PE-conjugated Abs. 
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Cells were fixed with 4% PFA for 20 min at RT and permeabilized with 0.2% 
Triton-x 100. Edu staining was conducted according to manufacturer’s protocol, 
followed by 3 washes and when applicable, staining with PE-conjugated Abs.   
 
 
Detection of Extracellular Cytokines 
The detection of secreted cytokines in culture medium was performed using 
BioLegend LEGENDplex beads according to the manufacturer’s directions. 
Briefly, culture medium from cells was centrifuged to remove contaminating cells 
and debris, and immediately stored at -80 °C until used. Samples and known 
standards for each cytokine analyzed were subsequently incubated with 
cytokine-capture beads and biotinylated-detection antibodies in polypropylene 
microfuge tubes shaking at 1000 rpm at room temperature for 2 hours. Following 
this incubation, SA-PE was added, followed by a 30 min incubation while shaking 
at 1000 rpm. Beads were washed and immediately analyzed via flow cytometry.  
 
LEGENDplex beads were analyzed on a LSRII (BD Bio-sciences). Standard 
curves were generated, and data were analyzed with LEGENDplex software 
(Biolegend/ VigeneTech). Cytokine levels in samples were confirmed using 
BioLegend LEGEND MAX sandwich cytokine-capture ELISA kits according to 
manufacturer’s protocol.     
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Cell Staining and Image Collection for Microscopic Analysis   
    
T cells recovered and isolated from the standard trogocytosis assay were 
cultured at low density (104 cells/ml) for three days in complete RPMI at 37 °C. 
Live cells were isolated using Lympholyte M density centrifugation prior to 
detection of trogocytosed molecules with fluorochrome-conjugated streptavidin 
and anti-I-Ek antibodies diluted in FACS buffer for 30 min on ice. Cells were then 
washed 3x in PBS and ~106 recovered T cells were placed in 0.01% poly-L-
lysine (Sigma) precoated #1.5 LabTek II eight-chambered coverslips (Nunc) for 
10 min at 37 °C in PBS. Cells were fixed with ice-cold fixative (4% 
paraformaldehyde and 0.5% glutaraldehyde in PBS) in a dark, a humidified 
chamber for 20 min at room temperature, followed by permeabilization with 0.2% 
Triton X-100 in PBS for 10 min. Intracellular cytokine and phospho-ZAP70 
staining was performed for 1 hour at room temperature in a dark humidified 
chamber followed by washing with PBS and addition of SlowFade Gold anti-fade 
reagent (Thermo Fisher, Eugene, OR). 0.3 µm optical sections were collected, on 
an Olympus Fluoview FV1000 laser scanning confocal mounted on an inverted 
IX81 microscope using a Nikon 60x objective with 1.4 N.A, housed in the UM 
Molecular Histology and Fluorescent Imaging core facility.  
 
Image analysis      
Constrained, iterative deconvolution was performed using the Applied Precision 
SoftWorx software package (GE Healthcare, Issaquah, WA). The integrated 
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intensity of streptavidin, which is a measure of the amount of fluorescently 
labeled molecules trogocytosed, was obtained for areas ≥ six-times above 
background fluorescence. For analysis of phosphorylated ZAP-70, the integrated 
intensity and mean fluorescent intensity was obtained for areas 6-fold above 
background. Between 25 and 55 trog+ cells were imaged in each of five 
independent experiments. Cells were selected for analysis by the presence of 
streptavidin or I-Ek (6-fold above background intensity). Unstimulated cells were 
also stained and examined to establish levels of background and non-specific 
staining. To determine IL-4 or IL-21 polarization towards trogocytosed molecules, 
cells were divided into 4 quadrants using the ImageJ quadrant picker plugin, with 
trogocytosed molecules in the center of one radian along the circumference of 
the cell. The presence of IL-4 staining in the same quadrant as trogocytosed 
molecules was defined as specific accumulation. Images presented are 
maximum intensity projections of three consecutive 0.3 µm-thick Z-axis optical 
sections centered around the highest intensity staining of trogocytosed molecules 
on the cells surface were created by stacking images in ImageJ.  IL-21 and Tcf-1 
images in chapter 4, and the additional images presented in Fig. S3.4, are single 
0.3 µm-thick optical sections  
 
Statistical Analysis and Graphing 
Statistical analysis was determined by student’s t test, and one-way ANOVA 
followed by Tukey’s multiple comparison test when more than two samples were 
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compared, using Prism 4 (GraphPad Software, La Jolla, CA). Significance was 
defined as * p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001, and **** p≤ 0.0001.  
 
 
 
Chapter 3 
 
 Trogocytosis-mediated Intracellular Signaling in 
CD4+ T cells Drives TH2-associated Effector 
Cytokine Production and Differentiation 
 
The following are results as presented in the Journal of Immunology, 2019, 
minus the materials and methods section which has been consolidated into 
chapter II, and references which have been consolidated in the bibliography of 
this dissertation. 
Trogocytosis-mediated Intracellular Signaling in CD4+ T cells Drives TH2-
associated Effector Cytokine Production and Differentiation1,2 
Jim Reed† and Scott Wetzel*†,§ 
† Program in Cellular, Molecular and Microbial Biology, Division of Biological 
Sciences, University of Montana, Missoula, MT 59812, USA 
§Center for Environmental Health Sciences, University of Montana, Missoula, MT 
59812, USA 
 
1. Work funded by R03AI122167 (to S.A.W).  Fluorescence Cytometry and 
Molecular Histology and Florescence imaging core facilities used to perform 
studies are supported by P30RR033379.  
 
2. Abbreviations used: 
BMDC, bone marrow-derived dendritic cells; FKBP, FK506-binding protein; ICS, 
Intracellular cytokine staining; Lck, P56Lck; MFI, mean fluorescence intensity; 
MCC, moth cytochrome-c; OVA, ovalbumin; pZAP-70, phosphotylated ZAP-70; 
Trog (+), trogocytosis-(positive); Trog (–), trogocytosis-(negative) 
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Abstract 
CD4+ T cells have been observed to acquire APC-derived membrane and 
membrane-associated molecules through trogocytosis in diverse immune 
settings. Despite this, the consequences of trogocytosis on the recipient T cell 
remain largely unknown. We previously reported that trogocytosed molecules on 
CD4+ T cells engage their respective surface receptors, leading to sustained 
TCR signaling and survival after APC removal. Using peptide-pulsed BMDC and 
transfected murine fibroblasts expressing antigenic MHC:peptide complexes as 
APC, we show that trogocytosis-positive CD4+ T cells display effector cytokines 
and transcription factor expression consistent with a TH2 phenotype. In vitro 
polarized TH2 cells were found to be more efficient at performing trogocytosis 
than TH1 or non-polarized CD4+ cells, while subsequent trogocytosis-mediated 
signaling induced TH2 differentiation in polarized TH1 and non-polarized cells. 
Trogocytosis-positive CD4+ T cells generated in vivo also display a TH2 
phenotype, in both TCR-transgenic and wild type models. These novel findings 
suggest that trogocytosis-mediated signaling impacts CD4+ T cell differentiation 
and effector cytokine production, and may play a role in augmenting or shaping a 
TH2-dominant immune response.   
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Introduction 
T lymphocytes acquire lipids and membrane-bound molecules directly from the 
surface of antigen presenting cells (APC) in a phenomenon termed trogocytosis 
[279, 373]. This event has been frequently observed in CD4+ T-helper (TH) [81, 
285, 287, 368-372], CD8+ [370, 373-376], and  [377] T cells. Though the 
consequences of trogocytosis on recipient cells are not completely understood, it 
has been described as “an inherent feature in CD4+ T cell activation” [420]. This 
phenomenon is not exclusive to T cells, as B cells [378, 379], NK cells [380-382], 
basophils [283], macrophages [383, 384], neutrophils [385-387], and dendritic 
cells [388, 389], have all been reported to perform trogocytosis. With elevated 
levels of trogocytosis documented in sites of autoimmune inflammation [391], 
viral and parasitic infections [282, 413, 414], rheumatoid arthritis [11], and in 
tumor environments [284, 403], this widely observed event has been proposed to 
play a role in the modulation of immune responses [277, 388, 415-419].  
            Work over the past decade has begun to decipher the mechanism of T 
cell trogocytosis. We, and others, have previously shown that trogocytosis by 
CD4+ T cells occurs at the immunological synapse formed between Ag-specific 
CD4+ T cells and APC [287, 392, 394, 397, 402]. The formation of the 
immunological synapse involves the spatio-temporal rearrangement of the TCR, 
costimulatory molecules, and adhesion molecules, into distinct, spatially-
segregated supramolecular activation complexes (SMACs) [51-54]. Upon binding 
MHC:peptide complexes, TCRs migrate towards the center of the SMAC where 
they become internalized by the T cell and are either recycled to the surface, or 
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ubiquitinated leading to their degradation [60]. Martinez-Martin et al., have 
proposed a model of trogocytosis in which APC-derived membrane and 
membrane proteins are internalized in tandem with TCR via T-cell phagocytosis. 
Recycling endosomes containing acquired APC fragments then fuse with the T 
cell plasma membrane resulting in APC-derived molecules being displayed on 
the T cell surface in their native topological orientation [278, 411]. Trogocytosed 
molecules are retained in a focused spot on the CD4+ T cell surface [81, 287] 
and remain fully functional, as demonstrated by the ability for trogocytosis-
positive (trog+) T cells to present antigen, in the context of other acquired 
molecules, to responding T cells [369, 371, 372, 415, 420-426]. The 
consequences of such presentation appear to correlate with the nature of the 
acquired molecules and phenotype of the trog+ cell. While trog+ CD4+ cells 
displaying acquired CD80 and MHC:peptide have been shown to activate 
responding naïve T cells [371, 410, 420, 424], presentation of Ag to activated 
cells has been reported to induce responder cell death [429]. In a regulatory 
context, trog+ T regulatory (Treg), or TH cells displaying trogocytosed molecules 
associated with immune-suppression, such as HLA-G, show enhanced 
suppressive capabilities [417, 420, 422, 432, 437, 438]. Collectively, the above 
findings underscore that CD4+ T cell trogocytosis, and the subsequent 
presentation of acquired molecules, are biologically significant events in the 
context of regulating immune responses. 
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While the ability of trog+ T cells to act as APC has been fairly well documented, 
much less is known about the biological consequences of trogocytosis on an 
individual trog+ cell. In our previous studies, we detected TCR signaling in trog+, 
but not trog–, CD4+ T cells up to 72 hours after separation from APC. This 
sustained signaling was mediated by trogocytosed molecules engaging their 
cognate receptors on the trog+ T cell, resulting in “autopresentation”, referred to 
here as “trogocytosis-mediated signaling”. This signaling led to the enhanced 
survival of trog+ cells compared to trog– cells, up to five days after APC removal 
[81]. Consistent with these findings, Zhou et al. found that trog+ CD4+ T cells 
displayed sustained activation of NFB and AP1, 24 hours after removal from 
APC. Interestingly, the trog+ cells also developed a unique cytokine profile [439], 
raising the possibility that a difference exists between trogocytosis-mediated 
signaling and signals received from APC. Taken together, the above results 
suggest that trogocytosis-mediated signaling has the potential to uniquely impact 
the survival, activation state, and effector cytokine production and/or 
maintenance of the trog+ CD4+ T cell after separation from APC.  
        In this study, we examined whether trogocytosis-mediated signaling 
impacted T cell effector cytokine production and differentiation in the context of 
the individual trog+ cell. Using non-polarized in vitro CD4+ T cell blasts, we found 
that shortly after APC removal, a high frequency of trog– cells expressed IFN, 
consistent with a T helper 1 (TH1) phenotype. The trog– cells did not maintain 
IFN expression over a subsequent 72-hour incubation, and by 72 hours only 
minimal levels of any effector cytokine examined were detected. In contrast, 5 
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hours after APC removal the frequency of IFN+ trog+ cells was significantly lower 
than IFN+ trog– cells. Interestingly, over the subsequent 72-hour incubation, IL-4 
expression was significantly increased in the trog+ cells, consistent with a TH2 
phenotype. Because trogocytosis-mediated signaling induces preferential 
survival of trog+ cells [81], the appearance of the TH2 phenotype by trog+ cells 
could be due to differences in the ability of TH1 and TH2 cells to perform 
trogocytosis. Consistent with this possibility, in vitro polarized TH2 
cells were more efficient at performing trogocytosis than TH1 or non-polarized 
CD4+ cells. However, further investigation revealed that trogocytosis-mediated 
signaling was directly contributing to the TH2-associated effector cytokine and 
transcription factor expression in non-polarized trog+ CD4+ cells. In addition, in 
vitro TH 1-polarized trog+ cells lost expression of IFN and T-bet, and began 
expressing IL-4 and GATA-3, suggesting that trogocytosis-mediated signaling 
was inducing TH 1 to TH2 conversion. Finally, using both TCR-transgenic and 
non-transgenic models, and distinct Ag systems, we show that in vivo, a 
significantly higher frequency of trog+ CD4+ T cells display a TH2 
phenotype when compared to trog– cells from the same animal. Cumulatively, 
these findings suggest that trogocytosis-mediated signaling has the potential to 
significantly impact CD4+ T cell effector cytokine production and differentiation, 
and subsequently may play a role in sustaining, augmenting, or shaping, TH2-
dominant immune responses.  
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Results  
Intracellular TCR signaling and elevated activation is maintained in trog+, 
but not trog– CD4+ T cells after APC removal. 
 
At sites of inflammation and immune activation, there is a correlation between 
CD4+ trogocytosis and a heightened activation state [397]. This is consistent with 
data showing that highly activated cells display enhanced trogocytic activity [287, 
391]. An additional explanation for the heightened activation observed in 
trogocytosis-positive (trog+) cells is that that trogocytosed molecules could 
engage their receptors on the trog+ CD4+ T cell and sustain intracellular 
signaling. Such trogocytosis-mediated signaling may be playing an important and 
unappreciated role in driving and/or maintaining T cell activation, effector 
functions, and differentiation. We have previously shown that that after APC 
removal, there is selective survival of trog+ cells over 5 days in vitro compared to 
trog– cells [81]. In addition, both TCR-proximal (ZAP-70 phosphorylation) and 
distal signaling (ERK 1/2 phosphorylation) was detectable in trog+, but not trog– 
cells 72 hours after APC removal. This sustained-signaling occurred 
independently of APC, and was driven by the engagement of trogocytosed 
molecules and their receptors on T cells (i.e. trogocytosis-mediated signaling) 
[81].  
 
To extend on our previous study, we began by comparing the activation state 
and TCR-proximal signaling in trog+ and trog– cells up to 72 hours after recovery 
from a 90-minute in vitro trogocytosis assay. Recovered T cells were analyzed 
immediately, or cultured for 3 days at low density (104 cells/ml) to minimize T:T 
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interactions, and samples were collected daily. At indicated time-points (Fig. 3.1), 
cells were analyzed via flow cytometry, and trog+ cells were identified by the 
presence of trogocytosed, biotin-labeled APC-derived molecules (Fig. S3.1C). 
Consistent with our previous findings, both trog+ and trog– cells showed similar 
levels of TCR downmodulation immediately after the trogocytosis-assay, 
indicating that both populations had recognized antigen (Fig. 3.11A, B). In 
agreement with the TCR downmodulation data, both trog+ and trog– cells also 
displayed elevated levels of the activation marker CD69, compared to 
unstimulated cells (Figs. 3.11C-E). However, after APC were removed from the 
system, only the trog+ cells maintained TCR downmodulation and an activated 
(CD69High) phenotype throughout the 72-hour incubation. In contrast, at the 48 
and 72-hour time points, the trog– cells displayed significantly lower TCR 
downmodulation levels compared to the trog+ cells (Fig. 3.1B), and surface TCR 
levels were similar to unstimulated T cell blasts (Figs. 3.11A, B). The loss of TCR 
downmodulation coincided with a decrease in CD69 expression by the trog–  cells 
to levels similar to unstimulated T cell blasts (Figs. 3.1C, D), and at the 48 and 
72-hour time points, the trog+ cells displayed significantly increased levels of 
CD69 compared to trog– cells (Fig. 3.1D). This marked difference was not only 
due to the loss of CD69 expression by trog– cells, but also a result of trog+ cells 
enhancing CD69 expression, and the loss of CD69Low trog+ cells (Figs. 3.1C-E). 
In agreement with our previous study [81], the trog+ cells displayed enhanced 
survival compared to the trog– cells, as seen by the increase in trog+ frequencies, 
and decrease in trog– frequencies after APC removal (Fig. 3.1C). While the 
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phenotype of the trog+ cells is consistent with active-TCR signaling, the 
phenotype displayed by the trog– cells is consistent with published data showing 
that CD69 expression peaks between 18-48 hours after removal of in vitro TCR 
stimulation [444].  
 
 
To confirm that the TCR engagement displayed by trog+ cells resulted in TCR-
proximal signaling, the levels of phosphorylated ZAP-70 (pZAP-70) were 
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assessed [445, 446]. In support of the data in Figs. 3.1A and B, and consistent 
with our previous studies [81], the trog+, but not trog– cells, maintained pZAP-70 
levels after APC removal (Fig. 3.1E). At each observed time-point, the trog+ cells 
had significantly higher levels of pZAP-70, as determined by MFI, compared to 
the trog– cells (Fig. 3.1F). Because nearly no APC were present in the cultures of 
CD4+ T cells following the trogocytosis-assay (Fig. S3.1B), the increased CD69 
expression, TCR downmodulation, and elevated pZAP-70 maintained in trog+, 
but not trog–, cells over the 72-hour incubation suggests that cell-autonomous, 
trogocytosis-mediated signaling sustained the T cell activation.  
 
Trog+ CD4+ T cells express elevated levels of IL-4 and IL-5, whereas trog– 
cells express high levels of IFN+ and little IL-4 or IL-5. 
 
The sustained activation and TCR proximal signaling in trog+ cells after removal 
from APC raised the possibility that trogocytosis-mediated signaling may impact 
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effector cytokine production within these cells. To examine this, culture 
supernatants from T cells recovered from the trogocytosis assay were analyzed 
for cytokines characteristic of various TH subsets using cytokine-capture beads. 
Five hours after recovery from the in vitro trogocytosis-assay, T cell supernatants 
contained high levels of IFN and IL-2, but negligible amounts of IL-4, IL-6, IL-21 
or IL-13 (Fig. 3.2A). Interestingly, by 72 hours IFN levels were significantly 
decreased, while IL-4 levels had increased significantly (Fig. 3.2A). To examine a 
potential correlation between trogocytosis and the observed cytokine production, 
intracellular cytokine staining (ICS) was performed on recovered cells at 24-hour 
intervals over a 72-hour incubation after APC removal. The fold-difference in MFI 
for TH subset-characteristic cytokine expression of trog+ and trog– cells compared 
to T cell blasts which did not undergo the trogocytosis-assay (unstimulated cells) 
is shown in Fig. 3.2B. Five hours post-recovery, neither the trog+ nor trog– cells 
showed increased levels of IL-4, IL-5, IL-12, IL-6, IL-9, or IL-17, and the only 
cytokine showing substantially increased expression compared to unstimulated 
controls was IFN (Fig. 3.2B). Interestingly, at 5 hours IFN levels were increased 
in the trog– cells significantly more than in the trog+ cells (Fig. 3.2D). By 72 hours, 
there were still minimal expression of IL-12, IL-6, IL-9, or IL-17 by both 
populations. The robust IFN expression seen in trog– cells at 5 hours was no 
longer apparent and had decreased to levels only marginally higher than that of 
unstimulated cells, while IFN levels remained minimal in trog+ cells. However, 
the trog+ cells had developed a striking 2.2-fold increase for IL-4 and 1.85-fold 
increase for IL-5, and 0.89-fold increase for IL-2, all of which were found to be 
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significantly higher in the trog+ cells compared to the trog– cells (Fig. 3.2B). 
Representative histograms for IFN and IL-4 expression by trog+, trog–, and 
unstimulated cells are presented in Fig. 3.2C. Enhanced IL-4 expression was 
also observed in trog+ cells from parallel experiments using MCC peptide-pulsed 
BMDCs as APC (Fig. S3.2). Because the only significant differences in subset-
characteristic cytokines detected between trog+ and trog– cells were TH1 and 
TH2-associated, the subsequent experiments focused on these subsets. 
 
Further assessment of the IFN and IL-4 production on a per-cell basis showed 
that the frequency of IL-4+ cells increased exclusively in the trog+ cells, from an 
average of 12.5% at 5 hours to an average of 73% by 72 hours (Fig. 3.2D). By 
comparison, the frequency of trog– IL-4+ cells remained below 5% at all time-
points. This resulted in significantly more trog+ IL-4+ cells than trog– IL-4+ cells at 
24, 48, and 72 hours (Fig. 3.2D left). In contrast, on average, 34% of the trog– 
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cells, but only 10% of trog+ cells were IFN+ at 5 hours. Unlike IL-4, IFN 
expression was not maintained in trog+ cells. Despite a dramatic loss of trog– 
IFN+ cells, there was still a significantly lower frequency of trog+ IFN+ cells 
compared to the trog– IFN+ cells at each observed time-point (Fig. 3.2D right). 
The decrease in trog– IFN+ cells over the 72-hour incubation correlates with the 
loss of TCR signaling and activation seen in Fig. 3.1, and the massive cell death 
in this population as observed in Fig. 3.1C and our previous study [81].  
 
The strong IFN+ expression in trog– cells at 5 hours further demonstrates that 
both trog+ and trog– cells are fully activated by the initial APC encounter. Thus, 
differences in the phenotype between trog+ and trog– cells do not simply reflect 
whether T cells have recognized Ag. In addition, although trog+ cells displayed 
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sustained signaling and activation (Fig. 3.1), IFN expression in these cells was 
not maintained. Combined with the increase in IL-4 expression by trog+ cells after 
removal from APC, these results are consistent with the possibility that 
trogocytosis-mediated signaling was impacting the effector cytokine production of 
the trog+ cells, in a manner consistent with a TH2 phenotype.   
 
TH2 cells are more efficient than TH1 or non-polarized CD4+ T cells at 
performing trogocytosis. 
 
One potential explanation for the increased IL-4 expression and frequency 
observed in trog+ cells is that pre-TH2 or TH2-like cells had performed 
trogocytosis more efficiently than pre-TH1 / TH1-like cells. Thus, the increase in 
IL-4+ trog+ cells may simply reflect the superior survival displayed by trog+ cells 
after removal from APC [81]. To compare the trogocytic potential of differentiated 
TH1 and TH2 cells, in vitro-polarized TH1 and TH2 blasts were used in an in vitro 
trogocytosis assay (Figs. 3.3A, B). Representative histograms in Fig. 3C and D 
show that GATA-3+ TH2 blasts were highly efficient at performing trogocytosis, 
with an average of 71.5% displaying biotin-labeled APC-membrane and 58.1% 
having I-Ek on their surface. In contrast, T-bet+ TH1 cells were weakly trogocytic, 
averaging only 14.2% of cells with detectable APC-membrane and 10.4% being 
I-Ek+. For comparison, non-polarized blasts, which showed a predominant TH1 
phenotype (Figs. 3.3A, B), averaged 26.8% of cells with detectable APC-
membrane, and 16.8% with trogocytosed I-Ek. Thus, while non-polarized cells 
had a significantly higher frequency of trog+ cells compared to polarized TH1 
cells, the TH2 cells performed trogocytosis at significantly higher rates than both 
103 
 
non-polarized, and TH1 cells (Fig. 3.3E). These results support the hypothesis 
that the predominant TH2-associated cytokine production in the trog+ cells at 72 
hours (Fig. 3.2) was, at least in part, due to the increased ability of TH2 cells to 
perform trogocytosis and their subsequent enhanced survival, which was driven 
by trogocytosis-mediated signaling.  
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Trogocytosis-mediated signaling is sufficient, and effective, in driving IL-4 
expression.  
 
Based on the data in Fig. 3.3 showing that TH2 cells possess higher trogocytic 
potential than TH1 or non-polarized cells, the increase in trog+ IL-4+ cells may 
simply be due to trogocytosis-mediated signaling enhancing the survival of 
predestined TH2 cells. If this were the case, then sustained-canonical TCR and 
costimulatory signaling would be expected to augment the TH2 phenotype of pre-
TH2 or TH2 cells. To examine this possibility, an aliquot of the same T cell blasts 
to be used in a trogocytosis-assay were stimulated with plate-bound anti-CD3 + 
anti-CD28 in parallel with T cells recovered from a standard in vitro trogocytosis-
assay. At 72 hours, on average, 77.4% of the trog+ cells were IL-4+, but only 
3.5% of trog– cells and 1.8% of Ab-stimulated blasts were IL-4+ (Figs. 3.4A-C). In 
contrast, Ab-stimulated blasts maintained a similar frequency of IFN+ cells over 
the 72 hours (Fig. 3.4A), while the frequency of IFN+ trog+ cells dropped from an 
average of 13.4% at 5 hours to 1.5% by 72 hours (Fig. 3.4C). The striking 
difference between the IFN and IL-4 expression patterns between the trog+ and 
Ab-stimulated blasts suggests that trogocytosis-mediated signaling provides 
additional, potentially unique, signals that favor TH2-associated cytokine 
expression, beyond the signaling induced by repeated CD3 + CD28 signaling. 
These results further strengthen the association between trogocytosis-mediated 
signaling, and a TH2 phenotype.  
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As seen in Fig. 3.3, the majority of non-polarized T cells did not displayed a TH1 
phenotype prior to the trogocytosis assay, yet the vast majority of trog+ cells 
developed a TH2 phenotype after APC removal. While the data thus far is 
suggestive that trogocytosis-mediated signaling was driving this phenotype, the 
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possibility that residual signaling from the T:APC interaction was driving the 
observed IL-4 expression in trog+ cells remained. To confirm that trogocytosis-
mediated signaling alone was capable of driving IL-4 production in trog+ cells, 
Lck signaling was interrupted in cells recovered from the trogocytosis assay with 
the reversible Src family kinase inhibitor PP2. Using this technique, we previously 
demonstrated that PP2 treatment terminated TCR signaling, however, after 
removal of PP2, signaling was re-initiated in trog+, but not trog– cells [81]. Here, 
we hypothesized that if trogocytosis-mediated signaling was driving IL-4 
expression, then cytokine production would resume in trog+, but not trog– cells 
after removal of PP2. If neither trog+ nor trog– cells re-initiated IL-4 expression 
after PP2 was removed, it would indicate that trogocytosis-mediated signaling 
alone was insufficient to drive the expression of IL-4. Immediately following the 
trogocytosis assay, recovered cells were treated for 20 min with PP2 to halt TCR 
signaling, and then incubated for an additional 2 hours after PP2 removal. 
Results in Fig. 3.4D show that PP2 treatment did not alter the engagement of 
TCR by trogocytosed MHC:peptide complexes, as nearly identical levels of TCR 
downmodulation were observed in PP2-treated trog+ and untreated trog+ cells, at 
2 (MFI reduced 2.9 fold or 2.81 fold vs. unstimulated controls, respectively) and 
72 hours (1.7 fold vs. 1.3 fold reduction, respectively) (Fig. 3.4D). Treatment with 
PP2 did however, reduce the frequencies of trog+ IL-4+ cells at 2 hours by an 
average of 83.5% (from 11% to 1%). However, 72 hours after PP2 removal, the 
frequency of IL-4+ trog+ cells had rebounded from 1% at 2 hours, to nearly 60% 
at 72 hours (Fig. 3.4D, right). PP2 treatment also decreased the modest IL-4 
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expression of trog– cells at 2 hours, and, as expected, neither the PP2-treated or 
untreated populations of trog– cells expressed IL-4 at 72 hours (Fig. S3.3C). The 
ability of trog+ cells to resume IL-4 production in absence of APC provides 
compelling evidence that trogocytosis-mediated signaling was sufficient to drive 
IL-4 expression in trog+ cells.  
 
Treatment with PP2 reduced the frequency of trog+ IFN+ cells by 72%, and trog– 
IFN+ cells by 80% at 2 hours (Fig. S3). However, consistent with the hypothesis 
that trogocytosis-mediated signaling was driving IL-4, but not IFN expression, 
the expression of IL-4, had rebounded in trog+ cells 24 hours after PP2 
treatment, while IFN expression was significantly lower in PP2-treated cells 
compared to untreated cells (Fig. 4E). This suggests that IFN expression was 
due to signaling occurring at the immunological synapse, and that trogocytosis-
mediated signaling was insufficient to maintain IFN production in these cells.  
 
Intracellular IL-4 is polarized towards trogocytosed molecules  
The sustained expression of IL-4 by trog+ cells up to 72 hours after removal from 
APC (Fig. 3.2) suggested that trogocytosis-mediated signaling may be 
contributing to the maintenance of TH2-associated cytokine production in these 
cells. As a major function of TH2 cells is to provide contact-dependent help to 
cognate B cells upon Ag recognition through B cell directed cytokine secretion, 
we hypothesized that trogocytosis-mediated signaling may mimic these T:B 
interactions. If so, intracellular IL-4 would likely be polarized towards areas of 
108 
 
trogocytosis-mediated TCR-signaling. Three days after recovery from a standard 
in vitro trogocytosis assay, recovered cells were stained for trogocytosed 
molecules, intracellular IL-4, and pZAP-70, and analyzed by confocal 
microscopy. Consistent with the flow-cytometry data (Fig. 3.2), IL-4 was only 
detected in 5% of trog– cells in which polarization of IL-4 towards any distinct 
region was only observed in 8% of trog– IL-4+ cells (Figs. 3.5C, S4). In contrast, 
the trog+ IL-4+ cells had significantly higher frequencies of polarized IL-4 
compared to the trog– IL-4+ cells, and 86% of these cells had IL-4 polarized 
towards trogocytosed molecules on the T cell membrane (Fig. 3.5C). 
Representative images illustrate that IL-4 was polarized towards trogocytosed 
molecules (Fig. 3.5A), and that proximal TCR-signaling was occurring at the 
trogocytosed molecules, as indicated by pZAP-70 staining (Fig. 3.5B). Additional 
images are presented in Fig. S3.4. These images are reminiscent of 
observations made by Kupfer et al., who revealed that during TH2 help for B 
cells, IL-4 delivery was localized to the TH2:B cell interface [447]. Thus, data in 
Fig. 3.5 are supportive of a model where trogocytosis-mediated signaling was 
stimulating polarized IL-4 secretion, and also further reinforce the TH2 phenotype 
displayed by trog+ cells. 
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Trog+ cells develop a TH2 phenotype while trog– cells maintain a TH1 
phenotype after separation from APC.  
 
Although IL-4 is widely accepted as the representative TH2 effector-cytokine, 
other T cell subsets, such as TFH, also express IL-4 [448]. Therefore, expression 
of IL-4 alone does not indicate TH2-differentiation. To determine whether trog+ 
cells were differentiated to TH2, the expression of subset-characteristic 
transcription factors was examined. The data in Fig. 3.6A show no detectable 
differences in expression of GATA-3 (TH2), T-bet (TH1), Foxp3 (Treg), Bcl-6 (TFH) 
or RORt (TH17) between trog+ and trog– cells, 5 hours post-recovery from an in 
vitro trogocytosis-assay. This further supported that the unstimulated blasts 
consisted of a homogenous population prior to use in the trogocytosis-assay. By 
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72 hours however, the trog+ cells displayed a 1.7-fold increase for GATA-3, and 
90% lower levels of T-bet compared to trog– cells, while only minimal differences 
were detected for Foxp3, Bcl-6, or RORt (Fig. 3.6A). In agreement with the 
cytokine profiles observed in Fig. 3.2, over the 72-hour incubation, T-bet 
expression in trog+ cells decreased to a level below unstimulated bulk T cell 
blasts, while trog– cells maintained elevated T-bet expression (Fig. 3.6B). In 
contrast, at 72 hours, the majority of the trog+ cells were GATA-3+, and GATA-3 
expression was negligible in the trog– cell population (Fig. 3.6B). While trog+ and 
trog– displayed similar levels of T-bet and GATA-3 five hours after recovery, by 
72 hours the trog+ cells displayed significantly increased GATA-3 expression, 
and significantly decreased T-bet expression compared to trog– cells (Fig. 3.6C). 
These results confirmed that the IL-4+ trog+ cells were consistent with a TH2 
phenotype, and support the hypothesis that trogocytosis-mediated signaling was 
driving TH2 differentiation rather than simply enhancing the survival of TH2-
commited cells.   
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Trogocytosis-mediated signaling, rather than IL-4 availability, is required 
for GATA-3 upregulation after APC removal.  
 
 While IL-4 is a major product of TH2 cells, it is also an inducer of this subset, as 
IL-4R-signaling significantly contributes to TH2 differentiation [449]. Because the 
trog+ cells produced significantly higher amounts of IL-4 than trog– cells (Fig. 3.2), 
it was possible that the TH2 phenotype displayed by the trog+ cells was simply 
the result of IL-4 availability. To examine whether IL-4R signaling was playing the 
central role in the TH2-phenotype observed in trog+ cells, exogenous IL-4 (20 
µg/ml) was added to cultures of cells immediately after recovery from the 
trogocytosis assay, and replenished at 24 hours. As seen in Fig. 3.6D, at 72 
hours, the addition of IL-4 had minimal effects on GATA-3 expression in 
unstimulated cells. Similarly, the trog– cells from cultures containing 
supplemented IL-4, showed only an 8.6% average increase in GATA-3 
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expression, while trog+ cells from the same cultures had increased GATA-3 
expression by an average of 25.5%, as determined by MFI (Fig. 3.6E). However, 
the addition of IL-4 had little impact on the frequency of GATA-3+ trog– or trog+ 
cells, as no significant differences between cells from untreated cultures, and 
cultures with supplemented IL-4, were detected in either population (Fig. 3.6F). 
Thus, IL-4R signaling was not playing the central role in the increase in GATA-3+ 
expression by the trog+ cells. These results confirm that trogocytosis-mediated 
signaling, and not simply the availability of IL-4, was essential for the observed 
TH2 phenotype developed in trog+ cells, consistent with the finding that GATA-3 
translation is dependent on TCR signaling [450].  
 
Trogocytosis-mediated signaling drives TH1 cells to express IL-4 and 
GATA-3 
 
The results in Figs. 3.4 and 3.6 are consistent with the hypothesis that 
trogocytosis-mediated signaling drives TH2 differentiation in trog+ cells. To 
examine this hypothesis, we tested whether trogocytosis-mediated signaling 
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could induce in vitro TH1 polarized trog+ cells to start producing TH2 characteristic 
proteins. If such conversion was observed in trog+, but not trog–, polarized TH1 
cells it would strongly support the hypothesis that sustained, trogocytosis-
mediated signaling was inducing a TH2 phenotype. In vitro TH1 and TH2 polarized 
blasts were generated and used in a standard in vitro trogocytosis assay. In 
parallel, polarized TH1 and TH2 blasts were stimulated on anti-CD3 + anti-CD28 
coated plates to provide sustained signaling throughout the 72-hour incubation. 
Because plasticity between TH1 and TH2 subsets occurs only after days of 
exposure to alternate polarizing conditions [144, 169, 451, 452], the 90 minutes 
of exposure to APC during the trogocytosis-assay alone would not likely be 
sufficient to induce TH1 to TH2 conversion. Cells were examined at 5 hours to 
examine baseline conditions, and at 72 hours after APC removal, to assess 
potential phenotypic changes.   
 
The results in Fig. 3.7A show that sustained Ab-stimulation resulted in stable 
IFN expression in polarized TH1 cells, with an average of 61% being IFN+ at 5 
hours, and 57% being IFN+ at 72 hours. As anticipated, these TH1 polarized 
cells did not express IL-4 at any time-point. The TH1 polarized trog+ cells showed 
a phenotype similar to Ab-stimulated TH1 cells at 5 hours, with an average of 
79% being IFN+, and only 8% expressing IL-4+ (Fig. 3.7B). However, unlike the 
Ab-stimulated TH1 cells, the frequency of trog+ IFN+ cells decreased at each 
successive time-point, and by 72 hours only ~5% remained IFN+. IFN 
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expression was not detected in the trog+ TH2, or the Ab-stimulated TH2 blasts at 
any time-point (Figs. 3.7 C, D).     
 
 
 
115 
 
In contrast to the significant decrease in IFN expression, the frequency of trog+ 
TH1 polarized cells expressing IL-4 increased from 8% at 5 hours, to 
approximately 70% at 72 hours (Fig. 3.7B). The presence of a unique population 
(averaging 4.7%) of TH1 polarized trog+ cells which were IFN+ IL-4+ double-
positive cells at 72 hours (Fig. 3.7B) supported the idea that these cells 
converted from TH1 towards a TH2 phenotype [178]. For comparison, while Ab-
stimulation of the polarized TH1 maintained IFN expression, on average, less 
than 0.2% of these cells were for IFN+ IL-4+ double-positive at 72 hours (Fig. 
37A). Within the polarized TH2 cells, on average only 0.22% of trog+, and 0.31% 
of Ab-stimulated cells were IFN+ IL-4+ (Fig. 3.7C, D).  
 
While the TH2 polarized trog+ population displayed an average of 84.2% of cells 
being IL-4+, somewhat unexpectedly, only 28% of Ab-stimulated cells were IL-4+ 
at 72 hours (Fig. 3.7C, D). These are similar to the results in Fig. 4, and further 
support that trogocytosis-mediated signaling is favorable for driving and/or 
augmenting a TH2 phenotype, while sustained anti-CD3 + anti-CD28 Ab-
stimulation is not.  
 
In addition to shutting down IFN expression and upregulating IL-4, the trog+ TH1 
polarized cells also displayed a shift in transcription factor expression. These 
cells were GATA-3 negative and expressed high levels of T-bet at 5 hours, but by 
72 hours, the trog+ TH1 cells had upregulated GATA-3 expression, and 
approximately half of the population lost T-bet expression (Fig. 3.7E). In contrast, 
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the Ab-stimulated and trog– TH1 cells remained GATA-3– and maintained 
expression of T-bet at 72 hours. While there were no significant differences in T-
bet or GATA-3 expression between TH1 polarized trog+, trog–, and Ab-stimulated 
cells 5 hours after recovery, by 72 hours the frequency of T-bet+ cells was 
significantly lower in the trog+ population compared to trog– population. This was 
concomitant with significantly more trog+ cells expressing GATA-3 compared to 
trog– and Ab-stimulated cells (Fig. 3.7F). Consistent with the cytokine expression 
data where the TH1 polarized trog+ cells expressed both IL-4 and IFN (Figs. 37A, 
B), significantly more trog+ cells also expressed both T-bet and GATA-3 
compared to trog– and Ab-stimulated cells (Fig. 3.7F). Taken together, the data in 
figure 7 strongly suggest that trogocytosis-mediated signaling induced TH1 to TH2 
conversion, strengthening the conclusion that trogocytosis-mediated signaling 
drove the observed TH2 phenotype in trog+ cells.  
 
Trogocytosis+ CD4+ T cells generated in vivo display a TH2 phenotype. 
The results so far strongly support the hypothesis that trogocytosed molecules 
engage cognate receptors on T cells to sustain intracellular signaling, leading to 
TH2 biasing. To examine whether this in vitro phenotype was consistent with in 
vivo immune responses, a protein immunization model in an adoptive transfer 
system, using TCR-transgenic T cells transferred into wild type animals was 
used, as well as the direct protein immunization of wild type animals. In the 
adoptive transfer model, B10.A mice were immunized subcutaneously with whole 
pigeon cytochrome-c (PCC) protein. Twenty-four hours later, naïve 5C.C7 TCR-
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transgenic T cells were adoptively transferred into the immunized animals (Fig. 
3.8). Five days after the adoptive transfer, cells were harvested from draining 
lymph nodes and analyzed. Of the recovered, adoptively transferred CD4+ T 
cells, there was significantly higher rates of trogocytosis in the PCC-immunized 
animals (averaging 19.4% trog+) compared to PBS-injected controls (averaging 
0.28% trog+) (Fig. 3.8A). Based on CD69 upregulation and TCR 
downmodulation, both trog+ and trog– adoptively transferred CD4+ T cells had 
recognized Ag and were activated (Fig. 3.8B). Consistent with the in vitro results 
in Fig. 3.1, the trog+ CD4+ T cells showed trends of higher activation and TCR 
downmodulation compared to trog– CD4+ T cells from the same animal (Fig. 
3.8B). Within the activated (CD69High) CD4+ T cells, there was a significantly 
higher frequency of trog+ IL-4+ cells than trog– IL-4+ cells (Fig. 3.8C). On average, 
15% of trog– cells and 11% of trog+ cells were IFN+ (Fig. 3.8C), resembling the 
phenotypes observed at 48 hours following recovery from the in vitro trogocytosis 
assay (Fig. 3.2D). Also, consistent with the phenotype of cells recovered from the 
in vitro trogocytosis assays (Fig. 3.2C), the expression of IL-4 on a per-cell basis, 
was higher in trog+ cells than similarly activated trog– cells (Fig. 3.8D).  
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In a parallel set of experiments, non-transgenic C57BL/6 mice were immunized 
with chicken ovalbumin (OVA), followed by a booster immunization 14 days later. 
CD4+ T cells were recovered from draining lymph nodes five days after the 
second immunization. These time-points were chosen to reintroduce antigen at 
the end of the effector stage of the immune response, but before establishment 
of a stable memory population. OVA-immunized animals had significantly higher 
frequencies of trog+ CD4+ T cells compared to PBS-injected control mice (Fig. 
3.8E). Consistent with our previous study [81], the trog+ cells displayed sustained 
survival ex vivo, as the frequency of isolated trog+ CD4+ T cells from OVA-
immunized mice increased from 8% on the day of harvest to nearly 60% after a 
five-day in vitro incubation (Fig. 3.8D). Similar to the results with the TCR-
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transgenic model, the trog+ CD4+ T cells were more activated than trog– CD4+ T 
cells as determined by CD69 staining (Fig. 3.8F). Within the activated (CD69High) 
CD4+ cell populations, the trog+ cells displayed increased expression of GATA-3 
and IL-4, whereas their expression in trog– cells from the same animal was nearly 
identical to that of CD4+ T cells recovered from PBS-control animals (Fig. 3.8F). 
Similar to results from in vitro and in vivo TCR-transgenic experiments (Figs. 3.2, 
3.8C), the frequency of GATA-3+ CD4+ cells was significantly higher in the trog+ 
cells compared to the trog– cells (Fig. 3.8G). Consistent with these results, of 
cells recovered from OVA-immunized mice, the frequency of IL-4+ cells was 
significantly higher in CD69High trog+ cells, at nearly 50%, compared to the 
CD69High trog– cells, of which 22.3% were IL-4+. (Fig. 3.8H). Collectively, the 
results in Fig. 3.8 provide strong corroboration of the results obtained from the in 
vitro experiments, as trog+ CD4+ T cells generated in vivo displayed enhanced 
survival in vitro, and displayed greater activation, as well as increased GATA-3 
and IL-4 expression, compared to trog– cells from the same animal. These results 
support the hypothesis that trogocytosis-mediated signaling may play a role in 
TH2 differentiation in vivo.   
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Discussion  
Trogocytosis by CD4+ T cells results in the presence of functional, APC-derived 
molecules, including MHC:peptide complexes, on the surface of the trog+ T cell. 
Many of these acquired molecules are not expressed endogenously by the T cell, 
but they clearly have an impact on T cell biology. This has been demonstrated by 
the ability of trog+ cells to impact the activation of other T cells through the 
presentation of trogocytosed molecules [372, 420]. We have found that 
trogocytosed molecules are also engaged by cognate receptors on the trog+ T 
cell [81], however the biological implications of this phenomenon are largely 
unknown. Because trogocytosis commonly occurs during the activation of CD4+ 
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T cells, it is important to develop a comprehensive understanding of the 
biological consequences of this event.  
 
In this study, we examined the impact of sustained, trogocytosis-mediated 
signaling on the activation, effector cytokine production, and differentiation of the 
trog+ T cell. trog+ cells have sustained TCR proximal signaling for at least 72 
hours after APC removal, consistent with cell-autonomous signaling resulting 
from engagement of the receptors on the T cell by trogocytosed molecules (Fig. 
3.1). This sustained signaling was not due to T:T presentation or the presence of 
contaminating APC, as only the trog+ cells maintained a phenotype consistent 
with active TCR signaling and sustained activation, despite the cultures 
containing both trog+ and trog– cells throughout the incubation period. This 
conclusion is further supported by images showing that active TCR signaling 
occurred proximal to trogocytosed molecules on the surface of trog+ cells, 72 
hours after removal from APC (Fig. 3.5). Similar to our previous studies, the 
sustained signaling led to preferential survival of the trog+ cells, as the frequency 
of CD4+ cells that were trog+ increased from roughly 25% immediately after 
recovery from the trogocytosis-assay, to nearly 80% 72 hours later (Fig. 3.1C, 
[81].  
 
Because the trog+ cells had sustained TCR signaling and remained activated 72 
hours after APC removal, we investigated whether trogocytosis-mediated 
signaling might impact the effector cytokine production of these cells. Intracellular 
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cytokine staining of cells 5 hours after recovery from the trogocytosis-assay 
showed that a significantly higher frequency of trog– cells were IFN+ compared 
to trog+ cells. However, IFN levels decreased to resting levels in both trog– and 
trog+ cells over a subsequent 72-hour incubation (Fig. 3.2B,C). While the 
frequency of trog– IL-4+ cells remained at approximately 5% over the 72-hour 
incubation, the average frequency of trog+ IL-4+ cells increased from 10% at 5 
hours, to over 70% at 72 hours (Fig. 3.2D). Because the trog+ cells also 
displayed enhanced survival after APC removal (Fig. 3.1C), the trog+ cells 
accounted for over 98% of the total IL-4+ CD4+ cells at 72 hours. The increase in 
the frequency of trog+ IL-4+ cells over the 72-hour incubation was likely not due to 
increased proliferation of the trog+ cells, as the amount of trogocytosed 
molecules on the trog+ cells remained constant and was not diluted, as would be 
expected for dividing cells. In addition, our previous study showed no discernable 
proliferation of trog+ cells, up to 5 days after removal from APC [81]. These 
results are consistent with the observations that trogocytosed molecules are 
retained in a punctate spot on the membrane of the trog+ cell (Fig. 4, [81, 287]. 
Thus, the data suggest that trogocytosis-mediated signaling led to sustained 
survival of IL-4+ cells, and/or directly impacted the IL-4 expression in the trog+ 
cells.  
 
If the trogocytosis-mediated signaling was simply sustaining the survival of IL-4-
expressing cells, the apparent increase in IL-4+ trog+ cells after APC removal 
might be due to a difference in the ability of TH1 and TH2 cells to perform 
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trogocytosis. We found that when in vitro polarized TH1 and TH2 cells and non-
polarized T cells were compared, the TH2 polarized cells were indeed more 
efficient at performing trogocytosis (Fig. 3). However, the difference in the 
efficiency of trogocytosis alone isn’t sufficient to account for the observed 
phenotypes. While the frequency of trog+ IL-4+ cells increased, the frequency of 
trog+ IFN producing cells decreased from 10% at 5 hours after recovery to 0.5% 
at 72 hours, suggesting that trogocytosis-mediated signaling was not simply 
boosting global intracellular signaling and enhancing the survival of all trog+ cells. 
If that were the case, the frequency of IFN-expressing and IL-4-expressing cells 
would be expected to remain relatively stable. Rather, our results suggested that 
trog+ cells were differentiating into TH2 (GATA-3+ IL-4+) cells after the 
trogocytosis-assay. While robust GATA-3 expression was detected in trog+ cells 
by 72 hours (Fig. 6), anti-CD3 + anti-CD28 stimulation of an aliquot of the 
unstimulated T cell blasts used in the trogocytosis-assay did not result in a 
similar TH2 phenotype (Fig. 4A). Furthermore, T cell blasts immediately prior to 
the trogocytosis assay displayed a relatively homogeneous TH 0/TH1 phenotype 
(Figs. 3.2, 3.3, 3.6). This is consistent with the inherent bias towards a TH1 
phenotype possessed by the 5C.C7 TCR transgenic mice used in our 
experiments [453, 454], and may explain the rapid IFN production, and delay in 
IL-4 expression, observed in the cells after recovery from the trogocytosis-assay. 
 
To eliminate the possibility that the observed IL-4 production in the trog+ cells 
was induced by residual signaling received from the T:APC interaction and 
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directly examine the role of trogocytosis-mediated signaling in the observed TH2 
phenotype of trog+ cells, the reversible Lck inhibitor PP2 was used to halt TCR 
signaling after APC removal, then washed out to allow trogocytosis-mediated 
signaling to resume. We found that after PP2 removal, IFN expression did not 
resume in either trog+ or trog– cells (Figs. 3.4D, 3.4E, S3.3), consistent with IFN 
production being induced by interactions with APC, and not induced further by 
trogocytosis-mediated signaling. In contrast to IFN, the frequency of trog+ IL-4+ 
cells from PP2-treated cultures rebounded to levels equal to untreated cells by 
24 hours after PP2 removal (Fig. 3.4E), and robust IL-4 production was observed 
in trog+ cells 72 hours after PP2 treatment (Figs. 3.4B, C). These significant 
findings show that trogocytosis-mediated signaling was sufficient to drive IL-4 
expression in trog+ cells. The results showing that in vitro TH1 polarized trog+ 
cells began expressing IL-4 and GATA-3, while at the same time decreasing 
expression of IFN and T-bet (Fig. 3.7), further support that, at least in absence 
of external stimuli, trogocytosis-mediated signaling promotes TH2 differentiation. 
Although it is possible that a portion of the trog+ blasts generated under TH1-
polarizing conditions were not fully differentiated to TH1 prior to use in the 
trogocytosis assay, the unique population of double-positive cells expressing 
both IFN and IL-4 (Fig. 3.7B), and the transcription factors T-bet and GATA-3 
(Fig. 3.7F), was only apparent within the trog+ cells generated under TH1-
polarizing conditions. Thus, the data in Fig. 3.7 supports the possibility that 
trogocytosis-mediated signaling is capable of inducing TH1 to TH2 conversion. 
That a greater frequency of TH2 polarized trog+ cells produced IL-4 than Ab-
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stimulated TH2 polarized cells at 72 hours (Fig. 3.7C, D), further supports the 
hypothesis that trogocytosis-mediated signaling is potent in driving IL-4 
expression. Taken together, the data presented here are consistent with the 
concept that trogocytosis-mediated signaling can drive the differentiation of CD4+ 
T cells towards a TH2 phenotype.   
 
The TH2 phenotype observed in vitro with trog+ cells was also apparent in in vivo 
immune responses. Using TCR-transgenic or wild type cells, and with different 
antigen sysTEMs, we observed that in vivo derived CD4+ trog+ cells expressed IL-
4 and GATA-3 at greater levels, and higher cell frequencies, compared to trog– 
cells from the same animal (Fig. 3.8B, C). The observed TH2 phenotype of in vivo 
trog+ cells was less robust than the phenotype developed in in vitro assays, 
however, this is consistent with findings that in some cases, GATA-3 expression 
in TH2 CD4+ T cells is less pronounced in vivo than in vitro [143]. The observed 
phenotype may also be attributed to the inherent nature of the mice used in our 
study towards TH1, which, consequently, further underscores the significance of 
the TH2 phenotype developed by trog+ cells in this study. Further studies are 
underway to characterize the TH2 phenotype of in vivo-generated trog+ cells at 
additional time-points, and after immunization with TH1-inducing components. 
 
It is interesting to speculate on the mechanisms leading to the observed 
association between CD4+ trog+ cells and a TH2 phenotype. It has been found 
that the strength, duration, and “summation” of TCR and costimulatory molecule 
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signaling can substantially impact T helper differentiation [143, 157, 455, 456]. In 
non-differentiated cells, it is possible that immune synapses that result in 
trogocytosis may be of shorter duration and/or generate weaker TCR signaling. 
This would be consistent with observations that weaker TCR signaling drives 
early IL-4 production by T cells [156, 157, 173, 457]. Because only a fraction of 
the APC molecules involved in the immunological synapse are transferred to the 
T cell, trogocytosis-mediated signaling is likely weaker than signaling at the 
synapse. This signaling could further promote IL-4 production, consistent with the 
increased levels of IL-4 observed in trog+ cells over a 72-hour incubation (Figs. 
3.2, 3.4, 3.7). The TH1 to TH2 conversion observed with TH1 polarized trog+ cells 
(Fig. 3.7) further supports this model, as weak TCR-signaling drives TH2 
differentiation, even under TH1- polarizing conditions [139]. In contrast, IFN 
production and TH1 differentiation have been shown to require strong TCR-
signaling [82, 140, 141].  
 
The differences in trogocytosis efficiency between polarized TH1 and TH2 cells 
may also be attributed to morphological differences in the immunological 
synapse formed. We have previously shown that at low Ag concentrations, TH1 
synapses form the classical “bull’s-eye” shape, while TH2 cells form multi-focal 
synapses [83]. In separate live-cell imaging experiments, we have observed that 
small “packets” of MHC:peptide are transferred from APC to non-polarized T 
cells from the immunological synapse, before becoming localized to a punctate 
spot at the distal pole of the T cell membrane [31]. It is inviting to speculate that 
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the multi-focal synapses formed by TH2 cells facilitate trogocytosis much more 
efficiently than the synapses formed by TH1 cells, although that was not directly 
tested here.  
 
There are many biological implications of trogocytosis-mediated signaling driving 
and/or augmenting a TH2 phenotype, while also antagonizing a TH1 phenotype. 
Such implications are amplified when considering that trog+ cells display 
sustained survival, along with enhanced activation and effector cytokine 
production (Figs. 3.1, 3.2, [81]). The TH2 phenotype itself may contribute to the 
enhanced survival displayed by trog+ cells (Fig. 3.2C, [81]), as IL-4 has been 
found to enhance CD4+ survival both in vitro and in vivo [458]. Additionally, a TH2 
phenotype may aid in the heightened activation commonly observed in trog+ 
cells, as TH2, but not TH1 cells, have been shown to be able to revert from an 
anergic state to resume effector functionality [459]. It is possible that trog+ TH2 
cells may significantly aid in the generation of B cell germinal centers, and/or 
increase the quality and duration of protective antibody generation when Ag is 
limited. On the other hand, the low trogocytic potential of TH1 cells, and the TH2 
phenotype induced by trogocytosis-mediated signaling, could act as checkpoint 
to limit unwanted TH1-associated inflammation after Ag clearance.  
 
In cases where a TH2 response is undesirable, excessive CD4+ trogocytosis may 
play a role in exacerbating TH2-mediated autoimmune diseases such as SLE and 
rheumatoid arthritis, heighten allergic reactions, or negatively impact protective 
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cell-mediated responses. In a study by Brown et al., CD4+ T cells from patients 
with multiple myeloma showed increased rates of trogocytosis and the trog+ cells 
displayed inhibitory effects on proliferation of stimulated T cells [284]. The 
authors proposed that trogocytosis might play a role in tumor-induced immune 
suppression through T-cell fratricide and deletion in patients with multiple 
myeloma. It is possible that in tumor environments where antigen is presumably 
abundant, a high frequency of CD4+ trogocytosis and subsequent TH2-
differentiation/conversion could significantly suppress an anti-tumor response. 
Such suppression may be attributed to the inhibition of anti-tumor promoting TH1 
cell differentiation by trogocytosis-mediated signaling, and the high IL-4 
production by trog+ cells, as IL-4 has been shown to both inhibit IFN production 
and prevent activation of naïve T cells [460]. 
 
Beyond driving a TH2 phenotype, continual trogocytosis-mediated signaling may 
aid in the generation of CD4+ memory and/or TFH cells, as both subsets require 
sustained-TCR signaling through repeated Ag-encounter for their differentiation 
[142, 143]. As TH2 to TFH conversion has been found to take between 5 to 7 days 
to occur in vivo [238], examining the phenotype of trog+ cells at extended time-
points is likely necessary to determine this possibility. Studies are currently 
underway in our lab to examine the potential role of trogocytosis-mediated 
signaling in the generation of both TFH and memory CD4+ T cells.   
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In conclusion, the results from this study provide further insight into the role of 
trogocytosis and trogocytosis-mediated signaling in the activation, effector 
cytokine production and differentiation of CD4+ T cells. We report a strong 
association between CD4+ trogocytosis and a TH2 phenotype, which is twofold, 
as TH2 cells are highly efficient at performing trogocytosis, while trogocytosis-
mediated signaling induced TH2 differentiation in both non-polarized, and 
polarized TH1 cells. We propose a model for trogocytosis-mediated CD4+ 
differentiation in which trogocytosed MHC:peptide complexes and costimulatory 
molecules sustain intracellular signaling by engaging their cognate receptors on 
the trog+ T cell. The relatively weak intensity of this signaling leads to early IL-4 
production, which is sustained by trogocytosis-mediated signaling. In the 
presence of IL-4, the sustained trogocytosis-mediated TCR-signaling drives 
GATA-3 expression, and thus, TH2 differentiation [450]. Because trog+ CD4+ 
possess the unique ability to remain activated independently of further APC 
encounter via trogocytosis-mediated signaling, results from this study raise the 
possibility that CD4+ trogocytosis may play a role in augmenting, or inducing a 
TH2-dominant immune response.  
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Introduction 
The adaptability of the immune response is largely defined by the differentiation 
of CD4+ T cells into specialized subsets. Despite extensive research efforts, the 
mechanisms which govern CD4+ T cell differentiation are not fully understood. 
This is largely due to variability in events at the immunological synapse which 
have been found to impact CD4+ differentiation such as TCR affinity [456, 461-
465], antigen density and dose [155, 157, 456, 462, 463], TCR dwell time [82, 
466], and costimulatory molecule signaling [155, 156, 217, 467-475]. In addition, 
TFH differentiation and effector-to-memory transition have been shown to require 
multiple signaling events through subsequent cognate interactions [145, 213, 
476, 477]. Further convoluting the process of deciphering pathways behind CD4+ 
differentiation is the growing evidence for plasticity between various CD4+ 
subsets [144-148, 178, 451, 452]. Due to the wide spread implications for CD4+ T 
cell differentiation in infectious and autoimmune disease, allergy and asthma, as 
well as vaccine and immunotherapy design, understanding the mechanisms 
behind CD4+ differentiation is critical for public health. 
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One notable but unappreciated deviation from the canonical model for T cell 
activation has been the discovery that T cells may act as APC themselves. This 
is accomplished through the acquisition, and subsequent presentation of APC-
derived signaling molecules including peptide:MHC (p:MHC) complexes, and 
costimulatory molecules such as CD80 and CD86, via trogocytosis [81, 285, 287, 
368-372]. Trogocytosed molecules may be fully functional and become properly 
re-expressed on the surface of trogocytosis-positive (trog+) T cells [278, 411]. 
Numerous studies have found that trog+ cells are able to impact the activation of 
responding T cells through the presentation of trogocytosed molecules [369, 371, 
372, 415, 420-426]. In addition, we previously reported that trog+ CD4+ T cells 
are able to perform cell-autonomous signaling through engagement of their 
receptors with trogocytosed ligands, which we have termed trogocytosis-
mediated signaling [81, 412]. In T cell blasts recovered from APC after a 90 min 
incubation, and cultured without additional stimuli, TCR signaling and a 
heightened state of activation was maintained for >72 hours in trog+, but not 
trog─, cells [81, 412]. The trog+ cells subsequently developed a TH2-phenotype 
and increased expression of IL-4, while the trog─ cells produced IFNγ shortly 
after removal of APC, but dramatically decreased IFNγ expression until reaching 
levels comparable to unstimulated cells [412]. These results are consistent with 
models of TCR signal strength in TH2 differentiation, in which the presumably 
weaker signal from trogocytosis-mediated signaling had induced IL-4 expression 
[139, 449, 457, 478]. It was also observed that IL-4 was directed towards 
trogocytosed molecules in a manner reminiscent of TH2 help of B cells [48]. As 
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both TH2 and TFH specialize in providing B cell help [21, 179, 479-481], TH2 
readily differentiate to TFH [238], and TFH differentiation requires multiple TCR 
signaling events [213, 214, 231, 479, 482]; it was possible that the observed 
sustained trogocytosis-mediated signaling could further promote the 
differentiation of trog+ cells towards TFH. Here, we researched this possibility 
using naïve, and activated TCR-transgenic MCC-specific 5C.C7 CD4+ T cell 
blasts and APC expressing CD80, and I-Ek with covalently attached MCC, or 
peptide-pulsed BMDC expressing high levels of CD80, ICOS, CD86, and I-Ek. 
We also examined the phenotype of trog+ cells in vivo using adoptively 
transferred 5C.C7 cells, and pigeon cytochrome c (PCC) or (ovalbumin) OVA in 
wild type animals.  
 
Our results suggest that trogocytosis-mediated signaling drives a phenotype 
consistent with TFH (CD69+ PD-1+ CXCR5+ ICOS+ IL-21+) in vitro, between 3-5 
days post removal from APC. Inhibiting signaling through trogocytosed I-Ek and 
CD80 with neutralizing antibodies, or removal of antigenic peptide from 
trogocytosed MHCII, significantly reduced the TFH phenotype. In vivo-generated 
trog+ cells developed a TFH phenotype more rapidly than trog─ cells following 
immunization with PCC in Sigma Adjuvant System (SAS). The trog+ cells also 
showed increased expression of IL-6, IL-21, and Bcl-6 compared to similarly 
activated trog─ cells 5 days post-immunization of WT mice with OVA.  
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At later time-points the trog+ cells in immunized mice contained a major 
population that resembled T central memory cells (TCM) [483, 484]. Interestingly, 
early TCM-precursors and TFH often share a similar phenotype including increased 
levels of CXCR5 and Bcl-6 [483, 485], and IL-21 has been found to be critical for 
T cell memory formation [440, 486-489]. In addition, repeat cognate-Ag 
interactions that are required for TFH also promote effector-to-memory transition 
[490]. These similarities raise the possibility that trogocytosis-mediated signaling 
may promote the formation of memory CD4+ cells, and is supported by the 
enhanced survival of trog+ cells in absence of APC [81, 412]. 
             Our results suggested that trogocytosis-mediated signaling enhances IL-
2 production, proliferation, and survival of trog+ cells after APC removal. The 
trog+ cells also showed higher expression of the anti-apoptotic protein Bcl-2, and 
CD127. Interestingly, proliferating trog+ cells appeared to unequally distribute 
trogocytosed molecules amongst progeny to produce a trog+ and a trog- 
daughter cell. The daughter cell that retained the trogocytosed molecules also 
expressed levels of Tcf1, reminiscent of memory-precursors formed through 
asymmetric division [491].  
 
Results from this study show that extended trogocytosis-mediated signaling is 
capable of driving CD4+ T cells to develop a phenotype consistent with TFH after 
separation from APC. We also report a strong correlation between trogocytosis 
and memory precursor cells and propose a model in which trogocytosis-mediated 
signaling maintains the survival of CD4+ T cells which have received weaker 
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signals from APC. These findings provide additional insights into both TFH, and 
memory generation in the absence of APC, through the non-conventional 
mechanism of trogocytosis-mediated signaling. 
 
Results  
Trog+, but not trog-, cells maintain a heightened state of activation after 
APC removal.  
 
While multiple studies have suggested that repeated cognate interactions with B 
cells are required for full TFH-differentiation, [209, 221-224], it been demonstrated 
that sustained TCR signaling can drive TFH differentiation independently of B 
cells [213]. As a critical component in TFH differentiation is sustained 
TCR/costimulatory signaling, we hypothesized that sustained trogocytosis-
mediated signaling may drive and/or augment TFH differentiation after separation 
from APC. To examine this possibility, in vitro trogocytosis assays were 
performed using T cell blasts from 5C.C7 TCR-Tg mice. Following the 
trogocytosis-assay, APC were removed resulting in cultures >95% CD4+ T cells 
and <0.1% APC [412]. Recovered T cells were analyzed immediately (day 0), or 
cultured at low density 104 cells/ml to minimize cell:cell interactions and analyzed  
3, and 7 days post-recovery, at 24 h intervals. We previously have shown that 
both trog+ and trog─ cells downmodulate TCR levels and increase CD69 levels, 
suggesting that both populations were similarly activated by APC during the 
trogocytosis assay [412]. Consistent with those findings; Figure 4.1 shows that 
the trog─ and trog+ cells have similar CD69 levels immediately after recovery 
from the trogocytosis assay with either MCC:FKPB APC or BMDC (Fig. 4.1).  
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As with previous results, the trog+, but not trog─, cells retained high CD69 
expression at 3 days and 7 days post recovery (Fig. 4.1). This supports the 
model of trog+ cells retaining active TCR-signaling and subsequent activation in 
the absence of APC. A notable difference in the activation state of cells 
recovered from BMDC or MCC:FKPB APC was observed at day 0. Both the trog+ 
and trog─ cells recovered from MCC:FKPB fibroblasts had significantly lower 
levels of CD69 compared to respective populations recovered from BMDC. This 
is likely due to substantially higher expression of both I-Ek and CD86, and slightly 
higher levels of CD80 and ICOS-L on BMDC compared to MCC:FKBP (Fig. 
S4.1). The trog+ cells recovered from MCC:FKPB APC increased CD69 
expression between Day 0 and Day 7, while the median CD69 expression of the 
trog─ cells decreased, by 43% on Day 3, and was only 30% higher than resting 
cells 5 days after removal of APC. In contrast, trog+ and trog- cells recovered 
from BMDC decreased in CD69 expression between Day 0 and Day 3, by 61% 
or 81% respectively. However, at 7 days post-recovery, the CD69 expression in 
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trog─ cells was unchanged, while on the remaining trog+ cells CD69 expression 
increased by 40% (Fig. 4.1).  
In vitro-generated trog+, but not trog─ cells, develop a TFH-like phenotype 
after separation from APC.  
 
Signaling from the inducible T cell costimulator (ICOS) has been found to play a 
major role in TFH differentiation, [209, 217, 242, 492, 493]. Immediately after 
recovery from APC, the trog+ cells showed moderately higher levels of ICOS 
compared to the trog─ cells (65% in cells recovered from BMDC, and 34% in cells 
recovered from MCC:FKBP) (Fig. 4.2, top). At 7 days post-recovery, there was a 
clear difference in expression in ICOS expression with the trog+ cells recovered 
from BMDC showing a 3.2-fold increase in ICOS levels over trog─ cells, and a 
2.2-fold increase in cells recovered from MCC:FKBP APC (Fig. 4.2, bottom).   
 
TFH cells are largely identified by high expression of CXCR5 and PD-1 [494-496], 
as well as CD69 [497], which was maintained in trog+, but not trog─ cells (Fig 
4.1). Consistent with the ICOS expression levels (Fig. 4.2), and the kinetics of 
TFH-differentiation [498], figure 4.3 shows that immediately post-recovery (Day 0), 
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a TFH-like phenotype, (PD-1+ CXCR5+), was apparent in 9.2% of trog+ cells, but 
only 3% of trog─ cells recovered from BMDC (Fig. 4.3, left). Similar levels were 
observed in cells recovered from MCC:FKBP (7.04% of trog+ and 3.54% of trog─ 
cells) (Fig. 4.3, right), suggesting that the higher activation induced by BMDC did 
not immediately impact CXCR5 and PD-1 surface expression levels. In cells 
recovered from BMDC, the trog+ cells maintained CXCR5 expression at both 3 
days and 7 days post recovery, while the frequency of the CXCR5+ PD-1+ 
population increased to 15%, and 19% of trog+ cells, respectively (Fig. 4.3, left, 
red). In contrast, the trog─ cells initially had lower CXCR5 levels at 3 days 
compared to trog+ cells, and by 7 days, CXCR5 expression was similar to 
unstimulated cells (Fig. 4.3 left, blue). Accordingly, only 2.23%, and 0.3% of the 
trog─ cells were PD-1+ CXCR5+ at 3 and 7 days post-recovery.  
               The trog+ cells recovered from MCC:FKBP APC showed markedly 
different expression patterns compared to those recovered from BMDC. High 
CXCR5 expression was maintained in the trog+ cells at 3 and 7 days post-
recovery, and the frequency of PD-1+ CXCR5+ cells increased to 26.2% by Day 3 
and had reached 57.5% on day 7 (Fig. 4.3, right, red). The trog─ cells showed a 
very slight increase from 3.5% at Day 0 to 5.0% by Day 3. By Day 7 the CXCRS+ 
PD-1+ cells were only 4.4% of trog- cells (Fig. 4.3, bottom, blue). 
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Consistent with a TFH phenotype, the trog+ cells from either APC cultures 
expressed higher levels of Bcl-6 and IL-21 compared to trog─ cells 7 days post-
recovery (Fig. 4.4). Consistent with the surface phenotype data (Fig 4.1-3), when 
trog+ cells from the two different APC cultures were compared, the cells recovered 
from MCC:FKPB APC expressed higher levels of Bcl-6 and IL-21 (Fig. 4.4A, 
right), compared to trog+ cells recovered from BMDC (Fig. 4.4A, left). When 
BMDC-stimulated populations were compared, a significantly higher frequency of 
trog+ cells were IL-21+ at days 2, 3, 5, and 7.  IL-21 expression by trog+ cells 
peaked on Day 5, when 29% of the cells were IL-21+ (Fig. 4.4B, top). Similarly, 
when cells recovered from MCC:FKPB APC were compared, a significantly higher 
percentage of trog+ cells were IL-21+ at each time-point observed from 1 to 7 days 
post-recovery (Fig. 4.4B, bottom).  
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Collectively, the data in Figs. 4.1 to 4.4 show that trog+, but not trog─, cells are 
highly efficient at developing a CXCR5+ PD-1+ BCl-6+, IL-21+ phenotype 
consistent with TFH, after APC removal. When trog+ cells recovered from both 
BMDC and MCC:FKPB APC were compared, cells recovered from MCC:FKPB 
showed a more robust TFH-like phenotype. Regardless of the APC type, these 
data strongly suggest that trogocytosis-mediated signaling promotes TFH 
differentiation in trog+ cells. 
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Trogocytosis-mediated signaling drives a TFH phenotype  
The data in Figs. 4.2-4.2 show that after removal of APC, a substantial 
percentage of trog+ cells developed a phenotype consistent with TFH, while the 
trog─ cells do not. However, initial priming of CD4+ T cells by DC may result in a 
pre-TFH phenotype including the upregulation of CXCR5 to promote T cell 
migration towards B cell follicles/GC [218]. Therefore, the observed TFH-like 
phenotype in the trog+ cells may be due to signals from APC promoting TFH 
differentiation, and not a direct result of trogocytosis-mediated signaling. To 
address the impact of trogocytosis-mediated signaling on development of the 
observed TFH phenotype, CD4+ T cell blasts were used in an in vitro trogocytosis 
assay with MCC-loaded BMDC or MCC:FKPB APC. Immediately following 
recovery from BMDC, peptide was removed from trogocytosed MHC by mild acid 
elution. Aliquots of acid-stripped cells were then cultured with 10 µM cognate 
MCC peptide or 10 µM irrelevant hemoglobin (Hb) peptide as a negative control. 
With cells recovered from MCC: FKPB APC, trogocytosed TCR and CD28 
signaling was neutralized using 20 µM anti-I-Ek and/or 20 µM anti-CD80 purified 
antibodies. Because the MCC: FKPB APC do not express CD86 (Fig. S4.1A), 
antibodies against CD86 were not included.   
 
After recovery on Day 0, cells recovered from BMDC and MCC:FKPB APC 
exhibited minimal difference in PD-1 and CXCR5 expression on trog+ and trog- 
cells, similar to the Day 0 in figure 4.1 (data not shown). As the TFH-phenotype 
peaked at 5 days post-recovery (Fig. 4.4B) cells were examined at this time-
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point. The acid-stripped cells cultured with Hb peptide had substantially 
decreased TCR signaling as determined by pZAP-70 signaling, compared to 
non-treated or acid-stripped cells cultured in the presence of MCC (Fig. S4.1B). 
Similarly, neutralization of I-Ek and CD80 in MCC:I-Ek-recovered cultures greatly 
decreased TCR signaling (Fig. S4.1B). 
 
 Figure 4.5 shows that removal of antigenic-peptide had a drastic impact on the 
phenotype of the trog+ cells, on Day 5, reducing the frequency of PD-1+ CXCR5+ 
trog+ cells by nearly 50% (15.2% PD-1+ CXCR5+) compared to untreated controls 
(29.7% PD-1+ CXCR5+) (Fig. 4.5, left). On the other hand, addition of MCC to 
peptide-stripped cells increased the frequency of PD-1+ CXCR5+ cells by 87%, 
with 55.6% of these cells displaying the TFH-like phenotype (Fig. 4.5, left). Similar 
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results were obtained with antibody neutralization as anti-I-Ek and anti-CD80 
reduced the frequency of trog+ PD-1+ CXCR5+ cells by 71% to 20.4% PD-1+ 
CXCR5+ compared to the untreated trog+ cells (70.5% PD-1+ CXCR5+) (Fig. 4.5, 
right). The frequency of PD-1+ CXCR5+ was very low in trog─ cells across the 
board, ranging from 2.91% in untreated BMDC cultures to 1.07% in Hb-
supplemented cultures, to 3.15% in MCC-supplemented cultures. Similarly, of 
cells stimulated with MCC:FKPB, the frequency of CXCR5+ PD-1+ trog- cells was 
2.91% in untreated cultures and 1.07% in Ab-neutralized cultures (Fig. 4.5, 
middle). 
 
In parallel cultures, T cell blasts were stimulated for 6 hours each day during a 5 
day incubation as a control. These cells did not develop a robust PD-1+ CXCR5+ 
population, consistent with the requirement for IL-21 or IL-6, and costimulatory 
molecules such as ICOS for TFH differentiation. It also suggests that the TFH-like 
phenotype displayed by the trog+ cells was not simply a result of sustained-
signaling TCR and CD28 signaling. 
 
Trogocytosis-mediated signaling drives a TFH phenotype in naïve T cells in 
absence of APC 
 
                 We next examined whether trogocytosis-mediated signaling could 
drive a TFH-phenotype in trog+ naïve CD4+ cells. Like the activated blasts, trog+ 
and trog- naïve cells displayed comparable levels of activation immediately after 
recovery from the trogocytosis assay (as determined by CD69 expression) (Fig. 
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4.6). As anticipated, naïve cells were more highly activated by MCC-loaded 
BMDC compared to MCC:FKBP APC (Fig. 4.6).  
 
Figure 4.6 shows that approximately 22.3% of the trog+ naïve T cells cultured for 
5 days after removal from an 18 hour trogocytosis assay using MCC-loaded 
BMDC were CXCR5+ ICOS+. In comparison, acid-stripped cells cultured in Hb 
peptide had a 4.5% decrease in the frequency of trog+ CXCR5+ ICOS+ cells to 
12.5% (Fig 4.6, left). Addition of MCC to acid-stripped cultures led to a 2.2-fold 
increase to 49.8% of the trog+ CXCR5+ ICOS+ cells (Fig. 4.6, left). The trog─ cells 
in Hb-supplemented peptide-stripped cultures showed a 78% decrease in the 
frequency of CXCR5+ ICOS+ cells compared to untreated cultures, to 4.07% 
CXCR5+ ICOS+. MCC-supplementation increased this frequency 2.5-fold to 
10.2%, which, while substantially higher compared to trog─ cells from untreated 
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cultures, was well below the frequency of trog+ cells displaying this phenotype 
(Fig. 4.6, left) 
 
To assess the individual roles of TCR and costimulatory signaling, neutralizing 
Abs anti-CD3 and anti-CD28 or anti-CD3 alone or anti-CD28 alone, were added 
to naïve cells recovered from MCC:FKBP APC as in Fig. 4.3. The data in Fig. 4.6 
(right) suggests that TCR signaling through trogocytosed-p:MHC complexes and 
CD80 signaling both played a role in development of the apparent TFH 
phenotype. Compared to trog+ cells from untreated cultures, the trog+ cells from 
cultures with only neutralizing CD80 Abs had a 42% decrease in CXCR5+ ICOS+ 
cells (Fig. 4.6, second from left). The trog+ cells from cultures containing 
neutralizing anti-I-Ek Abs showed a 61.5% decrease in this population (Fig. 4.6, 
second from right), while the trog+ cells from cultures containing both anti-I-Ek 
and anti-CD80 showed a further 83% reduction in the phenotype to 9.58% (Fig. 
4.6, far right), compared to trog+ cells from untreated cultures (Fig. 4.6, far left).  
 
Trog- cells can develop a TFH phenotype in the presence of APC  
It was apparent that trogocytosis-mediated signaling was playing a role in driving 
a TFH-phenotype in the trog+ cells, however it was also possible that the cells that 
performed trogocytosis were predisposed to developing the TFH phenotype, and 
trogocytosis-mediated signaling was simply sustaining their survival. To examine 
whether the trog+ cells inherently developed a TFH-like phenotype more readily 
than trog─ cells in cases where Ag receptor signaling was not limited to 
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trogocytosis-mediated signaling, unlabeled MCC:FKBP APC were added back at 
a 1:10 APC:T cell ratio to stimulate cultures of CD4+ T cell blasts immediately 
after recovery from an 90 min trogocytosis-assay with biotin-labeled MCC:I-Ek 
APC. Figure 4.7 shows that addition of MCC:FKBP to cultures after recovery 
from the trogocytosis assay, increased the frequency of PD-1+ CXCR5+ trog─ 
cells increased from 5.56% to 22.5%. Interestingly, in these same cultures the 
frequency of PD-1+ CXCR5+ trog+ cells decreased from 63.7% in untreated 
cultures, to 38.4% (Fig. 4.7, right). Consistent with previous data, neutralizing 
antibodies against trogocytosed I-Ek and CD80 led to a 67.2% decrease in the 
frequency of PD-1+ CXCR5+ trog+ cells compared to cells recovered from 
untreated cultures (Fig. 4.7, middle). 
 
IL-21 expression in trog+ cells is enhanced by trogocytosis-medited 
signaling in vitro 
 
In line with the observed decrease in PD1+ CXCR5+ trog+ cells, after acid-
stripping or Ab blockade of trog-mediated signaling (Fig. 4.5), the frequency of IL-
21+ trog+ cells at 5 days was significantly reduced by the same treatments (Fig. 
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4.8). Significantly fewer trog+ cells from peptide-stripped cultures supplemented 
with Hb were IL-21+ (22.8%) compared to untreated cultures (32.5%). In contrast, 
the frequency of IL-21+ trog+ cells in acid-stripped and MCC-supplemented 
cultures increased to 40.3% (Fig. 4.8, left). Similarly, neutralizing trogocytosis-
mediated signaling with anti-I-Ek and anti-CD80 decreased the frequency of IL-
21+ trog+ by 55% (Fig. 4.8, right).  
 
In absence of APC, the development of a TFH phenotype is dependent on 
trogocytosis-mediated signaling 
 
To confirm that the trog+ cells were developing a TFH-like phenotype in absence 
of APC, naïve 5C.C7 cells recovered from a standard 18 h in vitro trogyctosis-
assay were FACS-sorted into trog+ and trog─ populations. These purified trog+ 
and trog- cells were cultured individually in vitro and analyzed 72 hours later. At 
this early time-point, 11.2% of the trog+, but only 1.53% of the trog─ cells 
recovered from MCC:APC were CXCR5+ PD-1+ (Fig. 4.9, top). Similarly 11.8% of 
trog+ and 3.36% of trog- cells acid-stripped cells cultured in MCC peptide were 
CXCR5+ PD-1+ (Fig. 4.9, middle). Culturing with irrelevant Hb peptide after acid-
stripping led to a massive decrease in the frequency of CXCR5+ PD-1+ cells to 
only 2.72% of the trog+ and 1.75% of the trog─ cells (Fig. 4.9, bottom). Due to low 
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recovery following the FACS sort, later time-points were not examined in these 
experiments. 
 
TFH-associated cytokines IL-21, IL-4 and IL-6 are polarized towards 
trogocytosed molecules  
 
We previously reported that IL-4+ trog─ cells, >80% of trog+ cells had IL-4 
directed towards trogocytosed molecules, while there was no IL-4 polarization in 
trog- cells. To expand those previous studies, here intracellular polarization of IL-
6 and IL-21 was examined. As seen in figure 4.9, 3 days post-recovery, IL-21 and 
IL-6 were directed towards trogocytosed molecules. As TFH cells help cognate B 
cells through directed secretion of these cytokines, this data strengthens the 
case for development of a TFH-phenotype observed in the trog+ cells. 
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In vivo-generated trog+ cells can rapidly display a TFH-like phenotype  
The in-vitro data presented above suggests that trogocytosis-mediated signaling 
drives development of a TFH phenotype in trog+ cells after separation from APC. 
To examine whether a similar phenotype occurs in vivo, 105 naïve 5C.C7 CD4+ T 
cells were adoptively transferred into naïve WT B10.A mice. Six hours later, 
recipients were immunized S.C. with PCC protein emulsified in Sigma Adjuvant 
System (SAS). Mice with adoptively transferred cells immunized with SAS alone 
served as negative controls. Spleens were harvested 3, and 7 days post-
immunization and Ag-specific CD4+ T cells were identified by MCC:pMHCII 
tetramer staining (Fig. S4.1C). As murine CD4+ cells do not endogenously 
express MHCII, trog+ cells were identified by the presence of trogocytosed 
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MHCII. Three days post-immunization, 2.3% of MCC:MHCII+ CD44+ cells were 
PD-1+ CXCR5+ (Fig. 4.11A, left) This number increased to 7.4% by 7 days post-
immunization (Fig. 4.11A, middle). Transferred cells from mice immunized with 
SAS alone did not develop a TFH-phenotype, as expected in absence of Ag (Fig. 
4.11A, right). The data in Fig. 4.11B suggests that the transferred trog+ cells were 
able to more rapidly express PD-1 and CXCR5 compared to transferred trog- 
cells. Of the PD-1+ CXCR5+ cells recovered 3 days post-immunization, 78.4% 
were trog+ (Fig. 4.11B, middle). However, by 7 days post-immunization, the 
frequency of CXCR5+ PD-1+ cells that were trog+ had decreased to an average of 
37.2% (Fig. 4.11B, right). These findings suggest that even in the presence of 
APC, the trog+ cells were more proficient at rapidly developing a phenotype 
consistent with TFH. 
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Trog+ cells express higher levels of IL-21, IL-6, and Bcl-6 compared to trog- 
cells in vivo  
 
To further examine the in vivo relationship between trog+ cells and a TFH 
phenotype protein, WT B10.a mice were immunized S.C. with OVA protein in 
SAS, or SAS alone. Proximal draining lymph nodes were collected 5 days post-
immunization and recovered cells were analyzed via flow cytometry. Figure 
4.12A shows that of CD44+ similarly-activated (CD69High) CD4+ T cells, the trog+ 
cells (red) had increased expression levels of IL-21 (left), IL-6 (middle), and Bcl-6 
(right), compared to trog─ cells (blue). Meanwhile, the trog- cells had only slightly 
higher expression levels of IL-21, IL-6, and BCL-6 than CD4+ T cells from SAS-
only controls (shaded grey). A significantly greater frequency of trog+ cells were 
IL-21+ (10.2%), IL-6+ (17.1%), and BCL-6+ (6.8%) compared to CD4+ cells from 
SAS-control mice. The trog+ cells had significantly higher frequencies of IL-21+ 
(38.4%), IL-6+ (39.2%) and BCL-6+ (22.1%), compared to CD4+ cells recovered 
from SAS-control mice (Fig. 4.12B). 
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  In vitro-generated trog+, but not trog─, cells develop a TFH phenotype in 
vivo, in absence of exogenous antigen 
 
While the phenotype was consistent between in vivo-generated and in vitro-
generated trog+ cells, the role of trogocytosis-mediated signaling in the 
phenotype in vivo could not be determined above. To more directly examine the 
role of trogocytosis-mediated signaling in vivo, an 18 hr trogocytosis assay using 
naïve 5C.C7 T cells and MCC:FKBP APC was performed. Recovered T cells 
were purified from APC and adoptively transferred into naïve WT B10.A mice. 
trog+ cells were identified by the presence of biotinylated APC membrane-derived 
proteins. Similar to the in vitro data (Fig. 4.2), neither the trog+ or trog─ cells 
contained a substantial population of PD-1+ CXCR5+ cells 24 hrs post-adoptive 
transfer (Fig. 4.13A, left). However, by 72 hrs post-transfer, 17% of the trog+ cells 
were PD-1+ CXCR5+, while only 1.4% of the trog─ cells shared this phenotype 
157 
 
(Fig. 4.13, right). Since the only source of stimulation in these animals was 
trogocytosed pMHCII and other APC-derived proteins, the appearance of the 
CXCR5+ PD-1+ population only in the trog+ cells strongly supports the hypothesis 
that trogocytosis-mediated signaling can drive TFH differentiation both in vitro and 
in vivo. 
 
In vivo-generated trog+ cells display a TFH phenotype during an active 
immune response, but resemble T central memory cells after contraction of 
the immune response. 
 
The data thus far suggested that trogocytosis-mediated signaling was playing a 
critical role in the apparent TFH-like phenotype, however, the role of trogocytosis-
mediated signaling in maintaining this phenotype was unknown. We observed 
that 7 days following the adoptive transfer of naïve 5C.C7 cells into WT B10.A 
mice, and immunization with MCC+SAS as in Fig. 4.11, a significantly greater 
frequency of trog+ cells resembled PD-1+ CXCR5+ TFH-like cells at 25%, 
compared to only 2.9% of trog─ cells. Although the total numbers of PD-1+ 
CXCR5+ cells from each population was similar, due to only 10% of responding 
cells being trog+, and thus consistent with the data in Fig. 4.11. The TFH 
phenotype was not maintained beyond the expected time for Ag-persistence in 
trog+ or trog- cells, and by 28 days post-immunization the TFH-like PD-1+ CXCR5+ 
population had decreased by 95% and 68% in the trog+, and trog─ populations, 
respectively. (Fig. 4.13A, left).  
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We did however, observe a noticeable difference in the phenotype of the trog+ 
and trog- cell at this time-point, as a substantial percentage (57% on average) of 
the trog+ cells were expressing CXCR5, but not PD-1, compared to only 6.8% of 
trog─ cells. Interestingly, these results are consistent with a study by Pepper et 
al., which showed that early in the immune response, CXCR5+ PD-1- cells 
contain a high frequency of CCR7+ T central memory (TCM)-precursors which 
displayed sustained-survival after Ag-clearance [484]. In contrast, CXCR5+ PD-1+ 
TFH population decreased in frequency after Ag-clearance until disappearing 
altogether [484]. Looking back, a significantly higher frequency of the the trog+ 
cells were CXCR5+ PD-1- compared to trog- cells at 7 days post-immunization. 
In addition the trog+ cells also expressed higher levels of CCR7 compared to 
trog─ cells at D28 (Fig. 4.14B), consistent with a TCM-phenotype. Recent studies 
have found many similarities between TFH and CD4+ memory precursors, and TFH 
themselves are able to become memory cells. Thus the apparent TFH-like 
phenotype displayed early by the trog+ cells did not exclude the possibility that 
these cells were memory/memory-TFH precursors  
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Trogocytosis-mediated signaling increases memory-potential in CD4+ T 
cells 
 
The results in Fig. 4.14 indicated that the while the trog+ cells displayed a 
phenotype consistent with TFH, this phenotype was not observed at late time-
points. Rather, the phenotype of the trog+ cells 28 days post-immunization 
resembled that of memory-precursors. Interestingly, a recent study by Kaji et al., 
found that while GC B cells were critical for full TFH differentiation, a population of 
memory precursors that resembled TFH cells in CXCR5, PD-1, and BCL-6 
expression developed in absence of GC B cells [499]. In addition, TFH cells 
themselves are able to readily become memory TFH [222, 500, 501], and in human 
studies, circulating CXCR5+ memory cells represent a distinct subset of memory 
cells which are able to rapidly migrate to B cell follicles and promote secondary 
memory responses [483]. Thus, the collective results from Fig. 4.2-4.14 
substantiates the in vitro TFH data, while also raising the possibility that trog+ cells 
may also contain a high frequency of TCM precursors.  
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Trogocytosis-mediated signaling enhances CD4+ T cell survival.  
A defining hallmark of memory T cells is their ability to survive for extended 
durations after Ag clearance. [502-504]. While the exact mechanisms which 
permit the survival of CD4+ memory cells in absence of Ag is currently unknown, 
prolonged Ag exposure and sequential cognate T cells:APC interactions promote 
the transition to memory [318, 499]. Consistent with this, our previous reports 
show that after separation from APC, trog+, but not trog─ cells retain active 
signaling and that trog+ enhanced survival compared to trog─ cells up to 5 days in 
vitro [81, 412].  
 
To investigate whether the frequency of trog+ cells also increased in vivo as Ag 
became depleted, WT B10.A mice were immunized with PCC in SAS as in Fig. 
412. Spleens were harvested and MCC:MHC tetramer+ (Fig. S4.1D) CD44+ CD4+ 
cells were analyzed for the presence of trogocytosed MHCII and CD80/CD86 at 
5, 7, 15, 21, and 28 days post immunization. A sharp increase in the percentage 
of trog+ cells was observed between 7 and 14 days post-immunizationn from an 
average of 6.8% during the peak of the immune response (Day 7), to 22% 14 
days post-immunization. The frequency of trog+ cells further increased on Day 21 
to an average of 52% of cells being trog+, then decreased slightly to an average 
of 42.2% on 28 days post-immunization (Fig. 4.15A). 
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 However, in this in vivo system, it was unclear when these cells performed 
trogocytosis, and it was possible that cells present in later time-points had 
recently performed trogocytosis from APC expressing residual Ag. To directly 
assess the role of trogocytosis-mediated signaling in the enhanced survival 
displayed by the trog+ cells, the frequency of trog+ cells was measured in cells 
recovered from in vitro trogocytosis assays in the presence of neutralizing 
antibodies or with MCC peptide removed as in Figs. 4.4 and 4.5. Figure 4.15B 
shows that blocking trogocytosis-mediated signaling with neutralizing antibodies 
clearly impacted the survival of T cell blasts at 3, and 5 days post-recovery from 
a 90 min in vitro trogocytosis-assay with MCC:FKBP. While on average, 33.5% of 
recovered CD4+ T cells were trog+ immediately after recovery from the 
trogocytosis assay, by day 3, untreated cultures were on average, 61.4% trog+. 
Antibody blockade of trogocytosis-mediated signaling resulted in a significantly 
lower frequency of trog+ cells, and only 16.3% of cells from cultures containing 
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anti-I-Ek + anti-CD80 Abs were trog+ (Fig. 4.15B, left). At 5 days post recovery, 
the frequency of trog+ cells in cultures containing neutralizing Abs had dropped 
further to 1.8%, while 54% of the cells from untreated cultures were trog+(Fig. 
4.15B, left). Similar trends in survival were observed in cultures of T cell blasts 
recovered from a 90 min trogocytosis assay with MCC-loaded BMDC. While the 
frequencies of trog+ cells were nearly equal in untreated and peptide-stripped + 
supplemented MCC, the cultures where peptide was removed and supplemented 
with Hb showed a 79% reduction in trog+ cell frequencies to only 4.8% trog+, 
compared to the 22.8% trog+ from cultures where MCC was replenished (Fig. 
4.15B, left). By 5 days post-recovery, only 1.2% of CD4+ cells from peptide-
stripped cultures supplemented with Hb were trog+, which was significantly lower 
than the 4.8%, and 5.5% of trog+ cells in untreated, or MCC-supplemented 
cultures, respectively (Fig. 4.15B, right).  
                   Trogocytosis-mediated signaling also appeared to be critical for the 
survival of naïve T cells following activation. In cultures where naïve cells were 
used in an 18-hr trogocytosis assay with MCC:FKBP APC, 33.6% of recovered 
cells immediately after the trogocytosis assay were trog+ (Fig. 4.14C, left). 
Blocking trogocytosed I-Ek led to a significant decrease in the frequency of trog+ 
cells at 3 days post-recovery as only 4.7% of cells from cultures containing 
neutralizing Abs were trog+, compared to 16.5% of untreated cells (Fig. 4C, left). 
By 5 days post-recovery only 0.9% of cells from cultures containing neutralizing 
Abs were trog+, which was significantly lower than the 4.2% of cells from 
untreated cultures (Fig. 4.15C, left). Finally, in cultures of naïve cells recovered 
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from an 18-hr trogocytosis assay with MCC-loaded BMDC, 34.4% of CD4+ cells 
were trog+ immediately following recovery from the trogocytosis assay. At 5 days 
post-recovery, on average, 6.8% of cells from peptide-stripped cultures 
supplemented with MCC were trog+, compared to 4.7% of CD4+ cells from 
untreated cultures being trog+ (Fig. 4.15C, right). The removal of Ag-peptide 
however, led to a significant decrease in the frequency of trog+ cells to only 0.8% 
of cells from these cultures being trog+ cells (Fig. 4.15C, right). These results 
suggest that trogocytosis-mediating is critical for the survival of trog+ cells in the 
absence of exogenous Ag.  
 
Trogocytosis-mediated signaling drives IL-2 expression in trog+ cells 
To examine downstream effects of sustained trogocytosis-mediated signaling  
that could impact the survival of trog+ cells, expression levels of IL-2 and CD25 
(IL-2Rα) were examined, as early IL-2 signaling is critical for T cell activation, 
survival, and proliferation [505-507]. Naïve 5C.C7 CD4+ T cells were used in an in 
vitro 18 hr trogocytosis assay using either MCC-loaded BMDC, or MCC:FKPB 
APC. Five days post-recovery, cells recovered from BMDC were, on average, 
42.5% of the trog+ but only 18.2% of the trog─ cells were expressing both IL-2 
and CD25 (Fig. 4D, left). In cultures where peptide was stripped following the 
trogocytosis assay, the addition of irrelevant Hb peptide resulted in a significantly 
lower frequency (15.2% average) of IL-2+ CD25+ trog+ cells, compared to the 
59.6% average of trog+ cells recovered from MCC-supplemented cultures. While 
the trog─ cells from cultures supplemented with Hb showed a 41% decrease in 
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IL-2+ CD25+ cells compared to untreated cultures, from 24.6% to 14.7% (Fig. 
4.16, third from left). The addition of MCC appeared to have little impact on IL-2 
expression in trog+ cells, leading to an increase from 24.6% in untreated cultures, 
to 25.6% in MCC-supplemented cultures. The addition of MCC had substantial 
impacts on the trog+ cells however, increasing the frequency of IL-2-expressing 
CD25+ cells by 36% to 68.4% of trog+ cells (Fig. 4.16, third from left). Correlating 
with the massive cell death observed in Fig. 4.15, neutralizing trogocytosis-
mediated signaling with anti-I-Ek + anti-CD80 significantly resulted in an 80% 
decrease in IL-2+ CD25+ trog+ cells. From 62.6% of trog+ cells from untreated 
cultures, to only 12.5% of trog+ cells (Fig. 4.16, right). In addition to a decrease in 
frequency, there were clearly lower numbers of trog+ cells in peptide-stripped+ 
Hb (Fig. 4.16D, second from left), and cultures containing neutralizing Abs (Fig. 
4.16, far right), compared to untreated (Fig. 4.16, left), or peptide-stripped 
cultures supplemented with MCC (Fig. 4.16, third from left).  
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             Consistent with the decrease in IL-2 expression, and survival, inhibiting 
trogocytosis-mediated signaling by removing antigenic peptide or blocking the 
signaling with neutralizing Abs led to decreased activation (as indicated by 
CD69) (Fig. 4.17, top). The clear reduction in IL-2 expression resulting from the 
inhibition of trogocytosis-mediated signaling is further made apparent in 
histogram overlays (Fig. 4.17, bottom)  
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In vivo-generated trog+ cells showed a similar phenotype. Ninety-six hours post-
immunization with PCC+SAS, the trog+ adoptively transferred naïve 5C.C7 cells 
expressed higher levels of IL-2 and CD25 compared to trog─ cells from the same 
animals (Fig. 4.18).   
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Trogocytosis-mediated signaling sustains the survival of trog+ cells in an 
IL-2-independent manner 
 
The inhibition of trogocytosis-mediated signaling led to a reduced expression of 
pro-survival cytokines including IL-2 (Fig. 4.16) and IL-21 (Fig. 4.8) by the trog+ 
cells. While trogocytosis-mediated signaling appeared to clearly play a role in the 
survival of the trog+ cells in the absence of APC, the direct impact of 
trogocytosis-mediated signaling vs the presence of survival-associated cytokines 
was unclear. To address this, exogenous recombinant IL-2 (100 U/mL) was 
added to an aliquot of T cell blasts in cultures with, or without, anti-I-Ek/anti-CD80 
neutralizing antibodies. In cultures supplemented with IL-2 alone, there was a 
modest, but significant increase in the number of trog+ cells relative to input 
compared to untreated cultures from 26.5%, to 32%, respectively. The trog─ cells 
showed a greater response to IL-2, showing a survival rate of 23% compared to 
only 9.5% of cells from untreated cultures (Fig. 4.19, left). In cultures where anti-
I-Ek/anti-CD80 neutralizing antibodies were added, addition of exogenous IL-2 
led to significantly increased survival of both the trog- and trog+ cells. However, 
the increased survival was most apparent in the trog- cells, which increased from 
6.2% to 22% relative to input, which was similar to the trog- cell numbers in the 
absence of neutralizing Abs + IL-2. On the other hand, the trog+ cell numbers 
were only partially rescued by supplemented IL-2 in the presence of neutralizing 
Abs, increasing the survival rate from 12% to 18.2%, which was significantly 
lower than the survival rate of trog+ cells in cultures with IL-2 alone. 
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The data in Fig. 4.15 show that trogocytosis-mediated signaling plays a major 
role in the survival of both trog+ and trog─ cells after separation from APC, but 
through different mechanisms. While it appeared that the survival of recovered 
trog─ cells blasts was largely dependent upon exogenous IL-2, trogocytosis-
mediated signaling appeared to be playing a distinct role in the survival of the 
trog+ cells independently of IL-2 (Fig. 4.19).  
 Consistent with previous studies, the trog+ blasts recovered from 
MCC:FKPB APC showed enhanced survival compared to the trog─ cells (Fig. 
4.15, left). In contrast to this pattern, the frequency of naive trog+ cells recovered 
from either MCC:FKBP, or BMDC decreased between 0 and 3 days post-
recovery (Fig. 4.15C). Interestingly, at day 5 the frequency of trog+ cells 
recovered from MCC:FKBP APC had rebounded, while the cells recovered from 
BMDC continued to decrease (Fig. 4.15C). One explanation for these observed 
differences is that the cells more highly activated by BMDC were proliferating at a 
greater rate than the cells that were comparably less-activated by MCC:FKBP. 
As the trogocytosed material was limited to what was acquired during the 
trogocytosis assay, either trogocytosed molecules were being diluted or 
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internalized by the trog+ cells resulting in undetectable levels, or unequal 
distribution of trogocytosed molecules was occurring during the division of trog+ 
cells. It was also possible that the trog─ cells were showing greater rates of 
proliferation.  
 
Trog+ cells rapidly proliferate, and produce trog+ and trog─ progeny 
To ascertain whether the discrepancies in the frequency of trog+ cells in cultures 
where naïve cells were used in the trogocytosis-assay, or BMDC were used as 
APC, a series of experiments was conducted to assess the proliferation, and 
retaining of trogocytosed molecules on proliferating trog+ cells. First, we 
examined the proliferation in trog+ and trog─ cells using CFSE-labeled naïve 
5C.C7 T in an 18 h in vitro trogocytosis assay with MCC:I-Ek APC. For 
comparison, an aliquot of the CFSE-labeled naïve cells was added to anti-CD3 + 
anti-CD28 coated plates at the same time cells were added to the APC during 
the trogocytosis-assay (t= -18 h). Figure 4.20A shows that at 24 hrs post-
recovery, of CD44+ CD4+ cells, a small portion of the trog+ cells and nearly none 
of the trog─ or Ab-stimulated cells had performed a single cells division (Fig. 
4.20A, top). By 48 hrs the majority of the trog+ cells had performed at lest one 
cell division. Meanwhile a noticeably lower frequency of the trog─ cells had 
divided, and Ab-stimulated cells showed a similar proliferation pattern as the 
trog─ cells had undergone one or two cell-divisions (Fig. 4.20A, middle gray). 
Interestingly, at 72 hrs the majority of the trog+ cells remained at 1- 2 divisions, 
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while it appeared that the trog─ and Ab-stimulated cells had continued to divide 
(Fig. 4.20A, bottom).  
 
Antibody-blockade against I-Ek and CD80 dramatically reduced the proliferation, 
and survival of trog+ and trog- cells (Fig. 4.20B), suggesting that trogocytosis-
mediated signaling was necessary for the proliferation of the trog+ cells after APC 
removal. 
 
Compared to naïve cells recovered from MCC:FKPB APC, cells recovered from 
BMDC showed markedly different proliferation patterns. The trog─ cells appeared 
to undergo comparable, if not more rounds of cell division compared to trog+ cells 
at 48 hrs, and similar levels to the trog+ cells by 72 hrs (Fig. 4.21, left). Removal 
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of peptide and supplementation with Hb led to decreased survival of both trog+ 
and trog─ cells, consistent with the findings in Fig. 4.20 (Fig. 4.21A, left), 
however, there was no substantial difference in the extent of proliferation in the 
trog+ cells from Hb-supplemented cultures compared to MCC-supplemented 
cultures (Fig. 4.21 left). Somewhat unexpectedly, at 72 hrs, a higher frequency of 
the trog+ cells from Hb-supplemented cultures had undergone 4-5 rounds of cell 
division compared to trog+ cells from MCC-supplemented cultures (Fig. 4.21B, 
top right). However, in terms of cell numbers, the removal of Ag and 
supplementation with Hb led to a decrease in cell numbers within all cellular 
divisions (Fig. 4.21B, right bottom).  
 
Trog+ cells show increased proliferative responses compared to trog- cells 
The seemingly disproportionate increase in the number of trog─ cells that had 
undergone 3-4 divisions between 48 and 72 hrs (Fig. 4.20) could be due to a 
delay in the proliferation of these cells. Another possibility for this observation 
could be that the proliferating trog+ cells were producing trog─ progeny. To test 
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this, 5-ethynyl-2′-deoxyuridine (EdU)-incorporation was examined in proliferating 
trog+ and trog─ cells. Using a combination of EdU incorporation and Ki-67 Gossel 
et al. have reported a strategy to determine whether a cell is currently undergoing 
cell division or has recently divided but it not actively proliferating. If a cell is 
actively dividing, it will express both Ki-67 and have incorporated Edu. If a cell is 
not expressing Ki-67 but has incorporated Edu, this suggests that the cell has 
recently divided, but is no longer actively proliferating, or a progeny of an actively 
dividing cell [508]. Therefore, if unequal distribution of the trogocytosed 
molecules was occurring during cell division, it would be expected that the trog─ 
cells would contain a high proportion of EdU+ Ki-67─ cells, while a higher 
frequency of the trog+ cells would be both EdU+ and Ki-67+. The data in Fig. 
4.22A show that 48 hrs after naïve 5C.C7 cells were recovered form a standard 
in vitro trogocytosis assay, 25.6% of the trog+, but only 7.4% of the trog─ cells 
were actively dividing, as determined by Ki-67 expression (Fig. 4.21A). At 72 hrs 
post-recovery, 16.5% of the trog+ and 13.1% of the trog─ were expressing Ki-67. 
In comparison, 21% and 12.2% of anti-CD3 + anti-CD28-stimulated cells were Ki-
67+ at 48 and 72 hours, respectively. Between 48 and 72 hrs, the frequency of 
recently-divided (EdU+), Ki-67─ cells increased 3.13-fold in the Ab-stimulated 
cells, and 3.13-fold in the trog+ cells (Fig. 4.22, right, left). The trog─ cells 
however, showed a 5.79-fold increase in this population, which did not fit well 
with the frequency of actively proliferating cells detected at 48 hrs (Fig. 4.22, 
middle).  
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Trogocytosis-mediated signaling enhances the cellular division of trog+ 
cells  
 
As Ag-experienced CD4+ T cells require less stimulation compared to naïve cells 
to induce proliferation [37, 509], trogocytosis-mediated signaling may differently 
impact the proliferation of previously-activated and naïve cells. Due to the 
variability in the size of activated blasts, it is difficult to assess proliferation 
confidently with cell proliferation dyes. Ki-67 was instead used to identify actively-
proliferating cells. It appeared that trogocytosis-mediated signaling was impacting 
the proliferation of previously-activated trog+ cells, as antibody blockade against 
trogocytosed I-Ek and CD80 led to a decrease in Ki-67 in the trog+ cells (Fig. 
4.22B).  
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Trogocytosed molecules are retained through early cell divisions 
While trogocytosis-mediated signaling appeared to be playing a role in driving 
proliferation of lesser activated cells in vitro (Fig. 4.21), it was unclear whether in 
vivo-generated trog+ and trog─ cells would show similar patterns. To examine 
this, naïve CellTrace-labeled 5C.C7 cells were adoptively transferred into naïve 
WT B10.A mice. Six hours later, adoptive-transfer recipients were immunized 
with SAS alone, or PCC+SAS. Spleens were harvested 96 hrs later and cell 
proliferation was assessed by dilution of CellTrace dye. As expected, adoptively 
transferred cells in SAS-only immunized controls did not proliferate in the 
absence of Ag (Fig. 4.23A). In contrast, the transferred cells in SAS+PCC-
immunized mice underwent massive expansion. Interestingly, trogocytosed I-Ek 
and CD80 were clearly present on cells which had undergone fewer (1-5) rounds 
of cell division, but was scarce on cells which had undergone >6 rounds of cell 
division (Fig. 4.23A). Consistent with the phenotype of memory-precursors early 
in the immune response [510, 511], of adoptively transferred CD44+ CD4+ T cells 
that had performed 1-4 cell divisions, expression levels of the anti-apoptotic 
protein Bcl-2 were higher in trog+ cells compared to trog─ cells (Fig. 4.23B, left). 
However, this was not the case in the few trog+ cells that had performed 5+ cell 
divisions, as they displayed similar expression patterns to the trog- cells of similar 
cell divisions (Fig. 4.23B, right).  
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The results in Figs. 4.20-4.23 suggest that trogocytosis-mediated signaling was 
critical for the proliferation of weakly-activated cells, but the extent of proliferation 
in highly activated cells was occurring independently of trogocytosis-mediated 
signaling (Fig. 4.21). Although, it was apparent that trogocytosis-mediated 
signaling was playing a role in the survival of the trog+ cells, particularly those 
that had undergone fewer rounds of cell division (Fig. 4.21B). The 
disproportionate frequency of trog- cells that had divided between 48 and 72 
hours relative to the frequency of cells actively-dividing at 48 hrs (Fig. 4.22A) 
could be due to the increased survival of recently-divided cells. When also 
considering the maintained levels of trogocytosed material (as determined by 
staining intensity), through multiple rounds of cell division, these results raised 
the possibility that these molecules may be unequally distributed to daughter 
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cells during the division of the trog+ cells. Thus, potentially accounting for the 
increase of trog- cells which appeared to have divided multiple times at 72 hrs.  
 
During asymmetric division of trog+ cells, daughter cells that retain 
trogocytosed molecules resemble memory precursors.  
 
In addition to the effector-to-memory transition model, it has been found that 
naïve T cell progeny may become predestined for memory fate during the 
immune synapse through subsequent asymmetric division [329, 491, 512, 513]. In 
this model, the signaling molecules converged at the immune synapse, along 
with high levels of localized TCR and costimulatory signaling, form a region of 
polarity known as the proximal pole. Concurrent with the formation of the immune 
synapse, surface molecules including CD43 and CD45 migrate, and localize at a 
focal point opposite of the immune synapse to form the distal pole complex [70, 
514]. As this axis of polarity is established during the immune synapse, it has 
been proposed that asymmetric division occurs in the first few rounds of cell 
division following activation [329]. In this model, the daughter cell containing the 
proximal pole which received strong TCR and costimulatory signaling from the 
APC becomes an effector cell which continues to proliferate at high rates. 
Meanwhile, the cell containing the distal pole complex are more likely to be 
memory-precursors, which are less terminally differentiated, and do not expand 
as rapidly as the effector cell population [329, 330, 515]. Asymmetric division is 
not limited to naïve T cells, as memory T cells have also been observed to 
asymmetrically divide upon re-challenge [331]. Interestingly, we have previously 
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observed that during the immune synapse, >82% of trog+ cells had trogocytosed 
molecules localized to the distal pole [81] (Fig. 4.24).  
 
 
To examine whether the cells with retained trogocytosed molecules resembled 
memory precursors, we examined Tcf1 expression in trog+ and trog─ cells. In 
asymmetrically dividing CD4+ T cells, Tcf1 has been observed to be retained at 
high levels on the daughter cell resembling TCM precursors [516]. In an influenza 
model, of CD4+ T cells which had undergone only several rounds of divisions, 
Tcf1High cells retained the capacity to self-renew, producing Tcf1-silenced 
daughter cells which resembled terminally-differentiated effector cells, and a 
memory-like sibling cell which maintained high Tcf1 expression [491]. Consistent 
with these findings and the possibility that trog+ cells resemble memory-precursor 
cells, 48 hrs post-recovery from a trogocytosis assay using naïve 5C.C7 CD4+ 
cells, the trog+ cells recovered from MCC:FKBP APC largely maintained high 
Tcf1 expression through 1-3 cell divisions, while the trog─ cells within equal 
divisions expressed low levels of Tcf1 (Fig. 4.25A, top). This pattern was not 
observed in the cells recovered from BMDC, and both trog+ and trog─ cells 
showed lower levels of Tcf1 compared to trog+ cells recovered from MCC:FKBP 
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APC (Fig. 4.25B). Intriguingly, the trog+ cells recovered from BMDC which were 
peptide-stripped and supplemented with Hb, showed higher levels of Tcf1 
compared to the trog+ cells from peptide-stripped cultures supplemented with 
MCC (Fig. 4.25B).  
 
 
 
A similar phenotype was observed in in vivo-generated trog+ cells. Of adoptively 
transferred cells as in Fig. 4.23., in cells that had undergone 1-4 cell divisions 
following immunization with PCC+SAS, the trog+ cells showed higher levels of 
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Tcf1 compared to the trog─ cells (Fig. 4.26). Similar to the trends for Bcl-2 
expression (Fig. 4.23), of adoptively transferred CD44+ cells which had 
undergone >5 rounds of cell division, the difference between Tcf1 expression in 
trog+ vs trog─ cells was less apparent and did not resemble asymmetric 
distribution of Tcf1. However, the trog+ cells still showed 62% higher expression 
of Tcf1 as determined by MFI, compared to the trog─ cells (Fig. 4.26, right).  
 
 
To test the possibility that asymmetric distribution of trogocytosed molecules was 
occurring, naïve 5C.C7 cells were used in an 18 h in vitro trogocytosis assay with 
fluorescent NHS-Sulfo BODIPY-labeled MCC-loaded BMDC. Recovered cells 
were FACS sorted into trog+ and trog─ populations, CFSE labeled, then cultured 
separately in vitro for 72 h. While >95% of the trog+ cells were displaying 
trogocytosed molecules immediately following the FACS sort, by the end of the 
3-day incubation, the frequency of cells displaying trogocytosed molecules 
decreased within each successive cell division (Fig. 4.27, middle). The trog─ 
sorted as expected, did not display trogocytosed molecules within cells of any 
cell division. (Fig. 4.2, right),   
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The above data suggest that the trog+ cells had undergone asymmetric division, 
where one cell retained both the trogocytosed molecules and Tcf1. To confirm 
this, immunofluorescent imaging was performed on naïve 5C.C7 cells 32 hrs 
post-recovery from an in vitro trogocytosis assay with MCC:FKBP APC. Four 
hours prior to fixation and staining, cells were treated with the actin 
polymerization inhibitor cytochalasin D to inhibit cytokinesis. Consistent with the 
data in Fig. 4.27, in >70% of the dividing cell conjugates, the cells with 
trogocytosed molecules also had higher levels of Tcf1. Representative images 
are shown in Fig. 4.28. Interestingly, it also appeared that unlike observations in 
trog+ T cell blasts [412], the majority of naïve trog+ cells had multiple punctate 
spots of trogocytosed molecules. Suggesting that it is possible for a trog+ cell to 
produce more than one trog+ progeny throughout it’s proliferation cycle. 
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Collectively, the data in above strongly suggest that during cell division, at least 
in lesser activated naïve CD4+ T cells, trogocytosed molecules are unequally 
distributed to daughter cells in a manner reminiscent of asymmetric division. In 
this case, the daughter cells which retained the trogocytosed molecules 
resembled memory precursors, while the trog─ progeny did not.  
 
Trog+ cells rapidly increase expression of TFH-associated molecules PD-1, 
CXCR5, and IL-21 upon in vitro re-stimulation 
 
 In addition to extended periods of survival, another important function of memory 
cells is to display rapid recall responses. To test the recall responses of trog+ and 
trog- cells, naïve 5C.C7 cells were used in an 18-hr in vitro trogocytosis assay 
with MCC:FKBP APC. Recovered cells were cultured in vitro for 7 days and then 
re-stimulated for 3 hrs at a 1:1 ratio with MCC:FKBP APC, followed by a 3-hr 
incubation. Following this brief period of re-stimulation, the trog+ cells increased 
in their frequency of PD-1+ CXCR5+ cells by 50%, (from 39.5% to 59.3%), while 
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the trog- cells showed a 32% increase in the frequency of this population. 
Although, at significantly lower overall frequencies compared to the trog+ cells, 
the frequency of PD-1+ CXCR5+ trog- cells increased from 5.36% to 7.06% 
following in vitro re-stimulation (Fig. 4.29). To examine IL-21 expression in the 
context of a recall response, the trog+ cells generated in vivo from the experiment 
in Fig. 4.14 were isolated from spleens of PCC+SAS-immunized mice 28 days 
post-immunization, and were re-stimulated in vitro as in Fig. 4.29A. Here, the 
trog+ cells also displayed rapid expression of IL-21 upon re-stimulation while the 
trog- cells did not. Although, this may be an unfair comparison due to the overall 
lack of a robust TFH-like phenotype displayed by the trog- cells. Regardless, these 
results show that the trog+ cells were able to rapidly upregulate TFH-associated 
markers upon re-stimulation, consistent with a memory-phenotype.  
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In vitro-generated trog+ cells display prolonged survival in vivo, in absence 
of antigen 
 
The results thus far suggested that the trog+ cells displayed characteristics 
consistent with memory-precursor cells. However, the results showing that the 
trog+ cells can produce trog- progeny through asymmetric division, and the 
uncertainty of when trogocytosis occurred in the trog+ cells in vivo made it difficult 
to ascertain the long-term phenotype of the initial trog+ cell. To isolate the time 
frame for trogocytosis to occur to a set duration, and limit Ag to trogocytosed 
molecules, naïve 5C.C7 cells were used in an 18-hr in vitro trogocytosis assay 
with MCC:FKPB.  
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Immediately following recovery, cells were FACS sorted into CD4+ trog+ and 
trog─ populations. Immediately following the FACS sort, 2 x 105 FACS-sorted 
trog+, trog─, or unstimulated 5C.C7 cells were transferred into separate naïve WT 
B10.A recipient mice. An experimental timeline is shown in Fig 4.30A. In line with 
the in vitro data (Figs. 4.1, 4.5), 24 hrs after adoptive transfer, cells recovered 
from the spleens of trog+ and trog─ adoptive transfer recipients showed a 
similarly activated phenotype as indicated by CD69 levels (Fig. 4.30B), and high 
expression of CD44 and low CD62L (Fig. 4.30C).  
Five days post-adoptive transfer, the transferred (MCC:MHCII tetramer-positive 
CD44+) cells that had migrated to the LN of trog─ recipients contained a higher 
frequency of actively-proliferating cells (46.7% on average) as determined by Ki-
67 staining (Fig. 4.31), and had slightly increased numbers (Fig. 4.32) compared 
to the cells from trog+ recipients.  
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Consistent with the in vitro data, on average 73.4% of the transferred cells which 
retained trogocytosed I-Ek and CD80 (which accounted for on average 11% of 
CD44+ MC:MHCII+ cells in the spleen, and 8.5% in the lymph nodes) were 
actively proliferating, compared to 35.4% of the cells without detectable I-Ek / 
CD80 (Fig. 4.31). It also appeared that the trog+ had noticeably higher levels of 
CD44 in the cells recovered from spleens compared to the transferred cells from 
the trog─ recipients (based off of fluorescence intensity) (Fig. 4.31), suggesting 
that the cells from the trog+ recipients had remained highly activated, and that 
those from the trog- recipients were becoming less activated.  
 
It appeared that the trog+ cells more rapidly exited circulation compared to trog+ 
cells, as 24 hours post-transfer, there was a significantly lower frequency of 
transferred cells in trog+ recipients in circulation compared to trog─ recipients 
(Fig. 4.32, left), while similar frequencies of transferred trog+ and trog─ cells were 
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observed in cells recovered from the lymph nodes and spleen (Fig. 4.32, middle, 
right). In support of the in vitro data, the transferred cells in the trog+ recipients 
showed enhanced survival compared to the cells from trog─ recipients, and at 21 
days post-adoptive transfer, there was a significantly higher frequency of 
transferred cells in the spleens of trog+ recipients compared to trog─ recipients 
(Fig. 4.32, right). In support of the in vitro data, the transferred cells from trog+ 
recipients which had retained trogocytosed I-Ek/CD80 also expressed high levels 
of CXCR5, (Fig. 4.33, left) while neither the I-Ek/CD80─ cells in these animals, or 
the transferred cells recovered from trog─ recipients expressed CXCR5 (Fig. 
4.33, left). Similar to the transferred cells in immunized mice (Fig. 4.13), 21 days 
post-transfer, the transferred cells from trog+ and trog─ recipients did express 
high levels of PD-1, although the cells from trog+ recipients showed lower levels 
of PD-1 expression compared to those from trog─ recipients (Fig. 4.33, middle). 
Compared to transferred cells recovered from the trog─ recipients, the cells from 
trog+ recipients expressed higher levels of CCR7, consistent with CD4+ TCM cells 
(Fig. 4.33, right).  
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Consistent with the frequency observed in the immunized WT mice, an average 
of 61.5% of transferred cells in trog+ recipients had retained I-Ek and CD80 
expression on day 21, compared to only 6.95% of the cells from trog─ recipients 
(Fig. 4.34, left). To test the recall ability of the transferred cells, mice were 
immunized with MCC peptide alone or PCC emulsified in SAS on day 21. Forty-
eight hours later, spleens, proximal draining lymph nodes, and skin from the 
injection site were collected. While immunization with peptide alone in the 
absence of high costimulation typically leads to anergy in naïve CD4+ cells [33], 
memory CD4+ cells have been found to respond to injection with a single peptide 
epitope [517]. Interestingly, 47% of the MCC:MHCII+ cells recovered from the 
spleens of trog+ recipients displaying trogocytosed I-Ek/CD80, expressed Ki-67 
after immunization of peptide alone, while only 18% of the cells without 
trogocytosed molecules were Ki-67+. In transferred cells recovered from trog─ 
recipients, only 8.7% of all transferred CD44+ CD4+ cells were Ki-67+. It appeared 
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that proliferation in these cells was induced by peptide, as <1% of the cells from 
either trog+ or trog─ recipients were Ki-67+ on day 21 prior to the immunization. In 
the presence of adjuvant, the transferred cells from trog+ recipients showed only 
a slight increase in the frequency of Ki-67+ cells (49.6% on average) compared to 
MCC peptide-immunization (40.5% average Ki-67+). The I-Ek/CD80-negative 
cells showed a substantial increase in the frequency of actively-dividing cells 
however, from 18% in MCC-immunized animals, to an average of 44.3% in 
PCC+SAS-immunized animals (Fig. 4.34A, middle). Meanwhile, the cells from 
the trog─ recipients responded more robustly to immunization with MCC+SAS 
compared to MCC alone, increasing the total frequency of Ki-67+ transferred cells 
to an average of 15.5%.  
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Notably, 59% of the Ki-67+ cells in trog─ recipients on day 23 had acquired I-Ek + 
CD80, suggesting that these cells performed trogocytosis from APC in vivo and 
more readily proliferated than cells which did not perform trogocytosis (Fig. 
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4.34A, bottom right). This is supported by the fact that cells from trog─ recipients 
on day 21, and those recovered from mice 48 hrs post-immunization with MCC 
alone showed similar frequencies of I-Ek/CD80+ cells (6% and 6.9%, 
respectively), however after immunization with PCC + SAS, 26.7% of cells in 
trog- recipients had become trog+ (Fig. 4.34A, bottom).  
 Interestingly, the cells in the lymph nodes did not display the same pattern 
as those in the spleen, as both I-Ek/CD80 positive, and negative cells from the 
trog+ recipients response to peptide alone, and a lower frequency of the cells in 
the draining LN were I-Ek/CD80+ compared to those in the spleen (Fig. 4.34B). 
However, a noticeable difference was still observed between the cells recovered 
from the trog+ (71% Ki-67+) and trog─ (29% Ki-67+) recipients after immunization 
with MCC (Fig. 4.34B, right). The cells from the trog─ recipients responded to 
immunization with PCC+SAS, and 61% of MCC:MHCII+ cells in these animals 
were Ki-67+ 48 hours post-immunization (day 23), compared to 76% of cells from 
trog+ recipients (Fig. 4.34, right). To address potential TRM cells, skin was 
collected from the immunization site, as well as a portion of skin from the distal 
side of the mouse. Very few MCC:MHCII+ cells were detected in a similar-sized 
portion of the skin distal to the injection site (not shown). However, there was a 
striking difference between the cells in the trog+ and trog─ recipients at the site of 
the immunization (Fig. 4.34C). Using the markers CD69 and CD103 to identify 
TRM cells, of the transferred CD44+ cells in the trog+ recipients, 22.3% of cells in 
MCC-immunized mice, and 62.1% of cells in MCC+SAS-immunized mice 
showed a TRM-phenotype (Fig. 4.34C, top). In contrast, only 6.98% of transferred 
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CD44+ cells in trog─ recipients immunized with MCC, and 13.7% of SAS+PCC-
immunized mice shared this phenotype (Fig. 4.34C, bottom). 
 
To further assess the recall responses of transferred cells, the frequency of 
MCC:MHC+ cells relative to all CD4+ T cells in the spleens of mice at day 21 and 
48 hrs after immunization on day 21, was determined. Immunization with 
PCC+SAS led to a significantly higher frequency of MCC:MHCII-tetramer+ cells in 
naïve WT, trog+ and trog─ recipients compared to the frequencies on day 21. In 
naïve WT animals however, this frequency remained below 0.15% (Fig. 4.35A, 
left). Immunization with PCC+SAS also led to significantly higher frequencies of 
MCC:MHCII+ cells compared to MCC-immunized mice in naïve WT, and trog─ 
recipients, while the difference between MCC:MHCII+ cell numbers in  
PCC+SAS immunized trog+ recipients was found to be significantly greater 
compared to day 21, but was not significantly different compared to MCC-
immunized mice (Fig. 4.35A). This suggests that the response of the Ag-specific 
cells in the trog+ recipients was consistent with memory cells.  
 
Finally, IL-21 expression was examined in cells recovered from the spleens of 
trog+ and trog─ recipients 48 hrs after immunization with MCC or PCC+SAS. 
Despite the apparent increase in proliferation displayed by cells in the trog+ 
recipients after immunization with MCC alone, the IL-21 expression was similar in 
cells from MCC-immunized trog+ and trog─ recipients (Fig. 4.35B, left). The 
transferred cells from the trog+ recipients however displayed a 28% increase in 
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IL-21 expression compared to transferred CD44+ cells from trog─ recipients after 
immunization with PCC+SAS (Fig. 4.35B, right).  
 
 
As the early-memory checkpoint in mouse models typically falls between 21-28 
days after the start of the immune response [518], at 21 days it is difficult to 
confirm that these cells were true-memory cells, which can persist for months to 
years after infection. However, in typical models the early checkpoint has been 
based off of immunization models, where Ag-reserves may persist for weeks, 
and thus making it difficult to determine if the cells were true memory or were 
activated by Ag-reserves. In this system, Ag was limited to the APC during the 
trogocytosis assay, and trogocytosed molecules. Therefore, these results 
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suggest that trog+ cells contain a population of initial cells, or produce progeny, 
that show enhanced survival, and recall responses consistent with a memory-
phenotype. Because in the absence of exogenous Ag the rate of trogocytosis is 
expected to be low, that a substantial percentage of surviving cells in the trog+ 
recipients still displayed trogocytosed I-Ek / CD80 21 days post-transfer (Fig. 
4.34), suggests that the original cells which performed trogocytosis made up a 
major portion of the persisting early memory-like population.  
 
Discussion 
 The ability of CD4+ T cells to differentiate into specialized TH subsets is a critical 
component in generating protective immunity against a multitude of pathogens. 
Despite the central role these cells play in generating adaptive immunity, the 
mechanisms behind CD4+ differentiation are not completely understood. In 
particular, the multi-step signaling process required for TFH differentiation, [519], 
and the mechanisms governing memory T cell formation are largely unknown. 
Here, we set out to investigate the potential role for trogocytosis-mediated 
signaling in TFH differentiation. We hypothesized that, because TFH differentiation 
requires repeat-cognate TCR+costimulatory signaling events, that sustained 
trogocytosis-mediated signaling may promote TFH differentiation after APC 
removal.  
While it has been agreed on that TFH development requires repeat 
cognate interactions, the required source of these interactions has not been 
solidified. The proposed requirement for B cells in the development of TFH is most 
194 
 
likely due to the fact that the B cells become the most abundant APC for 
activated T cells in the lymph node following clonal expansion. This is supported 
by the fact that repeated interactions with DC can also drive TFH differentiation 
[213]. Irrespective of the APC type, TFH differentiation requires repeated TCR 
signaling after initial activation [213, 228, 231, 244]. In this system, T cells were 
cultured in absence of APC, but still developed a TFH-like phenotype. This 
strongly suggests that trogocytosis-mediated signaling is capable of driving TFH 
differentiation in the absence of APC. If there were contaminating residual APC 
in the cultures, then it would be expected that a higher frequency of the trog─ 
cells would also be able to develop a TFH phenotype. This is supported by the 
results that the addition of APC to cultures of recovered cells led to a significant 
increase in the amount of CXCR5+ PD-1+ trog─ cells (Fig. 4.7). Somewhat 
unexpectedly, the addition decreased the frequency of CXCR5+ PD-1+ trog─ cells 
compared to cultures containing only recovered T cells. This could possibly be 
due to hyporesponsiveness developed by the T cells, which can occur after 
repeat exposure to APC [520].   
The T cells recovered from the MCC:FKBP APC were highly efficient at 
developing a TFH phenotype, consistent with the positive correlation between 
TCR binding strength and TFH differentiation [521]. That trogocytosis-mediated 
signaling was contributing to the apparent TFH phenotype developed in the trog+ 
cells was further supported by the findings that removal of MCC from 
trogocytosed pMHCII complexes led to a dramatic decrease in CXCR5, PD-1, 
and IL-21 expression.  
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Following adoptive transfer of naïve 5C.C7 cells into naïve animals, and 
immunization with PCC, 3 days -post immunization we found that nearly 80% of 
the PD-1+ CXCR5+ cells were also trog+ (Fig. 4.11). However, the frequency of 
trog+ cells decreased to 40% by 7 days post-immunization. This strongly 
suggests that the trog+ cells are able to more rapidly become TFH compared to 
trog─ cells, while trog─ cells are able to efficiently become TFH given extra time. 
One explanation for these results could be that trogocytosis-mediated signaling 
contributed to the signaling required for TFH differentiation after the trog+ cells 
dissociated from APC. On the other hand, the trog─ cells would require re-
engaging APC to receive sequential TCR signaling, reflected by a delay in the 
differentiation to TFH. The kinetics of the immune response and TFH differentiation 
further support this theory. Because purified populations of CD4+ TCR-Tg T cells 
were transferred into the naïve animal, at early time-points, the number of 
responding B cells would be expected to be low. Therefore, due to the time it 
takes for TFH differentiation to occur (at least 2-3 days in vivo), the trog+ cells 
likely started developing a pre-TFH phenotype shortly after activation by DC 
outside of the B cell follicles. Seven days post-immunization, the host B cells 
would have had time to undergo clonal expansion, and thus effectively drive TFH 
differentiation in the trog─ cells through increased B:T cell interactions. These 
findings raise the possibility that trogocytosis-mediated signaling may have 
significant impacts on the kinetics of GC formation and B cell activation. 
Trogocytosis-mediated signaling appeared to enhance IL-21 expression in 
the trog+ cells, as blocking signaling or removal of Ag from MHCII led to a 
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significant decrease in the frequency of IL-21+ trog+ cells. These results, 
combined with the observation that IL-21 was polarized towards trogocytosed 
molecules, suggest that trogocytosis-mediated signaling may further promote TFH 
differentiation by driving IL-21 expression. The IL-21 produced by the trog+ cells 
may play a separate role in vivo, as IL-21 can impact multiple aspects of T cell 
immunity including maintaining cell survival, proliferation, effector function, and 
memory formation.  
          The observed proliferation of I-Ek/CD80- cells in the LN in response to 
immunization with MCC alone could be due to residual activation in the LN 
compared to the spleen, as a higher frequency of the LN cells were performing 
active cell division, and displayed higher levels of CD44 compared to those in the 
spleen 5 days post-transfer (Fig. 4.34B).  
It also appeared that the cells from the trog+ recipients were able to 
respond to immunization with PCC+SAS in the periphery more readily than the 
cells in the trog─ recipients. This was indicated by a massive recruitment of these 
cells to the site of injection in trog+ recipients compared to the trog─ recipients 
(Fig. 4.34C). Interestingly, these cells resembled TRM, however they were not 
largely present in the injection site of mice immunized with MCC peptide alone, 
suggesting that the presence of these cells may be an artifact of the adjuvant. 
However, it has been shown that human TRM are able to leave the tissue to enter 
circulation and take up residency in other sites. Therefore, it is possible that the 
trog+ cells also produce TRM. Without an initial site of Ag-delivery to induce a 
primary response in this model, it was difficult to assess TRM responses. In the 
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study shown in Fig. 4.14, skin from the injection site was collected at the time of 
harvest (7 and 28 days post-immunization), and no substantial differences in  
MCC:MHCII+ CD69+ CD103+ TRM cells were observed between cells isolated 
from the skin proximal, or distal, to the injection site (data not shown).  
From these experiments, the possibility for T:T presentation between the 
trog+ cells after adoptive transfer into animals cannot be ruled out. However, 
even with this possibility, the results suggest that the trog+ cells produce a more 
robust memory-like population compared to the trog─ cells in absence of 
exogenous Ag and is a novel finding.  
Collectively the results from chapter 4 suggest that trogocytosis-mediated 
signaling plays a role in the generation of cells resembling both TEM and TCM. 
Importantly, the results suggest that trogocytosis-mediated signaling plays a 
critical role early in the response by enhancing the survival and proliferation of 
cells weakly-activated by APC. Such activation may promote Tcf1 expression 
and enhance the differentiation to TFH, or transition to memory [522].  
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Chapter 5  
Discussion 
Although trogocytosis was first observed nearly a half-century ago [362], the 
biological implications of this event were not appreciated until recent decades 
with the discovery that trog+ cells can act as functional APCs through the 
presentation of trogocytosed molecules. T-T Ag presentation after trogocytosis 
can significantly impact the activation state of the responding cell. The various 
effector phenotypes and distinct migratory patterns of trog+ cells add additional 
layers of complexity to models of canonical T cell activation and differentiation. 
The biological implications of trogocytosis-mediated signaling are underscored by 
the fact that trogocytosis occurs at significant frequencies (~10-20%) in 
responding T cells during an active immune response. Collectively, the published 
literature, and the results from this dissertation, demonstrate the clear 
immunomodulatory potential of trogocytosis, and subsequent signaling events. 
 A largely-understudied component of trogocytosis is how this event 
impacts the trog+ cell itself. Studies have shown that irrespective of the context, 
the trog+ cells show enhanced effector ability compared to their trog─ 
counterparts [406][282, 374, 391, 400]. The authors in these studies suggested 
that trogocytosis was the result of a highly activated state in the trog+ cells. While 
the heightened state of activation likely contributed to trogocytosis, the findings 
here suggest that trogocytosis-mediated signaling itself could have been 
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responsible for the observed phenotype in trog+ cells. While activated cells 
perform trogocytosis more efficiently than naïve cells [391], the activation kinetics 
of trog+ cells are not consistent with those of trog- cells after removal of TCR 
stimulation [81,406,412]. This suggests that the trogocytosed molecules impact 
the activation and, potentially effector functions of the trog+ cell. We previously 
reported that T cells can engage their surface receptors with trogocytosed 
signaling molecules to achieve sustained TCR signaling [81]. This signaling 
correlated with a heightened activation state, and enhanced survival of the trog+ 
cells. Because the duration and frequency of TCR signaling can significantly 
impact T cell activation, effector function, and differentiation, it is possible that 
trogocytosis-mediated signaling impacts the trog+ cells beyond allowing for 
sustained survival. The objective of this dissertation was to examine how 
trogocytosis-mediated signaling impacted CD4+ effector function and subset 
differentiation in the context of the trog+ T cell.  
 
Part I. The Mechanisms of CD4+ Trogocytosis 
On the Requirement for Active Signaling in T cell Trogocytosis 
 T cell trogocytosis is largely dependent on active signaling, and primarily 
involves the acquisition of molecules that are bound to ligands on APC. However,  
the acquisition of “bystander” molecules such as MHC class-I have been 
observed on trog+ CD4+ T cells [523]. It has been proposed that such acquisition 
occurs due the proximity of the non-engaged molecules to recycling TCR bound 
to ligands on the APC. Support for this come from the findings by Gu et al., who 
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demonstrated that CTLA-4 knockout nTreg, or iTreg with CTLA-4 neutralized with 
anti-CTLA-4 Abs, acquired their CD80 and CD86 from DC [277]. This 
trogocytosis event was not due to CD28 engagement with CD80/CD86 as 
neutralizing antibody blockade against CD28 did not affect the acquisition of 
CD80 or CD86. Curiously, they also reported that the addition of an endocytosis 
inhibitor (unnamed) to T cell:DC co-cultures did not impact CD80/CD86 
acquisition by the Treg. Thus, they speculated that Treg acquire CD80/86 via an 
unknown mechanism independently of CTLA-4, CD28, or PD-L1 binding, or 
endocytosis. Why they did not examine MHC in this study was unclear. One 
possible explanation for these results could be that CD80/CD86 were transferred 
via APC-derived exosomes that were bound to T cell surface receptors.  
 
APC-Derived Exosome Acquisition as a Mechanism for Trogocytosis 
 The acquisition of pMHC complexes by T cells through APC or tumor-
derived exosomes has been found to confer T cells with antigen-presenting 
ability, and has been proposed as one mechanism of intercellular membrane-
protein transfer [524]. APC-derived exosomes include signaling, and non-
signaling molecules, including lysosomal membrane protein-1 (Lamp-1), CD86, 
CD37,  MHC1, MHCII, and transferrin receptor (TfR) [525-528]. Thus, the 
acquisition of these exosomes is consistent with the presence of non-engaged 
molecules detected on trog+ T cells. In support of this theory, cognate T cell 
interactions with DC or B cells increase the rate of MHCII-rich exosomal 
formation by APC [529]. Furthermore, DC and B cell-derived exosomes can 
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stimulate activated, but not naïve CD4+ T cells both in vitro, and in vivo [529]. 
However, evidence suggests that exosomal acquisition of APC-derived 
molecules is distinct from trogocytosis. For example, pre-treatment of DC with 
the ATPase inhibitor CMA (which also inhibits exosome formation) prior to co-
incubation with CD8+ T cells, led to only a minimal decrease in PD-L1 transfer to 
T cells [375]. However, separation of co-incubated T and DC by a trans-well 
membrane prevented transfer of PD-L1 to T cells [375], suggesting that the PD-
L1 trogocytosis was contact-dependent. In a similar study using human cells, 
while co-cultured DC and T cells resulted in high levels of HLA-DR acquisition, 
separation of T cells and DC by a trans-well membrane inhibited virtually all 
transfer of HLA-DR to T cells [410]. These studies did not account, for the fact 
that contact with T cells induces increased exosomal release by APC [529]. 
Interestingly, when exosomes containing p:MHCII complexes and costimulatory 
molecules were added to cultures of naïve CD4+ T cells, Ag-specific activation 
occurred only in the presence of DC CD80+/CD86+, but was independent of 
MHCII expression by the DC [530]. These results suggest that MHC acquired via 
APC-derived exosomes is only functional upon T cell:APC contact.  
Additional evidence discounting the role of exosomes as the mechanism 
for trogocytosis come from findings with DC whose membranes were labeled 
with the extremely stable lipophilic dye PHK26. Levels of PHK26 on the T cell 
decreased between 6 and 24 h of iTreg co-incubation with DC while, in contrast, 
levels of CD80 and CD86 increased [277]. This suggests that receptor-mediated 
transfer was occurring, rather than absorption of membrane-bound exosomes 
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which would be expected to increase the levels of PHK26 similarly to CD80/86 
[277]. Our previous data using APC-conditioned media also observed minimal 
acquisition of APC-derived exosomes by T cells [287]. In addtion, unpublished 
data from our lab using mild acid treatment of antibodies against trogocytosed 
molecules did not alter the amount of troocytosed molecules associated with a 
trog+ T cell. These data show that the trogoctosed molecules are integrated into 
the T cell membrane, even at early time points, and were not on APC-derived 
exosomes adsorbed to the T cell surface.  
While exosomes may contribute to the amount of transferred material to T 
cells, exosomal transfer alone is unlikely to result in intracellular trogoctosis 
mediated signaling. We, and others have observed trogocytosed molecules in 
distinct, punctate spots on the surface of the T cell. These spots are orders of 
magnitude larger than exosomes (~30-100 nm). Thus, dramatic re-arrangment of 
TCR/costimulatory molecules as well as APC-acquired molecules via exosomes 
would have to occur to form clusters equivelant to those which have been 
visualized. If the observed spots of trogocytosed molecule/TCR complexes were 
formed by T cell signaling events, then abolishing T cell signaling should lead to 
the dispersion of molecules and loss of these spots. Such dispersion was not 
observed in experiments where ZAP-70 signaling was inhibited with the Srk 
kinase inhibitor PP2 [81]. Taken together, the published data suggests that 
intracellular trogocytosis-mediated signaling is not dependent on exosomal 
transfer.   
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Microclusters as a Mechanism for Trogocytosis  
Another potential mechanism for trogocytosis is the transfer of APC 
molecules to the T cell via microclusters. We, and others have observed small 
clusters of MHC being transferred from APC to T cells during the immune 
synapse [397] [81]. In live-cell imaging experiments, it has been observed that 
clusters containing pMHC move away from the immunological synapse and 
migrate to the distal pole upon T cell:APC contact (Fig. 1.15). This transfer event 
is strikingly similar to the formation of the distal pole complex or, the 
“antisynapse” [70, 76]. A perplexing characteristic of the antisynapse is that, 
despite its location at the distal pole, it contains active TCR signaling molecules 
ZAP-70, LAT, PCLy1, P-Tyr, and Lck [76]. It has been proposed that the 
formation of the antisynapse likely involves TCR microclusters which were 
activated by pMHC that move to the distal pole [70]. That microclusters may be 
involved in the active TCR signaling at the anti-synapse is strengthened from the 
fact that TCR microclusters form an adhesion ring composed of LFA-1, focal 
adhesion molecules paxillin and Pyk2, and myosin II (MyoII) [71]. It has been 
proposed that this structure allows microclusters to exclude the suppressive 
molecule CD45 and thus are able to retain active TCR signaling [69, 72, 74]. 
However, even by exclusion of CD45, there is little evidence that the TCR 
proximal signaling complex would be sustained for the duration that has been 
observed at the antisynapse, in the absence of MHC binding and subsequent 
TCR signaling. Coincidentally, we have observed that the clusters of MHC which 
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transfer to the T cell and localize to the distal pole also co-localize with TCR and 
active proximal TCR signaling molecules ZAP-70, Lck, P-Tyr [81]. In fact, the 
images we previously reported are strikingly similar to those of antisynapses (Fig. 
5.1). 
 
 
 
Further support for microclusters as a mechanism for trogocytosis, is that 
microcluster formation is found to be resistant to treatment with PP2 [73]. This 
potentially explains how punctate signaling complexes, or what I will refer to as 
“trogosomes”, were observed after treatment of trog+ cells with PP2 [81]. The 
uncanny resemblance between the antisynapse and our studies on trogocytosis 
in the context of location and active signaling events, is consistent with the 
hypothesis that active-TCR signaling at the antisynapse is driven by pMHC 
complexes bound to the TCR.  
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 The location of APC-signaling molecules on the distal pole of the T cell 
could result in trogocytosis when the T cell dissociates from the APC. In this 
model, the transfer of APC-derived molecules is highly dependent on active 
signaling, consistent with current models for trogocytosis. This would also 
provide an explanation for the observed punctate spots on trog+ cells, which 
would be derived from pre-existing microclusters rather than having to 
independently form from re-expressed trogocytosed molecules. Consistent with 
this possibility is the data from Fig. 3.3 which shows that pre-polarized TH2 cells 
perform trogocytosis at significantly higher frequencies compared to polarized 
TH1, or non-polarized cells. As TH2 cells have been observed to form multi-focal 
synapses which resemble microclusters [83] this morphology could facilitate 
trogocytosis of pMHCII and costimulatory molecules.  
In this proposed microcluster model, it is possible that the acquired 
molecules are endocytosed with recycling TCR. However, if a focal point of 
signaling is already pre-established by the signaling complex formed at the distal 
pole this would promote the migration of newly-bound TCR:pMHC to the site of 
active signaling. This could be an explanation for the observed punctate 
trogosomes detected on trog+ cells days after APC removal (Fig. 3.5).  
           It is possible that highly activated cells are more efficient at tearing off 
membrane from the immunological synapse, as they have higher migration 
patterns and form shorter synapses. Perhaps trogocytosis through this 
mechanism would be more likely to enhance activation and effector functions of 
the trog+ cell. The live-cell imaging should also be further analyzed, as the data 
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show that as the T cell dissociates, the T:APC molecules bound near the dSMAC 
appear to get “pulled in” towards the central point of T:APC contact and torn 
away from the APC by the T cell. This is suggestive that the acquisition of 
microclusters may also occur upon T cell dissociation. 
The current literature has referred to trogocytosis in the context of all of 
the aforementioned mechanisms, however this broad categorization has led to 
contrasting results in not only the mechanisms of trogocytosis, but its biological 
outcomes as well. The microcluster model fits well with our previous results, and 
those in this study, showing that trogocytosis-mediated signaling is sustained for 
up to 72 hrs after APC removal, and leads to increased activation and effector 
cytokine production. In contrast, the acquisition of APC molecules not engaged 
with T cell receptors through bystander endocytosis or exosomes may lead to a 
different phenotype in the context of the trog+ cell. Whether there is a difference 
in the overall result between the different mechanisms of APC-derived signaling 
molecules remains to be determined.  
 
 
 
 
 
 
 
Part II 
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T:T Antigen Presentation and Trogocytosis-
Mediated Signaling in T cell Activation, and 
Immuno-Regulation 
 
The results in this study suggest that trogocytosis-mediated signaling enhances 
the activation state of the trog+ cell independently from activation by APC.  
However, other studies have reported T:T presentation of trogocytosed 
molecules signaling to inhibit the activation of responding cells. The most likely 
explanation for such conclusions is simply, that the trog+ cells which induce 
repressive modes of action are actually Treg, which are highly efficient at 
performing trogocytosis. In such a case, trogocytosis-mediated interactions 
would enhance the trog+ Treg suppressive capabilities rather than provide 
insufficient signaling to induce anergy in activated cells. While some studies 
claim that the trog+ cells which showed repressive functions were “not Treg”, the 
argument for this is questionable. For example, Helft et al. reported that when 
trog+ CD4+ cells were mixed with previously-activated T cells, T:T presentation of 
Ag to activated cells induced responder cell death, but stimulated naïve T cells to 
proliferate. The authors proposed that this was likely due to insufficient levels of 
costimulatory molecules upon p:MHC presentation by trog+ cells. Interestingly, 
when DC were added to cultures containing a mixture of trog+ and either 
activated or naïve T cells, the presence of trog+ cells inhibited the activation of 
activated, but not naïve cells, compared to controls which did not contain trog+ 
cells [429]. Firstly, activated cells require less stimulation than naïve T cells to 
maintain an activated state, thus the argument for insufficient stimulation for 
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naïve vs activated cells is not sound. Second, if insufficient stimulation by 
trogocytosis-mediated signaling was the reason for activated cells to become 
inactive, the addition of APC to mixed trog+/trog─ cultures should have rescued at 
least some of the phenotype. Rather than determining the phenotype of the trog+ 
cells, it was suggested that because the suppression of activated cells occurred 
in an Ag-specific manner, the trog+ cells were not Treg, which function in an Ag-
independent manner. In complete contradiction to this reasoning, a study by 
Bacheli et al found that Treg efficiently perform trogocytosis and formed contacts 
with responding T cells leading to a contact-dependent mechanism for 
immunosuppression by trog+ Treg. [432]. In addition, three years prior to the 
publication by Helft et al. it was published that Treg perform contact-dependent 
immunosuppression through granzyme B release onto ligated cells [296]. While 
insufficient levels of trogocytosed costimulatory molecules are likely to induce 
anergy, inadequate phenotyping of the trog+ cells in previous studies has 
resulted in a convoluted consensus of the impacts of non-Treg T:T presentation.  
Our results suggest that in effector CD4+ cells, trogocytosis-mediated 
signaling enhances the activation of the trog+ cells (Figs. 3.1, 4.1). This is 
consistent with a role for trogocytosis signaling in the heightened state of 
activation observed in trog+ cells from other studies. The sustained activation 
observed here occurred in the context of peptide bound to MHCII. This timing is 
the average t-1/2 half-life for peptide binding to MHC is ~72-96 hours, which is 
consistent with the kinetics of trogocytosis-mediated signaling we have observed 
in the activation state of trog+ cells recovered from BMDC, or other APC with 
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non-covalent peptide. At later time-points, as peptide dissociates from MHC, 
engagement with a combination of empty MHC and pMHC complexes would be 
insufficient to trigger T cell responses.  
Trogocytosis-mediated signaling also involves costimulatory receptor 
signaling, which could also contextually lead to differences in TH subset 
differentiation, for example, the acquisition of ICOS-L, and OX40L and 
subsequent trogocytosis-mediated signaling promoting a TFH phenotype. 
Costimulatory signaling through CD28 in the absence of TCR signaling has been 
found to be sufficient to induce the nuclear translocation of NF-κB [531]. Thus, as 
peptide dissociates from the MHC and TCR signaling dcreases, co-stimulatory 
signaling may be playing a larger role in the apparent phenotype at later time 
points.  
 
Part III 
Biological Implications of Intracellular Trogocytosis-
Mediated Signaling 
 
Implications of Trogocytosis-Mediated Signaling and a TH2 Phenotype 
The strong correlation between trogocytosis and the subsequent TH2 phenotype 
observed in chapter 3 supports the hypothesis that trogocytosis-mediated 
signaling plays a role in T cell effector function and subset differentiation. In cells 
that are weakly activated by APC (which also promotes TH2 differentiation), 
trogocytosis-mediated signaling could help overcome the threshold of signaling 
required for T cell survival and activation. In recently activated cells, or TH2 
effector cells, the production of IL-4 driven by trogocytosis-mediated signaling 
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could enhance cell survival [458]. By driving TH2 differentiation, trogocytosis-
mediated signaling could further promote the survival of the trog+ cells by 
increasing their resistance to Treg suppression. It has been found that TH2 cells 
are resistant to galectin-mediated apoptosis by Treg, while TH1 and TH17 are 
susceptible [299]. The TH2 phenotype could also aid in preventing an exhausted 
phenotype from sustained trogocytosis-mediated signaling as TH2 cells suppress 
the expression of the apoptosis-inducing antigen FAS Ligand, making them less 
susceptible to activation induced cell death (AICD) [532]. On the other hand, TH1 
cells are highly susceptible to AICD [533]. Interestingly, TH2, but not TH1, cells 
have been shown to be able to revert from an anergic state to resume effector 
functionality [459], which may promote the transition of TH2 cells to memory. 
These characteristics may be a reason for the observed bias for trogocytosis-
mediated signaling to drive a TH2 phenotype, over a TH1 or TH17 phenotype. The 
high susceptibility of TH1 cells to Treg suppression and AICD may also help 
explain the extremely low frequency of TH1 trog+ cells at later time-points.  
 The implications of trogocytosis-mediated signaling and development of a 
TH2 phenotype were discussed in detail at the end of chapter 3. One additional 
point of emphasis should be made regarding this phenotype in the context of 
solid tumors. Increasing evidence has been found from both animal studies and 
samples from human patients that trogocytosis occurs at high rates in solid tumor 
environments and by multiple cell types [388, 389, 399, 435, 534, 535]. In these 
cases of a localized tumor environment, a TH2 phenotype driven by trogocytosis-
mediated signaling could inhibit TH1 effector functions, and the activation of naïve 
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CD4 T cells. TH1 responses are generally considered protective in tumor models. 
As Ag is removed from tumor cells the responding T cells would receive weaker 
TCR signals from tumor cells or APC, leading to imbalanced TH2 differentiation 
and augmenting a localized TH2 environment. This could lead to generation of a 
non-protective humoral response. Effective immunotherapy against solid tumors 
has not yet been developed. The results from this study suggest that the 
differentiation/effector cytokine production by CD4+ trog+ T cells in the tumor 
microenvironment is worthy of consideration in future strategies to combat solid 
tumors.  
 
Trogocytosis-Mediated Signaling in the Apparent TFH Phenotype  
The phenotype observed in the trog+ cells in chapters 3 (TH2) and 4 (TFH) 
overlap in that both of these subsets specialize in providing B cell help. The 
differentiation towards TH2 could ultimately promote TFH differentiation by 
increasing the proximity of the T cell to the B cell and increasing the likelihood of 
interactions with cognate B cells. In addition, TH2 cells have been shown to 
readily become TFH themselves [148, 231, 238]. In these studies, trogocytosis-
mediated signaling drives cells towards a TFH-like phenotype, while still retaining 
qualities of TH2. This possibility is supported by observations that TFH-like cells 
can concurrently express Bcl-6 and GATA3 [148], and both TH2 and TFH cells 
commonly express IL-4 [234, 238, 448, 481, 536]. It is temping to conclude that 
the early TH2 phenotype developed by the trog+ cells may act as a favorable 
intermediate for the TFH phenotype observed at later time-points.  
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                An interesting observation from the results in chapter 4 was, in vivo, 
the trog+ cells developed a TFH-phenotype more readily than trog─ cells (Fig. 
4.11). In addition, when cultures of cells recovered from the trogocytosis assay 
were supplemented with APC, a greater frequency of the trog+ cells displayed a 
TFH-like phenotype compared to the trog─ cells (Fig. 4.7). These results suggest 
that the trog+ cells were more efficient at becoming TFH upon initial priming by 
APC compared to trog─ cells. This also raises the possibility that trogocytosis-
mediated signaling may have significant impacts on the kinetics of GC formation 
and B cell activation. By rapidly upregulating high levels of CXCR5 and 
producing high levels of IL-21 (Figs. 4.2-5), the trog+ cells could rapidly provide 
help to the B cells to increase Ab production, affinity maturation, class switching 
and proliferation to further increase the chances of B:T cell interactions early 
during the effector phase of the immune response. This is an area of active 
inquiry in the Wetzel lab. 
 It is also likely that trogocytosis-mediated signaling would have significant 
impacts on TFH differentiation in cases of low Ag. If a low number of APC 
displaying cognate-Ag were present, Ag-specific T cell:APC interactions would 
be less likely to occur. The current models of TFH differentiation require 2 or more 
distinct T-APC interactions. However, the necessity for additional APC could be 
circumvented by sustained trogocytosis-mediated signaling after the first 
interaction, thus making the trog+ cells more likely to differentiate to TFH than the 
trog─ cells.  
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Finally, trogocytosis-mediated signaling also resulted in the sustained 
expression of IL-21, and IL-4 by the trog+ cells (Figs. 3.3, 4.5). This is important 
because the initial T-DC interactions that result in pre-TFH cells do not induce IL-
21 expression, which has been proposed to occur only after subsequent 
interactions with B cells. This implies the Trog-mediated signaling is contributing 
to full TFH differentiation. It is possible that the trog+ cells would be more efficient 
TFH early in response by secreting high amounts of these cytokines in the GC 
without requiring cognate B cell interactions. Furthermore, if trogocytosis-
mediated signaling can drive TFH differentiation in the absence of B cells, then 
the trog+ cells could act also as extra-follicular TFH-like cells, that readily provide 
help to B cells outside of B cell follicles/GCs.  
The sustained activation and high production of IL-4 and IL-21 by trog+ 
cells could also play a major role in humoral autoimmunity. Hyperreactive TH2 
and TFH responses play a major role in Ab-mediated autoimmune diseases such 
as myasthenia gravis, autoimmune thyroiditis, Sjögren’s syndrome, rheumatoid 
arthritis (RA), multiple sclerosis, SLE, ulcerative colitis, Crohn's disease, 
ankylosing spondylitis (spinal arthritis), and type 1 diabetes [245, 246]. 
Interestingly, extrafollicular cells, which resemble TFH, have been found to be key 
mediators in such autoimmune diseases by forming ectopic lymphoid structures 
with B cells to induce class switching, affinity maturation, and high antibody 
production [537]. These structures have been observed in patients with RA [538], 
and have shown to play a major role in progression of SLE [539]. It is possible 
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that trogocytosis-mediated signaling could be contributing to the TFH-like 
phenotype of these cells outside of the GC.  
 
IL-21 promotes T cell Activation, Survival, Effector Function, and Memory 
Generation 
 
The high production of IL-21 by trog+ cells has biological implications 
beyond driving a TFH phenotype and providing B cell help. IL-21 may contribute 
to the sustained survival displayed by the trog+ cells, as IL-21 has been shown to 
be critical for the survival of activated CD4+ and CD8+ T cells in cases where IL-2 
is limited [540]. Is it also possible that IL-21 production by trog+ cells aids in their 
ability to sustain effector functionality, as addition of IL-21 has been shown to 
protect T cells from suppression by Treg [541]. In CD8+ T cells, IL-21 has been 
shown to preserve effector function in exhausted cells, and presence of IL-21-
producing CD4+ T cells has been shown to enhance Ag-presentation and the 
generation functional anti-tumor CTL [499]. This raises the possibility that IL-21- 
producing trog+ cells may also play an important role in anti-tumor immunity. 
Consistent with the results in chapter 4, IL-21 production driven by trogocytosis-
mediated signaling may aid in the transition of trog+ cells to memory, as IL-21 is 
critical for the formation of CD4+ and CD8+ memory T cells [440, 489].  
 
Tcf1 is a Common Feature in TH2, TFH, and Memory Cells 
A shared feature between the TH2, TFH, and memory-precursor 
phenotypes observed in the trog+ cells here is expression of the repressive 
transcription factor T cell factor 1 (Tcf1). The results in chapter 4 show that the 
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trog+ cells displayed higher levels of Tcf1 compared to trog─ counterparts, and it 
is possible that Tcf1 was playing a central role in the observed differentiation 
patterns.  
                Tcf1 likely contributed to the TH2 phenotype observed in chapter 3, as 
Tcf1 suppresses IFNγ and IL-17 expression, and it enhances the expression of 
GATA-3 [9, 244]. Consistent with the results from chapter 4, Tcf1 also is critical in 
TFH differentiation by regulating Blimp1 expression and repressing IL-2 signaling 
to promote the expression of Bcl-6 [227]. The high levels of Tcf1 expression in 
the trog+ cells may explain their ability to develop a TFH-like phenotype in the 
presence of high levels of IL-2. In addition, in a viral model Tcf1 had a critical role 
in TFH development, and was required for memory T cell formation [542]. Human 
lymph nodes have also been found to contain memory T cells which maintain 
high expression of TCF1, and these cells show superior functional potential 
compared to TCF1low memory cells [543]. Similar to the phenotype of the trog+ 
cells in chapter 4, during T cell asymmetric division Tcf1 is inherited by the distal 
daughter cell and correlates with self-renewal and the transition to memory [491]. 
 The regulation of Tcf1 is also consistent with a model in which 
trogocytosis and trogocytosis-mediated signaling are correlated with weaker TCR 
signaling. Strong TCR signaling has been shown to repress Tcf1 expression 
through high levels of PKCθ activation [522]. In addition, inflammatory cytokines 
such as IL-12 can suppress Tcf1 activation and drive effector differentiation 
[544]. It is possible that the IL-4 expression driven by trogocytosis-mediated 
signaling acts to shield the trog+ cells from inflammatory cytokines through a 
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negative-feedback loop and aids in their progression to become a memory cell. 
The compelling correlation between Tcf1 function in each of the phenotypes 
observed in trog+ cells in this study suggest that Tcf1 plays a central role in T cell 
differentiation via trogocytosis-mediated signaling. 
 
Trogocytosis-Mediated Signaling in CD4+ Memory Generation 
Trogocytosis-Mediated Signaling in Effector-to-Memory Transition 
Our previous results [81], and results from this study, show that despite similar 
activation by APC, the trog+ cells display superior survival compared to trog─ 
cells after APC removal (Fig. 2.1). Results in chapter 4 show that trogocytosis-
mediated signaling was necessary for the high levels of IL-2 expression by the 
trog+ cells, which was a major contributor the survival of both trog+ and trog─ cells 
(Fig. 4.19). These results suggest that trogocytosis-mediated signaling can 
promote effector-to-memory transition, as it has been found that autocrine IL-
2/IL-2R signaling induced by late-cognate interactions with APC are required for 
memory transition [317]. As mentioned above, it is also likely that the IL-21 
produced by the trog+ cells would aid in the transition to memory, as IL-21 has 
been found to be critical in CD4+ memory formation [440]. 
The sustained TCR downmodulation by the trog+ cells also has 
implications for memory transition. While trogocytosis-mediated signaling may be 
sustained at a level which promotes survival and licensing to become memory, 
subsequent interactions with APC may drive terminal effector differentiation of 
the trog+ cell. By maintaining low levels of surface TCR, the chances of 
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subsequent interactions between the trog+ cells and APC would be decreased, 
thus favoring memory formation over terminal-effector differentiation.  
 Currently, the mechanisms which allow memory cells to persist after Ag 
clearance are not well defined. The data presented here raise the possibility that 
trogocytosis-mediated signaling plays a role in the sustained survival of the trog+ 
cells and subsequent effector-to-memory transition.   
 
Trogocytosis-Mediated Signaling in T cell Memory Generation via 
Asymmetric Division 
 
The results in chapter 4 show a strong correlation for trogocytosis and 
asymmetric division. The presence of trogocytosed molecules on the cell 
resembling the distal daughter cell during asymmetric division could be 
established during the immunological synapse. However, our results showed that 
it was apparent that trogocytosis-mediated signaling enhanced the survival of 
trog+ cells and was critical for the proliferation, and survival of the lesser 
activated cells. The initial description of asymmetric division and memory 
development suggested differential signaling at the synapse and the distal region 
of the cell set up the asymmetry. Our imaging experiments show reduced, but 
present, signaling at the distal pole associated with trogocytosed molecules. This 
may have major biological implications in the context of memory formation, as 
cells which receive stronger signaling develop terminally-differentiated effector 
cells, while the cells which receive less intense signaling upon activation retain 
high memory-potential. 
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             In addition to promoting the survival of cells which received weaker 
signals from APC, it is possible that trogocytosis-mediated signaling plays a role 
in the asymmetric division of cells. An unknown variable in the model for 
asymmetric division is how a T cell which has been separated from an APC for 
several rounds of cell division is able to maintain its axis of polarity established at 
the immune synapse. One proposed mechanism is strong PI3K signaling and the 
formation of the proximal TCR signaling complex established this polarity [513]. 
However, this still does not explain how the polarity is maintained long after the T 
cell separates from the APC and has undergone multiple rounds of cell division. 
It is possible that the sustained trogocytosis-mediated signaling at the distal pole 
complex/antisynapse is responsible for maintaining this polarity.  
 
Proposed Model for the Presented Results 
 The phenotypes displayed by the trog+ cells in this study can be centered 
around a few common mechanisms, all of which can enhance the survival of the 
trog+ cell. In the context of trogocytosis-mediated signaling, the most obvious 
factor is the signaling itself. The results in this dissertation show that 
trogocytosis-mediated signaling can influence the activation, proliferation, and 
survival of the trog+ cell after APC removal. In addition, the primary cytokines we 
found trogocytosis-mediated signaling to promote were IL-2, IL-4, and IL-21. 
These cytokines are all able to promote CD4+ T cell survival, and depending on 
the context of TCR/costimulatory signaling, could differently impact the effector 
functions and differentiation of the trog+ cell. For example, strong trogocytosis-
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mediated signaling in the presence of IL-21 could lead to TFH differentiation, while 
weaker signaling would further promote IL-4 production. IL-4 in the context of 
trogocytosis-mediated signaling could then drive GATA-3 expression and TH2 
differentiation. Trogocytosis-mediated signaling could also enhance the T cell 
memory pool through the survival of memory-precursors formed through 
asymmetric division. By rapidly, and sustainably, producing high levels of IL-2 the 
trog+ cells could aid in the proliferation of not only the trog+ cell, but the 
surrounding trog─ cells as well. Later in the immune response IL-2 and IL-21 
have been found to be critical in generating a stable memory T cell population 
from effector cells, again, in the context of TCR signaling. The common theme in 
these potential outcomes, is these are all mechanisms that could enhance the 
survival of the trog+ cell through potentially self-sustainable mechanisms. 
              Throughout this dissertation I have also proposed that trogocytosis-
mediated signaling of relatively weak strength, at least when compared to 
signaling from interaction with APC. This hypothesis is supported in that, weak 
TCR signaling can drive TH2-differentiation, and promote memory formation, 
which is consistent with the phenotypes observed in trog+ cells in this study. TH2 
cells display superior survival mechanisms compared to inflammatory subsets 
such as TH1 and TH17. It is possible that the survival of the individual cell would 
be enhanced through phenotypic changes towards a less inflammatory-
associated subset such as the TH1 to TH2 conversion seen in Fig. 3.7 or become 
a memory T cell as proposed in chapter 4. Weak signaling also promotes Tcf1 
expression, which as mentioned above, can drive TFH, TH2, and memory T cell 
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formation. In addition, it is likely that strong trogocytosis-mediated signaling 
would lead to T cell exhaustion. Thus, the surviving trog+ cells are primarily those 
receiving a sustainable level of continual signaling.  
 This raises the question of whether the weak signaling by trogocytosis-
mediated signaling drives phenotypes, or simply maintains the survival of cells 
programmed towards a particular subset by APC. Both of these possibilities are 
likely scenarios.  
In an in vitro system where transgenic cells display uniform TCR and APC 
which display the same peptide antigen, if all T cells encounter Ag and are 
similarly activated, why do some cells perform trogocytosis while others do not? 
In this scenario, a major variable is the duration of contact between T cell and 
APC. If this is the case, then why did the trog+ cells display a phenotype 
associated with weaker T cell signaling (TH2), while the trog─ cells displayed a 
phenotype associated with stronger signaling (TH1)? These data are seemingly 
contradictory to the published data showing that T cell trogocytosis is associated 
with a heightened state of activation, which is also what was observed here, as 
indicated by CD69 levels in the trog+ and trog─ cells (Figs. 3.1, 4.1). 
 One possible example is that the acquisition of pMHC/costimulatory 
molecules occurs via microclusters. Microclusters can localize to the distal pole 
rapidly upon T:APC contact, but become recruited to the immunological synapse 
within minutes. Therefore, if a T cell were to form a short-lived synapse and 
spontaneously dissociate before the microclusters integrate into the SMAC, this 
would result in the transfer of pMHC/costimulatory molecules to the T cell. 
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Consequently, in the in vitro system used here, it is likely that a shorter synapse 
would also be associated with weaker TCR signaling events. The weaker 
signaling would allow the trog+ cells to retain high Tcf1 levels which could 
promote a TH2 and/or TFH phenotype, effector-to-memory transition, or memory-
precursor formation through asymmetric division. In contrast, longer-lived 
synapses would allow extra time for pMHC complexes in these microclusters to 
migrate back towards the immune synapse and thus would be less likely to be 
acquired by the T cell. The extended duration of the synapse would likely also 
subsequently lead to stronger signaling, providing an explanation for the 
predominant TH1 phenotype and nearly exclusive IFNγ expression by the trog─ 
cells observed in chapter 3.  
In addition, the morphology of microclusters granting them ability to 
exclude regulatory molecules allows them to sustain active signaling for longer 
durations compared to TCR in the sMAC. This could also play a significant role in 
the sustained trogocytosis-mediated signaling observed in this study. 
     If a weaker signal promotes TH2 and memory generation, then why do 
the trog+ display equal, if not greater levels of CD69 compared to the trog─ cells 
immediately after recovery from APC?  Figures 3.1 and 4.1 show that the trog+ 
cells not only maintained high CD69 expression after APC removal, but levels of 
CD69 increased over subsequent incubation. This strongly suggests that 
trogocytosis-mediated signaling was driving CD69 expression, as in absence of 
stimulation, CD69 levels peak within 24 hours of stimulation. Therefore, it is 
possible that compared to the trog─ cells, the trog+ cells were not as activated by 
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the APC, but this was not reflected in their activation state due to trogocytosis-
mediated signaling augmenting CD69 expression in the trog+ cells.   
This proposed models is intended to serve as an explanation for the 
results obtained in this study, however as described in earlier sections, the broad 
consequences of trogocytosis-mediated signaling are likely context dependent.  
 
Outro  
As the number of identified TH subsets continues to grow, and plasticity 
between differentiated subsets is becoming more apparent, determining the 
exact mechanisms governing TH differentiation has become a challenging topic 
of research. In particular, the multi-step processes involved in the generation of 
TFH comes with extra layers of complexity. In addition to TH differentiation, the 
mechanisms which drive memory formation are largely unknown. This combined 
lack of knowledge has been a major roadblock in vaccine design and efficacy, 
and anti-tumor immunotherapy. Therefore, improving our understanding of the 
mechanisms governing the differentiation of effector subsets, and memory cells 
are of paramount importance in human health. The results here provide insight 
into a novel mechanism for CD4+ T cells to differentiate towards TH2 and/or TFH 
in the absence of further interaction with APC. They also provide compelling 
evidence for trogocytosis-mediated signaling to play a role in the generation of 
CD4+ memory cells through effector-to-memory transition, and asymmetric 
division.   
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          I will end with a few questions for speculation. Could there be a distinct 
phenotype of T cell which displays all of these characteristics? Is trogocytosis 
simply a common, but understudied mechanism in the differentiation of these 
subsets?  And finally, does weak TCR signaling itself promote a TH2 phenotype 
and memory formation, or does weak TCR signaling actually promote 
trogocytosis? 
 
 
 
Future Directions 
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To address whether a shortened T cell:APC contact leads to increased 
trogocytosis via microclusters, additional live-imaging experiments should be 
conducted over a wider time-course to observe the rate of dissociation in 
comparison to the MHC that remains on the T cell microclusters. Additionally, 
collecting the cells which spontaneously dissociate from APC at different time 
points for immediate analysis, and assessment of the downstream phenotype will 
help address the hypothesis that shorter T cell:APC contact duration favors 
trogocytosis and memory cell generation.  
 
While the differentiation of previously-activated trog+ cells in chapter 3 was 
towards a TH2 phenotype, this could be an artifact of the APC used in the 
system. While a greater frequency of the trog+ cells from BMDC produced IL-4 
compared to the trog─ cells, the frequency of IL-4+ trog+ cells was substantially 
lower in cultures from BMDC vs MCC:FKPC APC. This is likely due to the 
weaker activation state induced by the FKPB:APC compared to BMDC which has 
been shown to promote TH2 differentiation. In addition, other model systems 
should be utilized with pathogen-associated antigenic proteins in in vivo studies, 
or the addition of different agonists which trigger separate TLR/RLR (PRR 
receptors) to observe whether the TH2 phenotype of trog+ cells holds true in 
inflammatory settings which promote a TH1 phenotype.    
 
While we observed a phenotype in the trog+ cells consistent with TFH, it was not 
actually demonstrated that the trog+ cells were indeed TFH, as defined by their 
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ability to help B cells. Further studies to examine the functional role of trog+ cells 
in the help of B cells should therefore be conducted to confirm this phenotype. 
Assays should include B cell help assays containing mixtures of trog+ and trog─ 
FACS sorted cells to assess B cell activation, class switching, and proliferation. 
To assess the migratory location, FACS-sorted trog+ and trog─ cells may be 
labeled with different dyes and adoptively transferred in to mice 3-5 days 
following immunization with either a cognate or irrelevant Ag. Histology on the 
lymph nodes to observe the proximity of the trog+ cells and trog─ cells to B cell 
follicles can be assessed 12-24 hours post-transfer, and 48-72h post-transfer to 
also stain for Ig class switching proximal to the trog+ or trog─ cells. If the trog+, but 
not trog─ cells migrate to the B cell follicle/GC in animals immunized with 
irrelevant Ag, this would suggest that the trog+ cells are able to home towards B 
cell follicles independently of cognate B cell interactions. The role of trogocytosis-
mediated signaling through costimulatory molecules shown to be involved in TFH 
differentiation such as ICOS:ICOS-L and OX40:OX40-L interactions, should also 
be assessed. The acquisition of these molecules is likely to impact IL-21 and Bcl-
6 expression through trogocytosis-mediated signaling. 
 
It is also possible that trogocytosis-mediated signaling could lead to the 
generation of extrafollicular cells displaying a TFH-like phenotype, including IL-21 
secretion, which have been observed in other studies [242]. This is a possibility 
that should be examined further, as this would be an area where trogocytosis-
mediated signaling would be most influential on the immune response, as 
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opposed to GCs where the all of the CD4+ T cells in proximity would have access 
to APC contact.  
 
In the context of asymmetric division, it is possible that the axis of polarity are 
maintained by trogocytosis-mediated signaling at the distal pole. This is an 
intriguing hypothesis that should be explored further. While it was difficult to 
ascertain whether this possibility was true due to the massive cell death and 
decreased proliferation of the trog+ cells when trogocytosis-mediated signaling 
was neutralized with anti-I-Ek/CD80 antibodies, it is possible that the 
supplementation of sufficient survival cytokines would allow the T cells to survive 
and proliferate long enough to examine this possibility. I did find some evidence 
for reduced asymmetric distribution in the few cells which divided in cases where 
trogocytosis-mediated signaling was neutralized (data not shown). However, due 
to extremely low cell numbers, I cannot conclude with confidence that 
trogocytosis-mediated signaling promotes asymmetric division.  
 
Following up with the asymmetric division model, another interesting possibility is 
the potential role for the molecule CD43. Thought to be due to its repressive 
activity and physically large size, CD43 has been observed to become excluded 
from the immunological synapse, and travel to the distal pole complex during the 
immune synapse. Interestingly, anti-CD43 Ab-induced CD43 signaling alone in 
TH2 cells led to IL-4 production, increased proliferation, and CD69 and CD25 
upregulation [545]. CD43 signaling has also been found to act as a costimulatory 
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molecule, acting independently of CD28 to enhance T cell activation, particularly 
in low levels of TCR signaling. High levels of CD43 signaling have been shown to 
inhibit TCR/CD3-mediated apoptosis, which may aid in the survival of trog+ cells 
expressing pMHC. Due to its physical size, CD43 has also been proposed to 
inhibit cell:cell interactions, and thus could prevent MHC-recognition and killing of 
trog+ by CTL. The role of CD43 in the activation, differentiation, and survival in 
the context of trog+ cells is worth examining further. 
 
Signaling through Notch proteins may also play a role in trogocytosis. These 
previously overlooked molecules have been shown to play significant roles in T, 
and other cell development and activation. Interestingly Notch signaling has been 
found to be important in activating the long isoforms of Tcf1, which promote TFH 
differentiation and are critical for memory formation, at least in the context of a 
viral model [542]. Therefore, the presence of these molecules should be 
assessed on trog+ cells, as well as determining whether they play a role in 
trogocytosis, and/or trogocytosis-mediated signaling.  
 
In the context of Tcf1, the Wnt/-catenin pathway is an important regulator of 
Tcf1 and should be further examined in the context of trogocytosis-mediated 
signaling.  
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